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 “There exists a passion for comprehension, just as there exists a passion for music. 
That passion is rather common in children, but gets lost in most people later on. 
Without this passion there would be neither mathematics nor natural science “ 
―Albert Einstein – 
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PRELIMINARY NOTE 
This PhD thesis is written as cumulative dissertation in accordance to the study and 
examination regulations of the Philipps University of Marburg (15.07.2009 §9). It 
summarizes three thematically linked publications as well as unpublished data. The 
unpublished data have been included in the thesis to underlie the broad application of 
measles virus-based vaccines against emerging viral infections. The incorporated 
publications are listed below. Descriptions pointing to published figures will cite the author 
and year of publication and the figure number in the publication (for example Scheuplein et 
al., 2015, Fig. 1B). Descriptions pointing to unpublished figures include an ongoing 
numbering (for example Fig. 1).   
 
1) High secretion of interferons by human plasmacytoid dendritic cells upon 
recognition of Middle East respiratory syndrome coronavirus. Scheuplein VA, 
Seifried J*, Malczyk AH*, Miller L, Höcker L, Vergara-Alert J, Dolnik O, Zielecki F, 
Becker B, Spreitzer I, König R, Becker S, Waibler Z, Mühlebach MD. J Virol. 2015 
Apr;89(7):3859-69. doi: 10.1128/JVI.03607-14. Epub 2015 Jan 21. 
 
2) Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and 
Induce a Strong Antigen-Specific Cytotoxic T Cell Response. Uhlig KM, Schülke 
S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, 
Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD. J Virol. 
2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17. 
 
3) A Highly Immunogenic and Protective Middle East Respiratory Syndrome 
Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. 
Malczyk AH, Kupke A*, Prüfer S*, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, 
Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, 
Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, 
Eickmann M, Becker S, Mühlebach MD. J Virol. 2015 Nov;89(22):11654-67. doi: 
10.1128/JVI.01815-15. Epub 2015 Sep 9. 
 
*equally contributed 
ZU S A M M E NF A S SU N G  
 
 1 
ZUSAMMENFASSUNG 
Hochpathogene Viren stellen eine globale Gefahr dar, da sie im Zuge des internationalen 
Personen- und Warentransportes fast ungehindert verbreitet werden können. Eine 
besondere Bedrohung geht dabei von neuartigen viralen Erregern aus, für die keine 
adäquaten Behandlungsmethoden implementiert sind. Um auf lokale oder sogar globale 
Ausbrüche dieser Viren angemessen reagieren zu können, besteht eine Maßnahme in der 
frühzeitigen Entwicklung schützender Impfstoffe. Vektorbasierende Impfstoffplattformen, 
wie z. B. replikationskompetente rekombinante Masernviren (rMV), sind für diese Zwecke 
besonders interessant, da diese nach Standardisierung einen einfachen Austausch der für 
Antigene kodierender Genabschnitte ermöglichen und somit eine schnelle Produktion 
erlauben können.  
Um ihre Eignung als protektive Impfstoffplattform gegen hochpathogene virale Erreger zu 
untersuchen, wurden innerhalb der vorliegenden Arbeit rMV hergestellt, welche jeweils für 
Antigene der neuartigen Erreger Middle East respiratory syndrom coronavirus (MERS-
CoV), Influenza-Virus H7N9 oder des Erregers des hämorrhagischen Krim-Kongo-Fiebers 
(engl. Crimean-Congo haemorrhagic fever virus, CCHFV) kodierende Gene enthalten. Dieser 
Einbau ermöglichte eine hier nachgewiesene Expression des MERS-CoV Spike 
Oberflächenproteins in membrangebundener (MERS-S) oder löslicher Form (MERS-solS), 
des MERS-CoV Nukleokapsidproteins (MERS-N), des Hämagglutinins bzw. der 
Neuraminidase von H7N9 (H7 bzw. N9), des CCHFV Glycoproteins Gc (CCHFV-Gc) oder des 
CCHFV-Nukleokapsidproteins (CCHFV-N) in mit dem jeweiligen Impfstoff infizierten Zellen.  
Die Immunisierung MV-suszeptibler Mäuse mit MERS-S-, H7- oder N9-exprimierenden 
rMVs zeigte, dass humorale Immunantworten ausgelöst werden, bei denen nach 
Vakzinierung mit MV-MERS-S, MV-MERS-solS oder MV-H7 Virus-neutralisierende 
Antikörper (nAKs) nachgewiesen werden konnten. Die Herstellung von für die jeweiligen 
Antigene transgenen, zum Mausmodell syngenen Dendritische Zellen (Dendritic cells, DC)- 
Zelllinien ermöglichte zudem eine effiziente Re-stimulation von Antigen-spezifischen T-
Zellen unabhängig der Kenntnis jeweils immunogener Epitope oder der Verfügbarkeit des 
Antigens in Proteinform. Mit Hilfe dieser Antigen-spezifischen DC-Zelllinien konnten durch 
MV-MERS-S, MV-MERS-solS, MV-MERS-N sowie MV-H7 induzierte zelluläre 
Immunantworten über IFN-γ-ELISpot nachgewiesen werden. MERS-S spezifische CD8+ T-
Zellen aus immunisierten Tieren reagierten zudem mit einer MERS-S-abhängigen 
Proliferation und MERS-S spezifischen Zytotoxizität auf entsprechende Re-stimulation. Mit 
MV-MERS-S oder MV-MERS-solS vakzinierte Mäuse zeigten im Belastungsversuch mit 
MERS-CoV eine Reduktion der Viruslast sowie Virus-induzierter Entzündungsreaktionen 
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im Lungengewebe. Dies demonstrierte eindrucksvoll die Schutzwirkung eines MV-
basierenden Impfstoffkandidaten gegen MERS-CoV.  
In einem zweiten Teil dieser Arbeit wurden zudem durch MERS-CoV ausgelöste angeborene 
Immunreaktionen in humanen und murinen Antigen-präsentierenden Zellen untersucht. 
Dabei wurden humane plasmazytoide DCs (pDCs) als Quelle erheblicher Mengen antiviraler 
Typ I (IFN-α, IFN-β) oder Typ III (IFN-λ) Interferone identifiziert, die in Folge einer 
Infektion dieser Zellen mit MERS-CoV ausgeschüttet wurden. pDCs könnten als bisher 
einzig nachgewiesene Quelle antiviraler Typ I Interferone eine wichtige Rolle innerhalb der 
Pathogenese von MERS-CoV im Menschen einnehmen.  
Diese Arbeit zeigte folglich beispielhaft Interaktionen eines neuartigen Erregers, MERS-
CoV, mit genau definierten Immunzellen, was die Entwicklung zukünftiger Therapien 
maßgeblich unterstützen könnte. Als potentieller Impfstoffkandidat wurde innerhalb 
dieser Arbeit eine MV-basierende Impfstoffplattform erzeugt und deren Schutzwirkung 
gezeigt. Die schnell umsetzbare Erzeugung solcher MV-basierenden Impfstoffkandidaten 
gerichtet gegen drei unterschiedliche virale Erreger, die effiziente Induktion humoraler und 
zellulärer Immunantworten sowie die Schutzwirkung im Belastungsversuch verdeutlichen 
das Potential von rMV als effiziente Impfstoffplattform gegen neuartige Erreger. 
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SUMMARY 
Highly pathogenic viruses are a significant global danger since they can be spread by 
worldwide travel and trade almost without restriction. One particular threat comes from 
emerging infections, for which no adequate treatment options currently exist. To guard 
against local or global outbreaks of these viruses, the development of protective vaccines at 
an early stage is therefore a desirable form of intervention. Vector-based vaccine platforms, 
such as that of replication-competent recombinant measles virus (rMV), constitute good 
prospective vaccine candidates, since they have the potential to allow for an easy exchange 
of antigen-encoding genes, thereby enabling rapid vaccine production after standardisation.  
To assess their suitability as a potential vaccine platform against highly infectious viral 
pathogens, rMVs were generated as part of the practical element of this thesis. These 
encoded for antigens of the following emerging pathogens: Middle East respiratory 
syndrome coronavirus (MERS-CoV), influenza virus H7N9 or Crimean-Congo haemorrhagic 
fever virus (CCHFV). Insertions of antigen-encoding genes resulted in the detectable 
expression of the MERS-CoV spike glycoprotein in both membrane-bound (MERS-S) and 
soluble form (MERS-solS), the MERS-CoV nucleocapsidprotein (MERS-N), haemagluttinin 
or neuraminidase of H7N9 (H7 or N9), the CCHFV glycoprotein Gc (CCHFV-Gc); and the 
CCHFV-nucleocapsid protein (CCHFV-N), in cells infected with respective vaccines.  
Immunisation of MV susceptible mice with MERS-S-, MERS-solS-, H7-, or N9-encoding 
vaccines also resulted in the induction of humoral immune responses. These included virus-
neutralising antibodies (nAbs), if mice were vaccinated with MV-MERS-S, MV-MERS-solS or 
MV-H7. Generation of syngeneic for the respective antigens' transgenic dendritic cell (DC) 
cell lines, moreover, enabled an efficient re-stimulation of antigen-specific T cells without 
knowledge of immunogenic epitopes or the availability of antigens as proteins. When using 
these transgenic DC cell lines, MV-MERS-S-, MV-MERS-solS-, MV-MERS-N-, and MV-H7-
induced cellular immune responses were demonstrated in an IFN-γ-ELISpot. Moreover, 
MERS-S specific CD8+T cells of immunised mice responded to respective re-stimulation by 
MERS-S-dependent proliferation and MERS-S-specific cytotoxicity. A reduction of viral 
loads, as well as virus-induced inflammation of lung tissue, was observed in MV-MERS-S- or 
MV-MERS-solS-vaccinated mice within a MERS-CoV challenge model. This impressively 
demonstrated the protective efficacy of an MV-based vaccine against MERS-CoV.  
In the second part of this thesis, MERS-CoV-induced innate immune responses in human 
and murine antigen-presenting cells (APCs) were analysed. As a result, human plasmoid 
DCs (pDCs) were identified as a source of significant amounts of antiviral type I (IFN-α, IFN-
β) and Typ III (IFN-λ) interferons (IFNs), which were secreted upon infection with MERS-
SU M M A R Y  
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CoV. As a so far exclusively-identified source of type I and III IFNs pDC might hence play a 
significant role in MERS-CoV-induced pathogenesis in humans. 
Thus, by using MERS-CoV as an example, this thesis identified several key interactions 
between an emerging pathogen and defined immune cells, which might prove to be of 
clinical significance, particularly in the future development of antiviral drugs. As potential 
vaccine candidate, an MV-based vaccine platform was generated as part of this thesis; and 
its protection efficacy was demonstrated. A rapidly conducted production of MV-based 
vaccine platforms against three different viral pathogens, an efficient induction of humoral 
and cellular immunity as well as protection efficacy in a challenge model indicated the 
potential of recombinant MV to be used as an effective vaccine platform to protect against 
emerging viral pathogens. 
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1. INTRODUCTION 
1.1. Emerging infections 
Over the last few decades, several new infectious diseases, caused by bacteria, viruses or 
parasitic pathogens, have suddenly emerged or re-emerged (220, 257). Of these pathogens, 
viruses most commonly enter the human population through so-called zoonoses, a 
transmission from an animal reservoir to human patients. In fact, 50-60% of all viruses 
(271) and 70% of emerging or re-emerging viruses (64, 132) are of zoonotic origin. Among 
these are the human immunodeficiency virus (HIV)-1, which emerged in the early 20th 
century (328), the Ebola virus in 1976 (117), and severe acute respiratory syndrome 
coronavirus (SARS-CoV) in 2002 (227). More recently, the coronavirus Middle East 
respiratory syndrome coronavirus (MERS-CoV) (320), and the avian influenza virus (H7N9) 
(135) entered the human population in 2012 and 2013, respectively, and still cause severe 
disease.  
Zoonotic viruses can be transmitted to human patients directly through wildlife or more 
commonly, through livestock such as Arabian dromedary camels in the case of MERS-CoV 
(108); or poultry, which transmits H7N9 (162). Such transmission events most frequently 
occur in developing countries, where close contact between animals and people favours 
contagion (317). However, the emergent viruses can then be spread by worldwide travel 
and trade (257) making the development of vaccines during a pre-pandemic phase sensible, 
so as to be prepared for the possible onset of a global pandemic.  
Thus, the next subsections will describe pathogenicity and assess the pandemic risk of 
selected highly pathogenic viruses in order to emphasise the need for pre-pandemic 
vaccines. Due to their phylogenetical distance and recent emergence, the biosafety-level 
(BSL) 3 viruses MERS-CoV and H7N9, or the frequently re-emerging BSL-4 pathogen 
Crimean-Congo haemorrhagic fever virus (CCHFV) were chosen as targets for this thesis.  
 
1.1.1. Middle East respiratory syndrome coronavirus  
(MERS-CoV) 
In November 2012, a virus isolated from a Saudi Arabian patient was identified as a new 
member of the coronavirus family (Coronaviridae), initially termed hCoV-EMC (320), but 
later renamed as Middle East respiratory syndrome coronavirus (MERS-CoV). Comparable 
to the related severe acute respiratory syndrome coronavirus (SARS-CoV), an infection with 
MERS-CoV induces severe pneumonia in human patients, which is often accompanied by 
leukopenia and lymphopenia (320). In severe cases, MERS-CoV additionally induces septic 
IN T R O DU C T IO N  
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shock, renal or multi-organ failure (79). To date, the virus has infected 1,905 patients in 27 
countries, of whom 677 have succumbed to disease, yielding a mortality rate of 
approximately 36%. Eighty percent of confirmed cases were reported from Saudi-Arabia 
(297) (Fig. 1).  
 
Fig. 1 Distribution of MERS-CoV and epicurve of confirmed cases.  (A) Global distribution of human cases 
with confirmed MERS-CoV infection. Countries of confirmed cases are marked purple.  (B) Epicurve of 
confirmed human cases from 2012 to 2016. Dark blue, Saudi -Arabia; red, Korea; light blue, other countries. 
Modified after (297). 
 
As with all coronaviruses, MERS-CoV is a 
spherical, enveloped virus with a single-stranded, 
positive-sensed (ss(+)) RNA-genome (25, 300). Its 
genome encodes for four structural proteins, the 
nucleocapsid protein (N) wrapping the viral RNA, 
and three proteins anchored in the viral 
membrane: envelope protein (E), membrane 
protein (M) and spike glycoprotein (S) (199) (Fig. 
2). The spike glycoprotein binds the cellular 
receptor Dipeptidylpeptidase-4 (DPP-4) and 
mediates viral entry into the cell (167) via fusion 
with the plasma or endosomal membrane (217).  
MERS-CoV is of zoonotic origin, capable of infecting dromedary camels (54, 93, 191). Since 
virus isolates originating from this host are genetically similar to human viruses (108, 179), 
it is proposed that most human cases arise from contagion from camels. So far, the virus is 
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poorly transmitted from person to person. However, 106 confirmed third-generation and 
11 fourth-generation cases during an outbreak in Korea in 2015 (58, 210) indicate 
substantial transmission amongst the human population. By way of comparison SARS-CoV 
caused a significant outbreak in 2002, in which approximately 1,000 of more than 8,000 
patients succumbed to disease (293). The analogy of symptoms between SARS- and MERS-
CoV (320) and MERS-CoVs higher case fatality rate of 35% (297) arouses the fear that 
MERS-CoV could induce a comparable or even worse global outbreak than SARS-CoV. 
Although the human-to-human transmission of MERS-CoV is generally limited, the ongoing 
level of infections since 2012 make the generation of an efficient vaccine advisable so as to 
be prepared for the potential onset of a global pandemic. In any event, a MERS-CoV-vaccine 
would be helpful in fighting the local epidemic in Saudi-Arabia and the Middle East.  
 
1.1.2. Influenza virus H7N9 
Since 2013, 918 laboratory-confirmed infections with another recently-emerged virus, the 
avian influenza A virus H7N9, have been reported to the World Health Organisation (WHO) 
(296)(Fig. 3A). The virus was originally isolated from three Chinese patients in February 
and March 2013 (100), who fatally suffered from severe respiratory tract infections and 
pneumonia (129). The contagion of people is presumably mediated through contact with 
infected poultry, mostly in poultry markets (162, 317). Although the virus occasionally 
infects humans with limited human-to-human transmission, and exhibits a restricted 
distribution in China (312), the high case fatality rate of about 36% is alarming (129, 262) 
(Fig. 3B). By comparison, the pandemic induced by Influenza H1N1 resulted in a mortality 
rate of about 0.03% (43, 74). 
 
 
Fig. 3 Distribution of H7N9 and epicurve of confirmed cases. (A) Global distribution of human cases with 
confirmed H7N9 infection. Countries of confirmed cases are colored. Beige, brown, orange and red; cases in 
China; light-blue, imported cases. modified after (90). (B) Epicurve of confirmed human cases from 2013 to 
2016. Dark blue, number of Cases; red, number of Deaths. Modified after (296). 
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As with other influenza A viruses in the family Orthomyxoviridae, H7N9 is a segmented, 
single-stranded negative-sense (ss(-)) RNA virus. The eight RNA segments encode for the 
structural proteins, which are the polymerase subunits (PB1, PB2, PA, PB1-F2), 
nucleocapsid protein (N), hemagglutinin (HA), neuraminidase (NA), and matrix proteins 
(M1, M2) as well as two non-structural proteins (NS1, NS2) (Fig. 4) (273, 304).  
 
 
 
 
 
 
 
 
 
The HA, which is like NA, embedded in the viral envelope, mediates binding to the entry 
receptor sialic acid and subsequent uptake via the endocytic route. NA on the surface of 
productively infected host cells catalyses the cleavage of the receptor to release the virus 
particles (273, 304). Since human cells are covered with α2,6-linked sialic acids (56), they 
are normally not infected by avian influenza viruses, which predominantly utilize α2,3-
linked sialic acids for entry (20). However, the influenza virus subtype H7N9 bears genetic 
changes associated with an adaptation to mammalian cells (100), resulting in an efficient 
replication in human airway epithelial cells (22). Moreover, the virus is efficiently 
transmitted between infected ferrets via direct contact (22, 327) and at least for the 
Anhui/1 strain also through airborne transmission (323). Although human-to-human 
transmission of H7N9 is still limited to few family clusters (296), the adaptations to 
mammalian cells, especially the principle capacity of airborne transmission (323), are 
alarming. Moreover, the shedding of the infectious virus by ferrets before the onset of 
influenza symptoms (323) makes a rapid transmission of H7N9 likely, especially if the virus 
adapts more efficiently to the human host. The potential spread of the virus could be 
prevented; and people at risk, protected if efficient vaccines were available.    
 
1.1.3. Crimean-Congo haemorrhagic fever virus (CCHFV) 
During World War II, an until then unidentified virus was isolated from 200 soldiers in the 
Crimea who had suffered from severe haemorrhagic fever (120, 185). The isolated virus 
was later shown to be antigenically indistinguishable from the Congo virus isolated in the 
Belgian Congo in 1956 (305) and consequently termed Crimean-Congo haemorrhagic fever 
Fig. 4 Structure of H7N9. Schematic 
depiction of an Influenza virus particle  
(as H7N9). The RNA is organized in 
eight segments, which are complexed 
with nucleocapsid proteins (N) and 
RNA polymerase proteins (PB1, PB2, 
PA) and surrounded by the Matrix 
proteins (M1). The viral envelop 
proteins hemagglutinin (HA), 
neuraminidase (NA), the matrix 
proteins (M2) are embedded into the 
membrane. 
Neuraminidase (NA)
Hemagglutinin (HA)
Matrix 
protein (M2)
Matrix 
protein
(M1)
RNA with nucleocapsid
proteins (N) and
RNA polymerase
(PB1, PB2, PA)
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virus (CCHFV) (120). Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne viral 
disease, which is endemic in the Balkans, the Middle East, Asia and parts of Africa (120) (Fig. 
5). There, the virus frequently infects patients, and is, thus, responsible for 140 outbreaks 
and 5,000 cases since its discovery (10). Infected patients suffer from haemorrhage, myalgia 
and fever, and succumb to disease in 3 to 30% of cases (86, 185). The virus is transmitted 
to humans or other mammals by arthropod tick vectors of the Hyolomma genus (120, 185). 
However, people may also become infected via contact with body fluids of patients in the 
acute phase of infection, or by contact with blood or tissue of viraemic livestock (292).  
 
CCHFV is an enveloped single-stranded negative-sense (ss(-)) RNA virus and belongs to the 
family of Bunyaviridae and the genus Nairovirus (83). The segmented genome consists of 
three RNA segments, the S (small), M (medium), and L (Large) segment, which encode for 
the nucleoprotein, the glycoproteins Gn and Gc (previously G1 and G2), and the RNA-
dependent polymerase, respectively (110) (Fig. 6). The glycoproteins, probably Gc, are 
responsible for viral attachment to the receptor, which so far remains unidentified, but is 
presumably nucleolin in humans (308).  
 
Although the M segment encoding for Gn and Gc reveal 31% nucleotide or 27% amino acid 
(aa) variability among seven different strains (71), Gn and Gc are usual targets of 
experimental vaccines. So far developed vaccines include a DNA vaccine (256), transgenic 
plants (101), or modified vaccinia virus Ankara (MVA) (40, 77). Indeed, in contrast to the 
more conserved N protein (20 and 8% nucleotide or aa variability, respectively) (76), 
expression of the glycoproteins by MVA was shown to induce protective immune responses 
Hyalomma tick vector presence
5-49 cases per year
50 and more cases per year
Number of reported cases:
CCHFV virological or serolocical evidence and vector presence
50°North latitude: Limit for geographic distribution of genus Hyalomma ticks
Gn
Polymerase (L)
Gc
L
S
MNucleoprotein (N)
Glycoproteins (G)
Fig. 6 Structure of CCHFV.  Schematic 
depiction of a Crimean-Congo haemorrhagic 
fever virus (CCHFV) particle. The RNA is 
organized in three segments, the small (S), 
middle (M) and large segment (L). The S 
segment encodes for the nucleocapsid 
proteins (N), the L segment for RNA 
polymerase proteins (L) and the M Segment 
for the glycoproteins (G) Gc and Gn.  
Fig. 5 Distribution of 
CCHFV.  Global 
distribution of human 
cases with confirmed 
CCHFV infections. 
Countries of confirmed 
cases are colored in 
yellow or red 
depending on case 
numbers. White, 
presence of the genus 
Hyalomma ticks. 
Modified after (299). 
 
IN T R O DU C T IO N  
 
 10 
in mice (40, 77). However, the only vaccine used in humans so far, which was introduced in 
1974, is based on inactivated material of infected mouse brains (207). Although the vaccine 
induced antibody (Ab) responses in 96 % of immunized patients (185), it is not well 
characterised and the method of preparation makes a broad applicability unachievable. 
Moreover, antiviral treatment of infected patients with ribavirin is beneficial, but not 
approved in many countries (87). Consequently, the wide distribution of the BSL-4 virus; 
the severity of the disease; high-case fatality, as well as a fear of bio-terrorism, makes 
development of appropriate vaccines prudent (87). Moreover, factors like climate change 
favour the distribution of ticks as vectors and may thus lead to infection cases in more 
temperate climate zones (88, 104). 
What the emerging viruses MERS-CoV and H7N9, as well as the frequently re-emerging 
CCHFV, have in common is that they reveal a high pathogenicity and an alarming case 
fatality rate in human patients. Pathogenicity of a virus is mostly determined by the 
capability of the human innate and adaptive immune system to control the virus. Viruses 
which evade or suppress the immune responses will usually persist in the patient’s body for 
a longer period of time. This, consequently, may not only increase the frequency of virus-
induced damages to the organism, but may also extent the period of virus transmissibility 
among patients. Thus, the role of the innate and adaptive immune system in viral clearance, 
as well as potential evasion strategies will be described in the following sections. 
 
1.2. Viral clearance by type I INFs 
Usually, pathogen associated molecular patterns (PAMPs) such as conserved molecular 
motifs of viral RNA or DNA, are immediately recognised by pattern recognition receptors 
(PRR) after pathogen entry (193). This recognition then initiates signalling cascades, 
resulting in innate immune responses which are mediated by, for example, the secretion of 
various proinflammatory cytokines. These cytokines may act antivirally by, for example, the 
recruitment of other immune cells (chemokines) or binding to specific receptors in an 
autocrine or paracrine manner. The binding then results in the expression of antiviral 
factors through the activation of signal cascades (106). A potent group of antiviral 
proinflammatory cytokines exists in the family of interferons (IFNs), the type I, II, and III 
IFNs (127). Among these, the type I IFNs, including the well-characterized IFN-αfamily and 
IFN-βare the most immediate and most effective innate immune response against many 
viruses (106, 173, 240). Therefore, this section will focus on mechanisms inducing type I 
IFNs and their downstream effects.  
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Fig. 7 Expression and effects of type I IFNs . (A) Schematic depiction of signal cascades triggering type I IFN 
expression. Viral nucleotides are sensed by TLR3 (dsRNA), 7, 8 (ssRNA) and 9 (CpG motives of DNA) in the 
endosome or RIG-I (dsRNA) in the cytosol after viral entry. TLR activation results in a TRIF or MyD88 
dependent activation of transcription factors (TF) IRF3/7, NFκB and activating transcription factor -2/c-Jun 
(ATF-2/c-Jun). RIG-I sensing causes an MAYS dependent activation of IRF3, NFκB and ATF -2/c-Jun. The 
binding of TFs to the IFN-α/β promotors results in the expression of IFN -α/β. (B) Schematic depiction of signal 
cascades downstream of IFNAR binding. IFN-α/β bind in an autocrine or paracrine manner to the IFN-α/β 
receptor (IFNAR), which induces an Tyk2/JAK1 dependent activation of STAT. IRF9 forms a complex with 
activated STAT molecules resulting in the transcription of ISRE including IRF7 and other antiviral molecules. 
IRF7 induces further expression of IFN-α/β. Modified after (240, 115). 
Almost every cell type is capable of secreting type I IFNs upon viral infection (193). 
However, while non-immune cells like epithelial cells or fibroblasts predominantly secrete 
IFN-, haematopoietic cells, especially plasmacytoid dendritic cells (pDCs), are the major 
producer of IFN-α in addition to IFN-β (127). The expression and secretion of both type I 
INFs upon viral infection is induced after sensing viral nucleotides within the cells (29) or 
for some viruses like cytomegalovirus (CMV) (28, 52) or respiratory syncytial virus (RSV) 
(113, 156) by the recognition of viral proteins via Toll-like receptors (TLR) 2 or 4 at the cell 
surface (29, 306). Viral nucleotides, including DNA and RNA, are sensed by TLR3, 7, 8, or 9 
within endosomes (4), or by retinoic acid inducible gene (RIG-I)-like receptors (RLRs), 
including RIG-I (315), MDA5 (melanoma differentiation factor 5) (9), or LPG2 (laboratory 
of genetics and physiology 2) (316) in the cytosol (315). After binding their cognate PAMP, 
both PRR families, TLRs and RLRs, induce signal cascades resulting in the phosphorylation 
of the transcription factors IRF-3, IRF-7, NF-κB, or activating transcription factor-2/c-Jun 
(ATF-2/c-Jun) (193)(Fig. 7A). These factors initiate the expression of IFN-α/β and, 
simultaneously, genes encoding for another group of IFNs, the type III IFNs IFN- λ1, IFN- λ2 
and IFN- λ3, which have the same antiviral functions (204).  
Subsequently, IFN-α/β bind in an autocrine or paracrine manner to the IFN-α/β receptor 
(IFNAR) resulting in the expression of IFN stimulated genes (ISGs). These genes encode for 
various antiviral and immune-modulatory factors, which mediate further IFN-α/β secretion 
through a positive feedback loop (IRF-7) (119, 127, 240); or trigger mechanisms like the 
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degrading of viral RNA, or an inhibition of viral translation (193) (Fig. 7B). Several reports 
demonstrated that IFNAR knockout mice (IFNAR-/.) reveal significantly higher lethality 
upon infection with various viruses; among others CCHFV (24), chikungunya virus (CHIKV) 
(234) or the measles virus (189). These data clearly emphasise the significant role of type I 
IFN-induced immune responses for viral defence. 
Many viruses therefore, usually develop mechanisms to evade these innate immune 
responses. Influenza A viruses, for instance, are known to hide their dsRNA from 
recognition by RIG-I through encapsidation (111). Moreover, influenza viruses inhibit the 
activation of IRF-3 (268), NF-κB (286) or ATF-2/c-Jun (166) by the viral non-structural 
protein NS1. Coronaviruses likewise encapsidate IFN-inducing-RNA PAMPs (152, 168) and 
hide cytosolic dsRNA in double-membrane vesicles during replication (151, 277, 278). 
These strategies make viral RNA less visible for cytosolic PRR recognition. Moreover, 
proteins encoded by SARS-CoV-like nsp-16, prevent RNA recognition by MDA-5 (180, 334) 
or interfere with upstream (for example, IRF3-activation (70, 98)) or downstream IFN 
signalling (for example, STAT1 phosphorylation (289)). Interestingly, MERS-CoV has also 
failed to induce type I IFN responses in human epithelial cells (46, 147, 330) or 
macrophages (325), thus indicating that the virus does also counteract the IFN system. In 
fact, MERS-CoV encodes for IFN suppressive proteins like ORF4a, that interact with dsRNA 
(200, 249), suppresses the PACT mediated activation of RIG-I and MDA-5 (250) and inhibits 
ISG transcription (311).  
Evasion strategies from innate immune responses like those described for SARS- or MERS-
CoV might result in inefficient viral clearance and thus, increased pathogenicity or 
prolonged persistence of the virus (149). On the other hand, a dysregulation of cytokine 
secretion by cells of the innate immune system, might even cause immuno-pathogenicity, 
as is already assumed for SARS-CoV (41, 63). Both immune evasion and exaggerated 
immune responses, demonstrate that pathogenicity of a virus might be associated with an 
aberrant innate immune response. However, in addition to viral clearance mediated by cells 
of the innate immune system, viral infections are also counteracted by adaptive immune 
responses. Thus, the important role of the adaptive immune system in viral defence, which 
is utilised by vaccination, will be described in the subsequent section.  
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1.3. Viral clearance by immunological memory  
As a reaction to a primary infection by a given pathogen, a T and B cell-mediated adaptive 
immune response develops, which is based on specific recognition of individual pathogens. 
The necessity of adaptive immunity for efficient viral clearance has been demonstrated for 
various viruses, amongst others, rotavirus (222), coronavirus JMH (122), influenza virus 
(206) or hepatitis B virus (310).  
The high specificity of adaptive immune responses is due to the fact that each maturing T 
and B lymphocyte expresses an individual B (BCR) or T cell receptor (TCR) which 
specifically binds to a distinct antigen (193). When TCRs of naïve T cells recognise their 
specific peptide, presented by professional antigen presenting cells (APCs) on major 
histocompatibility complexes (MHCs), they will differentiate into effector T cells (17, 178, 
214). Among these are cluster of differentiation (CD)8+ cytotoxic T cells (CTLs), which 
recognise intracellularly-produced peptides presented on MHC class I (258). CTLs induce 
apoptosis in infected cells by a binding of upregulated Fas ligands (FasL) to Fas (CD95 or 
APO-1), that is expressed on the target cell (68, 228), or by the release of cytotoxic granules 
containing perforin and granzymes (193, 211). In addition to direct cell killing, and thus 
cellular immunity, CTLs induce antiviral immune responses through the secretion of the 
antiviral or immunomodulatory cytokines IFN-γ, Tumor necrosis factor-α (TNF-a), and IL-
2 (68). CTLs are normally detected 5-7 days after onset of infection (68, 106) (Fig. 8). 
Another effector T cell population, so-called T helper cells (TH), are activated if extracellular 
antigens are internalised, processed and presented on MHC class II to naïve antigen-specific 
CD4+ T cells by APCs (106). Their role in viral clearance consists in the secretion of antiviral, 
but also immunomodulatory cytokines, which regulate adaptive and innate immune 
responses (186, 263, 275). Moreover, CD4+ T cells interact with CTLs and B cells by direct 
cell contact and the secretion of immunomodulatory cytokines. Thereby TH cells support 
those to fulfil their respective effector function or to differentiate into memory cells (263).  
Humoral immune responses are characterised by the secretion of immunoglobulin(Ig)s, the 
antibodies (Abs), by plasma cells. Naïve B cells will differentiate into plasma cells, if those 
recognize an a specific antigen (extracellular or presented by follicular DC (FDC)-presented 
antigen) (243) and, consequently become activated in a TH cells dependent or independent 
manner (2). Abs secreted by plasma cells can attach to proteins on the viral surface and 
thereby induce aggregation, or prevent surface proteins from binding to the respective 
receptor and thus viral entry (neutralising Abs; nAbs) (53, 106). Moreover, Ab-covered 
pathogens are recognised by the complement system or Fc-receptor-expressing phagocytes 
resulting in viral clearance by phagocytosis (39, 53). In addition to the pathogen, Abs also 
bind to infected cells covered by viral proteins on their surface. Subsequently, such 
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opsonized cells are lysed through complement-dependent cytotoxicity (CDC) or antibody‐
dependent cellular cytotoxicity (ADCC), mediated by, for example, NK cells or macrophages 
(112, 272, 284).  
A few days after pathogen 
exposure, secreted antibodies are 
mostly composed of IgMs usually 
revealing a relatively low affinity to 
the antigen (2). Highly affine IgGs, 
which underwent affinity 
maturation and isotype switching, 
are, by contrast, detectable 
approximately one week after 
onset of infection at the earliest 
(14) (Fig. 8). Thus, highly affine 
antibody and efficient CTL 
responses take at least one week to 
develop during a primary infection. In contrast, these are immediately triggered in 
subsequent infections, which is based on the development of immunological memory (2). B 
cells contribute to this immunological memory by affinity-maturation into long-lasting 
plasma cells (155) or memory B cells expressing class-switched highly-affine BCRs (150, 
270). Long-lived plasma cells in the bone-marrow are capable of secreting Abs for more 
than 8 months after clearance of infection (60, 159, 252). These Abs, which are mostly 
composed of highly-affine IgGs, can than immediately coat and neutralise newly intruding 
viruses (251). The pool of Ab-producing long-lived plasma cells is replenished by 
immediately activated highly-affine memory B cells upon pathogen exposure, resulting in a 
protection persisting for decades (59). T cells will also differentiate into memory T cells if 
effector cells, which are normally removed after viral clearance to re-balance the immune 
system, evade activation-induced cell death (AICD) (2). CCR7+ effector memory T cells are 
immediately activated in subsequent infections to take over effector function and are 
continuously replenished by re-activated CCR7- central-memory T cells under these 
conditions (158). 
During a second exposure to a pathogen then, an immediate, highly-affine, and effective 
protection is mediated by pre-formed Abs, as well as memory B and T cells. Such an 
immunological memory is not only induced by natural infections, but also by the use of 
vaccines. Effectiveness of vaccines is thus optimally characterised by an induction of long-
lasting Abs and memory T and B cells.  
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Fig. 8 CD8+ T cell and Ab responses after an initial and 
secondary pathogen exposure.  Immune responses after a 
secondary exposure are more rapidly activated. Abs secreted 
by B cells consists of more highly-affine IgGs and less low-
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1.4. Induction of adaptive immunity by vaccination 
The efficacy of classic anti-viral vaccines is mostly ascribed to induction of humoral immune 
responses, since protection often correlates with the presence of specific Abs, particularly 
nAbs (331, 332). Such correlation between humoral immunity and protection has been 
shown for several viruses like SARS-CoV (261, 313), HBV (8) or CHIKV (3, 33). However, 
highly variable viruses like influenza (75) or HIV (246) often evade humoral immune 
responses since broadly reactive Abs are rarely induced and viral escape mutants arise 
quickly (19). CTL responses, on the contrary, are known to target more conserved motifs, 
particularly of inner proteins. Thus, induction of cellular immunity often correlates with 
protection against more variable viruses as, for example, has been determined for Influenza 
viruses (95, 176, 177). Consequently, modern vaccine approaches aim to activate both or 
rather, an appropriate arm of immunity dependent on the individual biology of the 
respective virus. Since immune responses, which might protect against emerging viruses, 
are mostly not known, an induction of both humoral as well as cellular immune responses 
will maximize the chance of being prophylactic.  
 
1.4.1. Classic vaccine strategies: Live-attenuated pathogen, 
inactivated pathogen, or subunit vaccines 
To evoke protection, similar or even superior to that induced by infections, but without 
pathogenicity, less virulent (live-attenuated) strains of the respective pathogen have been 
developed for a range of pathogens like polio virus (7), measles virus (102) or tuberculosis 
(290). In the late 18th century, Edward Jenner observed that cowpox, a bovine, less virulent 
relative of smallpox, prevented smallpox infection (128). This observation was later 
transferred to specifically attenuate virulent microorganisms by passaging them in another 
species or on different cells in vitro (193). However, the use of life-attenuated vaccines may 
also carry risks of reversion to a pathogenic form, as observed in poliovirus (114) or yellow 
fever virus vaccines (160). Furthermore, life-attenuated vaccines can become virulent in 
immunodeficient patients (193). To avoid the risks of reversion, vaccines have also been 
generated by inactivating the pathogen using, for example, formaldehyde (229), gamma 
irradiation (6), or UV treatment (37). The inactivation process may, however, alter epitopes 
or induce atypical immune responses, which might even worsen pathogen-induced disease 
in vaccinated patients after exposure (231). Such adverse effects have actually stopped any 
further application of formaldehyde-inactivated respiratory syncytial virus (RSV) (136) or 
formaldehyde-inactivated measles vaccines (103). Moreover, vaccines based on whole 
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pathogens like killed Bordetella pertussis vaccine (225) might include components which 
display toxic effects or alter immune responses in general (61).  
With the purification or recombinant production of single pathogen subunits, such toxic or 
immunogenic components are removed and their respective side-effects reduced. However, 
the choice of appropriate immunogenic and non-toxic antigens depends on extensive 
knowledge of the pathogen's interaction with its host, such as immune evasion strategies 
(61). Although subunit vaccines offer a more preferable safety profile than inactivated or 
life-attenuated vaccines and face fewer regulatory licensure hurdles than life-attenuated 
pathogens (321), they include the critical disadvantage of low intrinsic immunogenicity 
(Tab. 1). Therefore, application of multiple doses or the addition of immune-stimulatory 
adjuvants becomes necessary (61, 209), which raises the costs of production or 
administration (231). Live-attenuated vaccines, on the contrary, have the advantage of a 
strong inherent immunogenicity. Moreover, they efficiently initiate CTL effector responses 
due to the intracellular production of antigens (30, 163) (Tab. 1). Even though live-
attenuated vaccines bear a potential risk of residual pathogenicity (61) effectively used 
vaccines against diseases like measles, mumps and rubella (Tab. 1) have never reverted to 
a pathogenic form (102). This indicates an excellent safety profile in these examples.  
 
Tab. 1 Comparison of life-attenuated, inactivated and Subunit vaccines. ++, very beneficial; +, beneficial; 
-, unfavourable. 
 
 
1.4.2. Modern vaccine strategies: Enhancement of 
immunogenicity and antigen delivery into cells  
Modern molecular biological techniques enable the development of new vaccine strategies 
which combine the safety of subunits with the immunogenicity of life-attenuated vaccines. 
Recombinant proteins become more immunogenic if they are, for example, fused to 
immune-stimulatory components like flagellin (274) or assembled into virus-like particles 
(VLPs) (201). Indeed, VLPs presenting viral antigens are already successfully used as 
commercial vaccines against HBV (259), human papillomavirus (HPV) (97, 244), or 
hepatitis E (326). Such modernised subunit vaccines nevertheless still have a disadvantage 
in that they normally fail to induce CTL responses (30). Consequently, new vaccine 
Life-attenuated vaccines Inactivated vaccines Subunit vaccines
Immunogenicity
Safety
Costs + ++ -
Induced immune 
humoral and cellular humoral humoral
responses
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approaches not only aim to enhance the immunogenicity, but also to deliver the antigen into 
the cell. Then, processed antigen peptide becomes presented on MHC-I to trigger CTL 
responses. Intracellular expression can be gained, for example, by transfection of DNA 
plasmids encoding the antigen (140, 163) or by a gene transfer through viral vectors. 
Focusing on the latter, suitable vectors are, for example, replication-competent or -
incompetent adenoviruses (Ads), replication-competent vesicular stomatitis virus (VSV), or 
replication-incompetent modified vaccinia virus Ankara (MVA) (198, 226). Several 
preclinical studies using viral vectors targeting viral diseases like AIDS (137) or Ebola (133) 
have shown that respective vectors elicit both humoral as well as cellular immune 
responses and may protect animals from lethal challenge.  
One important advantage of vector-based vaccines is that they provide an opportunity for 
genetic manipulation to, for example, specifically alter vector tropism to target cells like 
APCs (62, 309). Such alteration of tropism can be mediated by expression of foreign 
glycoproteins (62, 99, 181, 309) or a fusion of, for example, single chain fragments directed 
against a specific receptor to already expressed glycoproteins (254, 99, 196). Furthermore, 
immunomodulatory molecules can be co-expressed with inserted antigens to further 
enhance immunogenicity (1). Depending on the organism that the vectors are derived from, 
they also vary in the way the antigen is transferred (198). Retroviral vectors, for instance, 
stably integrate reversely transcribed vector genome into the host's genome. Thus, 
respective genes of interest, for example, the antigen-encoding genes, become stably 
expressed and peptides continuously presented (36). Other viral vectors like those derived 
from Ad, VSV or MV, are characterized by a lack of integration into the host genome. Here, 
antigens are temporary expressed by infected cells and peptides thus presented for a 
limited period of time (224). A temporal presentation of peptides can also be achieved by 
fusion of proteins fused to structural vector proteins, which are then transferred into 
respective target (276, 279). These different methods of manipulation then enable specific 
targeting of individual cell populations, a regulation of immunogenicity, or antigen 
persistence and thereby, adaption to individual characteristics of pathogens.    
Indeed, several viral vectors are already licensed as veterinary vaccines like a vaccinia virus 
vector against rabies (35) or canarypox vector against canine distemper virus (CDV) (213). 
Moreover, the protective efficacy of the VSV vector-based Ebola-vaccine in a phase III trial 
during the recent Ebola outbreak in West Africa (153) demonstrates the future potential of 
vector-based vaccines for application also in human medicine. Indeed, a recombinant 
chimeric yellow-fever based vaccine (YFV 17D) expressing the structural prM and E 
proteins of Japanese-encephalitis Virus (JAV) strain JEV SA14 -14-2 is already available for 
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human vaccination against JAV in Australia and Thailand (ChimeriVax-Je, IMOJEV, JE-CV, or 
THAIJEV) (226, 319). 
Thus, potential vaccine strategies against MERS-CoV, H7N9 or CCHFV may consist in life-
attenuated or inactivated whole viral particles. While these approaches would include risk 
of reversion to wild type form or of altered immune responses by inactivation, 
administration of purified antigens would reveal poor immunogenicity. To combine the 
immunogenicity of life-attenuated vaccines with the safety of recombinant proteins, 
antigens of these pathogens might be co-expressed by already characterised (and hence, 
safe) vaccine platforms. Among life-attenuated virus vaccines, the measles virus (MV) 
vaccine combines efficacy, characterized by long-lasting immunity, with remarkable safety 
(102) and may thus be used as a suitable vaccine platform.    
 
1.5. MV as vaccine platform 
The approval of the life-
attenuated measles virus (MV) 
vaccine in the 1960s (102, 238) 
resulted in a significant 
reduction of MV-associated 
worldwide death cases, from 
more than 6,000,000 yearly in 
1963 to approximately 345,000 
in 2005 (302) (Fig. 9). This 
illustrated efficacy is, moreover, 
accompanied by an excellent 
safety profile, which is depicted 
by a low rate of adverse effects 
during its application as vaccine in billions of doses over more than 60 years (102, 238).  
Attenuation of the original Edmonston wild type (wt) MV isolate from 1959 to vaccine 
strains was conducted by passages in chicken embryo fibroblasts (84). This in vitro 
passaging resulted in mutations which, amongst other effects, shifted the virus tropism 
(267). MV, in its virulent form, targets the signalling lymphocyte activation molecule (SLAM 
or CD150) expressed on immune cells (269) as well as Nectin-4 on epithelial cells (190, 
202). The SLAM-mediated specificity for immune cells is expected to be a cause for MV-
induced immunosuppression (12, 187, 203) and thus causative for serious secondary 
infections (96, 124). MV vaccine strains, on the contrary, use CD46 as an additional receptor, 
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which is expressed on all nucleated cells. Thus, additional binding to CD46 results in a 
reduction of the virus specificity for immune cells (197).  
 
Due to availability of a recombinant rescue system (175, 218) recombinant MV vaccines 
(rMVs) can be rapidly produced from DNA plasmids. This allows genetic manipulations like 
the insertion of additional gene segments. In general, MVs non-segmented viral ss(-)RNA 
genome is organised in gene cassettes separated by intergenic regions, which contain 
sequences regulating viral gene transcription. Since each transcription unit is flanked by 
individual start and stop sequences, the viral polymerase complex individually transcribes 
each genome cassette. This organisation allows easy insertion of additional transcription 
units (ATUs) up to 6 kb between different genome cassettes into the genome (27). These 
ATUs are then co-expressed with the viral proteins, the nucleocapsid protein (N), 
phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin (H) and the large 
proteins (L) (78) (Fig. 10). Re-initiation of transcription is not 100% successful at each start-
stop signal, and thus leads to a transcription gradient of the MV genome from 3’ to 5’ with 
the highest expression of the N- gene (42). This property can be utilised to regulate the 
expression of the inserted genes by the choice of genomic position the genes are inserted 
into (67).  
Recombinant rescue technology enables not only the production of MV expressing marker 
genes (81) or immunomodulatory proteins like IL-12 (247), but also foreign bacterial (125) 
or viral antigens, as summarised in Tab. 2. These experimental MV-based vaccines were 
shown to induce both antigen-specific humoral as well as cellular immunity against viruses 
like HIV (164), SARS-CoV (161), or chikungunya virus (CHIKV) (33). Moreover, induced 
immune responses protected mice (HIV, WNV, CHIKV) (33, 69, 164) and non-human 
primates (HIV, WNV) (32, 164) against lethal challenge with HIV, WNV or CHIKV and thus 
demonstrated MVs efficiency as a vaccine platform. Interestingly, pre-formed immunity 
against MV was shown to have no effect on the induction of pathogen-specific antibodies in 
MV-CHIKV vaccinated mice (33, 164), MV-HIV vaccinated non-human primates (164) or 
N P/C/V M F H L3‘ 5‘
Hemagglutinin (H)
Fusion 
protein (F)
Matrix 
protein (M)
Nucleocapside
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Large 
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Fig. 10 Measles viruses 
structure. Schematic 
depiction of a measles virus 
particle. The genome 
encodes for the structural 
proteins nucleocapsid 
protein (N), phosphoprotein 
(P), matrix protein (M), 
fusion protein (F), 
hemagglutinin (H) and the 
large (L) proteins as well as 
the accessory proteins C and 
V. The genes are organized 
in transcriptions units. 
 
IN T R O DU C T IO N  
 
 20 
even in MV-CHIKV vaccinated human patients (219). Moreover, vaccinated mice were 
protected against CHIKV exposure (33) irrespective of pre-existing immunity. These results 
indicate that MV-based vaccine platforms are applicable in both naïve and pre-immune 
patients. 
Tab. 2 Experimental MV-derived vaccines . n.t not tested 
Pathogen Antigen Position Response Protection Reference 
HBV sHBsAg P, H, L α-HBsAg-Abs, nAbs n.t. (MV) (248, 67) 
Mumps HN or F P n.t. n.t. (287) 
SIVmac Env (+ Gag) P α-SIV-env-Abs n.t. (287, 333) 
WNV E P nAbs Yes (69) 
HIV-1 Env P α-HIV-1-env-Abs, nAbs, IFN-γ-ICS n.t. (164, 165) 
Dengue EDIII, ectoM P α-EDIII/M-Abs, nAbs, Cytokines  n.t. (31) 
SARS-CoV S, N P α-SARS-S-Abs, α-SARS-N-Abs nAbs, 
IFN-γ-ELISpot  
n.t. (161) 
CHIKV C-E3-E2-6K-E1 
(VLPs) 
P α-CHIKV-E2-Abs, nAbs, IFN-γ-
ELISpot, nAbs in humans 
Yes (33, 219) 
 
Taken together, rMVs can be rapidly and easily produced and allow the insertion and co-
expression of antigens encoded by heterologous gene fragments up to at least 6 kb. 
Moreover, they induce both humoral and cellular immunity, which have been shown to be 
protective in challenge experiments. These characteristics, as well as MV’s efficacy and 
safety, illustrated by a 50-year application without severe adverse effects, make it a 
promising pre-pandemic vaccine platform. 
 
1.6. The aim of this thesis 
The aim of this PhD thesis was to generate and characterise potential pre-pandemic vaccine 
candidates derived from the well-known replication-competent MV vaccine platform. To 
test MV's applicability against phylogenetically distinct viruses, the highly-pathogenic 
emergent viruses MERS-CoV and H7N9, as well as the frequently re-emergent CCHFV have 
been chosen as examples. However, the development of most efficient antiviral drugs and 
vaccines is based on detailed knowledge of how viral mechanisms mediate pathogenicity. 
Since knowledge is limited for emerging viruses, this thesis also aimed to gain insights into 
MERS-CoV's pathomechanisms, thereby focusing on induced innate immune responses.  
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Interaction of MERS-CoV with innate immune cells: Previous studies demonstrated that 
MERS-CoV failed to induce a secretion of antiviral type I IFNs in human epithelial cells (330, 
46, 147) or macrophages (325). These observations indicate that MERS-CoV developed a 
mechanism to inhibit type I IFN responses, which might be crucial for the progress of 
disease. Consequently, this thesis aims to identify potential alternative sources of type I and 
II IFN production via the inoculation of different human and murine APCs (Macrophages, B 
cells, pDCs, or mDCs) with MERS-CoV. The insights gained into the interaction of MERS-CoV 
with cells of the innate immune system might uncover new opportunities to develop 
antiviral drugs and vaccines in the future.      
Setting up a system to re-stimulate T cells ex vivo and to analyse T cell responses: In 
conjunction with the generation of vaccine candidates, appropriate immune assays such as 
the neutralisation test, ELISpot- or T-cell killing assays, had to be established in advance to 
analyse immune responses in vaccinated animals. For this purpose, antigen-transgene DC 
cell lines were generated and tested to re-stimulate in vivo primed T cells, independent of 
knowledge about immunodominance and commercial availability of respective 
immunogenic peptides. Respective DC cell clones should not only be used to test material 
from mice vaccinated with recombinant MVs, but also with a distinct platform: LV protein 
transfer vectors (LV-PTVs).  
Generation and characterisation of vaccine-derived MV as pre-pandemic vaccine platform: 
The main part of this thesis aims to test the applicability of MV as a vaccine platform against 
emerging infections. For that purpose, recombinant MVs expressing full-length and 
truncated forms of envelope or nucleoproteins of MERS-CoV, H7N9 and CCHFV should be 
generated to identify the most immunogenic vaccine candidates. Subsequent in vitro 
characterisation of these vaccines should than include a validation of their stable 
integration into rMV's genome, as well as antigen expression and their impact on the 
vaccine's replication. After vaccination of MV-susceptible IFNAR-/-CD46Ge mice, induced 
humoral and cellular immunity should be tested using the established methods. Finally, a 
set of appropriate challenge experiments had to be established to demonstrate whether the 
induced immune responses are effective in protecting against viral infection.   
Consequently, the results gained from this thesis will uncover whether MV constitutes a 
sufficiently robust and efficient platform to protect against emerging infections. It is hoped 
that recombinant vaccine-derived MVs can be used in the future to immediately react to 
increased pandemic threats involving key viruses, as well as offering a way to act against 
any new emerging pathogens.  
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2. OWN CONTRIBUTION 
Three publications form part of this cumulative PhD thesis. My own contribution to these 
publications in detail is as follows: 
a) High secretion of interferons by human plasmacytoid dendritic cells upon 
recognition of Middle East respiratory syndrome coronavirus. Scheuplein VA, 
Seifried J*, Malczyk AH*, Miller L, Höcker L, Vergara-Alert J, Dolnik O, Zielecki F, 
Becker B, Spreitzer I, König R, Becker S, Waibler Z, Mühlebach MD. J Virol. 2015 
Apr;89(7):3859-69. doi: 10.1128/JVI.03607-14. Epub 2015 Jan 21. 
*equally contributed 
As a contributing author to the publication “High secretion of interferons by human 
plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome 
coronavirus”, I provided detailed, hands-on support during the planning and execution 
phases of the experiments. In detail, I supported Dr Scheuplein in isolating murine bone-
marrow derived cells in two independent experiments. Moreover, I participated in several 
infection experiments of murine and human immune cells with MERS-CoV, as well as the 
execution of ELISAs (Fig. 1A, Fig. 2A, Fig. 3A-L, Fig. 4C), the determination of MERS-CoV's 
replication kinetics on different APCs (Fig. 1B, Fig. 2A) and the isolation of viral RNA (Fig. 
2B). Additionally, I was responsible for western blot analysis (Fig. 5 B-D) and for the design 
of Fig. 6. Furthermore, I participated in the data analysis of all respective experiments and 
in the proofreading of the final manuscript.  
b) Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and 
Induce a Strong Antigen-Specific Cytotoxic T Cell Response. Uhlig KM, Schülke 
S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, 
Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD. J Virol. 
2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17. 
Regarding the publication “Lentiviral Protein Transfer Vectors Are an Efficient Vaccine 
Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response”, I was responsible 
for the set-up and implementation of assays for determining T cell-mediated cellular 
immunity. For that purpose, I conducted preliminary experiments to establish appropriate 
cell numbers and peptide concentrations in order to re-stimulate T cells which were 
isolated from vaccinated mice. I supported the diploma student Bianca Bodmer by 
performing preliminary experiments aimed at revealing the applicability of the Ova-
transgenic DC cell line JAWSIIGreen-Ova (generated by Bianca Bodmer) to stimulate Ova-
specific T cells using OT-1 or OT-2 T cells from respective transgenic mice. I also assisted 
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during the isolation of splenocytes from vaccinated mice, magnetic bead sorting and the re-
stimulation of T cells (Fig. 7, Fig. 8). Moreover, I evaluated the ELISpot analysis (Fig. 7, Fig. 
8) and operated the western blot analysis detecting VSV-G, MV-H, or MV-F (Fig. 2D-F, 3G-I). 
In addition, I participated in data analysis of the respective experiments and proofreading 
the manuscript. 
c) A Highly Immunogenic and Protective Middle East Respiratory Syndrome 
Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. 
Malczyk AH, Kupke A*, Prüfer S*, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, 
Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, 
Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, 
Eickmann M, Becker S, Mühlebach MD. J Virol. 2015 Nov;89(22):11654-67. doi: 
10.1128/JVI.01815-15. Epub 2015 Sep 9. 
*equally contributed 
In connection with the publication, “A Highly Immunogenic and Protective Middle East 
Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine 
Platform”, I was responsible for the set-up of the main experiments. I obtained the 
recombinant MV-MERS vaccines in passage 3 by Steffen Prüfer and subsequently 
characterised the vaccines in vitro. Here, I was responsible for the isolation and sequencing 
of viral RNA, as well as validation of antigen expression, analysis of replication kinetics, and 
long-term passaging of viral vaccines until passage 10, with subsequent re-characterisation 
for conserved vaccine properties. I also generated respective lentiviral gene transfer vectors 
(cloning, transfection, purification) to produce MERS-S- or MV-N-transgenic DC cell lines 
and selected the most appropriate cell clones after validation of stable antigen expression. 
Furthermore, I established the assays for analysis of cellular (ELISpot, proliferation, killing 
assay) and humoral (α-MERS-S ELISA and α-MERS neutralisation assay) immune responses. 
Supported by Steffen Prüfer and Dr Scheuplein, I immunised MV-susceptible IFNAR-/-
CD46Ge mice, which had been bred with the assistance of Dorothea Kreuz, using C57BL/6 
background IFNAR-/- mice provided by Prof Kalinke. Supported by Steffen Prüfer, Dr 
Scheuplein, and Dr Hutzler, I collected mouse tissue, and with support of Dr Scheuplein, I 
analysed the induced humoral and cellular immune responses. Additionally, I was 
responsible for vaccinating mice for the challenge experiments. These were shipped to our 
collaborating partners in Marburg, where a challenge model had been set up (in cooperation 
with colleagues from the University of Gießen). In Marburg, the transduction as well as 
challenge of mice were conducted. I was responsible for generating respective figures based 
on all experimental data. Together with Dr Mühlebach, I also wrote the text for the 
manuscript.   
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The results published in these manuscripts, as well as some as yet unpublished data, are all 
described in Section 3 as continuous text, irrespective of my own contribution. Nonetheless, 
those experiments where I did not participate are clearly indicated and the respective 
persons who did in fact conduct the experiments, are all named in footnotes.  
 
With my signature, I confirm the correctness of the declaration in section 2. 
 
Marburg, 28-02-17 
 
 
Anna Fiedler                  Prof. Dr Stephan Becker 
(author)       (supervisor) 
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3. RESULTS 
3.1. Analysis of interactions of MERS-CoV with the innate 
immune system 
Among antiviral innate immune responses, the secretion and action of type I IFNs has a 
significant role in virus clearance (193). However, initial studies have demonstrated that 
MERS-CoV fails to induce the production of type IFNα/β in human epithelial cells (330, 46, 
147) and macrophages (325), thereby indicating that the virus somehow inhibits the 
production of IFNs. Interestingly, the coronavirus relative SARS-CoV, does provoke a type I 
IFN response by pDCs (44) even though the virus failed to induce a secretion of IFN-α or 
IFN-β by epithelial cells (46) or macrophages (47, 329). Since MERS-CoV is even more 
sensitive to type I IFN treatment than SARS-CoV (330), a comparable IFN-α/β production 
by pDCs or other APCs may prove to be crucial for the outcome of disease. Thus, the first 
part of this PhD thesis aimed to identify possible sources of type I or III IFNs upon MERS-
CoV infection by the inoculation of different APCs of murine and human origin with MERS-
CoV.  
 
3.1.1. Analysis of type I IFNs and viral replication in murine and 
human APCs 
To first test the capability of murine APCs to secrete type I or III IFNs upon MERS-CoV 
infection, mDCs, pDCs and macrophages were derived from bone marrow cells and 
peritoneal exudate cells (PECs) isolated from the peritoneal cavity of wildtype (wt) 
C57BL/6 (BL/6) mice1. After inoculation with MERS-CoV, the secretion of IFN-α, -β, and -λ 
into supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA). 
However, none of the analyzed murine APCs secreted type I or III IFNs upon MERS-CoV 
infection, although they were in general responsive to treatment with appropriate positive 
controls (Scheuplein et al., 2015, Fig. 1A). Moreover, the virus did not replicate in murine 
cells (Scheuplein et al., 2015, Fig. 1B), which is consistent with absent capacity of MERS-CoV 
to infect murine cells, as later published (51).  
To analyse the IFN response by human APCs, B cells, pDCs, and monocytes were isolated 
from the blood of healthy human donors and monocytes were differentiated into monocyte-
derived DCs (MDDCs), M1, or M2 macrophages2. APCs were then inoculated with MERS-
CoV. Subsequent analysis of type I and III IFN secretion showed that neither M1 
                                                             
1 For most experiments, cells were isolated by Dr Miller and Dr Höcker, Paul-Ehrlich-Institut, Langen 
2 Cells isolated by Dr Scheuplein, Dr Miller, or Dr Seilfried, Paul-Ehrlich-Institut, Langen 
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macrophages, M2 macrophages, B cells, nor MDDCs secreted IFN-α, -β, or -λ upon MERS-
CoV infection (Scheuplein et al., 2015, Fig. 2A). Furthermore, the virus did not replicate in 
those cells (Scheuplein et al., 2015, Fig. 2C). On the other hand, pDCs, secreted both IFN-β 
and -λ, as well as high amounts of IFN-α. The secretion of IFN-α and IFN-β was significantly 
enhanced in comparison with SARS-CoV (Scheuplein et al., 2015, Fig. 2A). Moreover, pDCs 
became initially infected by MERS-CoV, since viral RNA copy numbers of MERS-E protein 
(Scheuplein et al., 2015, Fig. 2B) and expression of MERS-CoV nucleocapsid protein (MERS-
N) (Scheuplein et al., 2015, Fig. 5) was demonstrated in infected cells. However, as observed 
in other APCs, the virus failed to fully replicate in pDCs (Scheuplein et al., 2015, Fig. 2C). 
 
3.1.2. Role of receptor binding and endosomal transport for 
MERS-CoV infection and IFN secretion  
While MERS-CoV did not trigger a type I or III IFN response in most human APCs, pDCs 
secreted high amounts of, particularly, IFN-α. Interestingly, human, but not murine pDCs, 
were responsive to MERS-CoV inoculation. Since MERS-CoV has in the meantime been 
shown to utilise human DPP-4, but not murine DPP-4 for cell entry (49), it was hypothesised 
that the observed IFN secretion depends on receptor binding. To test this hypothesis, pDCs 
were pre-treated with the receptor binding domain (RBD) of MERS-CoV Spike protein 
(MERS-S), which binds to huDPP-4 and thus hinders MERS-CoV from receptor binding 
(188). It was discovered that, pre-incubation with RBD, but not control protein, is in fact 
responsible for the inhibited production of IFN-α, -β, and -λ (Scheuplein et al., 2015, Fig. 3D-
F). However, in the case of unspecific CpG treatment, used as general stimulus for the IFN 
induction, IFN secretion of RBD-co-treated pDCs also became abolished (Scheuplein et al., 
2015, Fig. 4C). This indicates that MERS-S RBD may possess general immune-suppressive 
properties. Nevertheless, both the RBD and, in particular, polyclonal sera binding DPP-4, 
inhibited the expression of MERS-N in pre-incubated cells. This demonstrates that the 
infection of pDCs depends on the binding of MERS-CoV to DPP-4 (Scheuplein et al., 2015, 
Fig. 5C). 
When the acidification of endosomes was blocked by chloroquine treatment, the numbers 
of MERS-CoV-N and MERS-CoV-E RNA copies appeared to be significantly reduced 
(Scheuplein et al., 2015, Fig. 5A). The secretion of IFN-α, -β, or -λ was likewise significantly 
inhibited, indicating that the infection and IFN secretion depends on endosomal uptake 
(Scheuplein et al., 2015, Fig. 3G-I). Moreover, pre-treatment with the TLR7 inhibitor IRS661, 
reduced the secretion of IFN-α, -β, or -λ (Scheuplein et al., 2015, Fig. 3J-L). These results 
imply that secretion of these IFNs is most likely, at least in part, mediated through 
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recognition of viral RNA via TLR7. Interestingly, UV-inactivated MERS-CoV3 induced similar 
amounts of IFN-α and IFN-λ, but significantly less IFN-β (Scheuplein et al., 2015, Fig. 3A-C). 
These results further indicate that secretion of IFN-β depends on recognition of intact viral 
RNA. 
Thus, this data, published in Scheuplein et al., demonstrated that MERS-CoV predominantly 
triggers secretion of type I and III IFN by human pDCs. These antiviral innate immune 
responses were shown to depend on endosomal, probably DPP-4-mediated, uptake and at 
least in part, on the sensing of viral RNA via TLR-7 in the endosome. The relevance of the 
exclusively pDC-attributed type I and III IFN production for MERS-CoV pathogenicity is so 
far not understood. However, to protect against pathogenicity of MERS-CoV, the generation 
of vaccines against MERS-CoV is considered to be beneficial to efficiently clear virus 
infection.  
 
3.2. Generation and in vitro characterisation of MV-MERS-
CoV, MV-H7N9 and MV-CCHFV vaccines 
During the ongoing epidemic in the Middle East, MERS-CoV was identified as a priority 
pathogen for vaccine development in the WHO research and development (R&D) blueprint 
plan, in addition to, CCHFV and other highly pathogenic viruses (295). Consequently, the 
aim of this thesis was to produce broadly immunogenic MV based-vaccines, not only against 
MERS-CoV and CCHFV, but also against influenza A virus subtype H7N9 - another highly 
pathogenic emergent virus.  
For this purpose, certain envelope glycoproteins that mediate receptor binding were chosen 
to act as suitable antigens to induce particulary neutralising antibodies (nAbs). The 
glycoproteins chosen were spike protein (MERS-S) of MERS-CoV, the haemagglutinin of 
subtype 7 (H7) of H7N9, and Gc and Gn of CCHFV. However, in contrast to membrane-bound 
proteins like viral envelope glycoproteins, soluble antigens are normally more efficiently 
taken up by B cells (16, 21, 208) and are thus more efficient in inducing humoral immune 
responses (85). Since protection against SARS-CoV correlates with humoral immunity (261, 
313), a truncated soluble version of MERS-S (MERS-solS) was consequently cloned to 
further enhance humoral immunity. This approach was also applied to the prospective 
CCHFV-vaccine. Soluble and membrane-bound variants of CCHFV-Gc and CCHFV-Gn were 
inserted into the MV genome (Fig. 11). Since influenza viruses are known to evade nAbs 
directed against HA, the more conserved envelope glycoprotein neuraminidase (NA) N9 
                                                             
3 Inactivation performed by Dr Scheuplein, Paul-Ehrlich-Institut, Langen 
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was chosen as another suitable antigen for an MV-based vaccine against H7N9. The 
nucleocapsid proteins of MERS-CoV (MERS-N) and CCHFV (CCHFV-N) were additionally 
selected to induce cellular immune responses directed against the more conserved inner 
proteins of MERS-CoV and CCHFV.  
 
These antigens were inserted into additional transcription units (ATUs) after the gene 
cassettes encoding for the P (post-P) or the H protein (post-H) (Malczyk et al., 2015, Fig. 1A) 
of the Moraten vaccine strain clone MVvac2, respectively. The insertion into two different 
positions enabled a different expression of the antigens, which is normally higher in the 
post-P, as opposed to the post-H, position. All viruses were successfully rescued and MVvac2-
MERS4 and MVvac2-H7N95 viruses passaged until passage 10 (P10). 
No mutations in the extra expression cassettes in the viral genome were identified, even 
after ten passages, indicating the genetic stability of these vaccines. Moreover, the viruses 
efficiently expressed MERS-S, MERS-solS (Malczyk et al., 2015, Fig. 1B), MERS-N (Fig. 12A), 
H7 (Fig. 12B), N9 (Fig. 12E), CCHFV-Gc, CCHFV-Gc-FL, CCHFV-preGc, CCHFV-preGc-FL, 
CCHFV-G-FL (Fig. 12D) or CCHFV-N (Fig. 12C). As expected, all viruses, except for MERS-S 
and MERS-solS, revealed stronger antigen expression when the antigens were encoded by 
the post-P ATU. However, the Ab utilised for the detection of CCHFV-Gn failed to display 
expression of Gn variants encoded by the respective recombinant vaccines, or in an 
appropriate positive control, inactivated CCHFV-particles (data not shown). 
                                                             
4 Plasmids cloned by Christiane Tondera, viruses rescued by Steffen Prüfer, Paul-Ehrlich-Institut, Langen 
5 Plasmids and viruses generated by Bianca Bodmer during her internship under supervision of Dr Hutzler,  
  Paul-Ehrlich-Institut, Langen 
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Fig. 12 Antigen expression triggered by prospective MV derived vaccines against MERS -CoV, H7N9, or 
CCHFV. (A-E) Immunoblot analysis of Vero cells infected at an MOI of 0.03 with indicated viruses. Uninfected 
cells served as mock controls. Arrows indicate specific bands. Lower blots were probed using a mAb reactive 
against MV-N. Upper blots were probed using (A) α-MERS-CoV rabbit serum, (B) rabbit serum reactive against 
H7N1, (C) a mouse α-CCHFV-N # 9D5 mAb, or (D) a mouse α-CCHFV-preGc # 11E5 mAb. (E) Neuraminidase 
activity assay for analysis of N9 expression. Uninfected or MV vac2-GFP(N) infected cells served as negative and 
pGAGGS-NA transfected 293T cells as positive controls (PC); *transfected 293 T cells;  n=3. 
Despite the insertion of gene fragments up to 5 kb, 22 out of 24 viruses showed no 
significant changes in their replication pattern when compared to control viruses 
expressing GFP (Malczyk et al., 2015, Fig. 1C-D) (Fig. 13A-E). However, MVvac2-CCHFV-
solGn(P) and MVvac2- CCHFV-G-FL(P) reached 34-fold (7.6x104 TCID50/ml versus 2.6x106 
TCID50/ml MVvac2- GFP(P)) and 45-fold (5.8x104 TCID50/ml versus 2.6x106 TCID50/ml 
MVvac2- GFP(P)) reduced maximum cell-associated titres compared to control viruses, 
respectively, indicating that the expression of these antigens somehow impairs viral 
replication (Fig. 13C, E; red curves). 
 
Fig. 13 Growth kinetics of prospective MV-derived vaccines against MERS-CoV, H7N9, or CCHFV. Growth 
kinetics of recombinant MV on Vero cells infected at an MOI of 0.03 with  indicated MVvac2 encoding for (A) 
MERS-CoV-N, (B) H7, N9, or  (C) CCHFV-G-FL, CCHFV-N, (D)CCHFV-preGc-FL, CCHFV-preGc, CCHFV-Gc-FL, 
CCHFV-Gc, (E) CCHFV-preGn, CCHFV-Gn, or CCHFV-solGn. MVvac2-GFP viruses served as control vaccines 
(green). Means ± SD; n=3. 
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Taken together, recombinant MVs encoding for antigens of three distinct viruses, MERS-
CoV, H7N9, or CCHFV, were produced, which expressed the inserted antigens, mostly 
without significant effects on viral replication. Moreover, long-term passaging did not result 
in mutations, thus demonstrating the genetic stability of these viruses. After successful in 
vitro characterisation, vaccines against MERS-CoV and H7N9 were tested for their ability to 
induce immune responses in vivo. 
 
3.3. Characterisation of induced humoral immune responses  
Based on their high levels of antigen expression, the prospective vaccines MVvac2-MERS-
S(H), MVvac2-MERS-solS(H), MVvac2-H7(P), and MVvac2-N9(P) were chosen for subsequent in 
vivo characterisation. Although the expression of MERS-N was higher after insertion into 
the post-P ATU of MVvac2, MVvac2-MERS-N(H) was selected to enable an appropriate 
comparison to MVvac2-MERS-S(H) and MVvac2-MERS-solS(H). For this purpose, IFNAR-/-
CD46Ge mice, which transgenically express the human CD46 and lack the type I IFN 
receptor 6  , were vaccinated with 1x105 TCID50 of the respective vaccines, as well as a 
medium (OptiMEM) or control vaccine 
virus (MVvac2-ATU(P)) in a prime-
boost setting (Fig. 14). Sera collected 
on days 0, 28 and 72 were then 
analysed for the presence of total (α-
CoV-S, α-H7N9) and neutralising 
antibodies (nAbs) (α-MERS-CoV, α-
H7N9, and α-MV).  
 
3.3.1. Induction of humoral immune responses by prospective 
MV-MERS vaccines  
The analysis of humoral immune responses directed against MERS-CoV demonstrated that 
a vaccination with MVvac2-MERS-S(H) and MVvac2-MERS-solS(H), but not with OptiMEM or 
MVvac2-ATU(P), resulted in the production of α-MERS-S Abs, determined in an α-MERS-S 
ELISA 7  (Malczyk et al., 2015, Fig. 2). To test whether these Abs were functional and 
neutralised forms of MERS-CoV, nAbs in mouse sera were titrated to determine respective 
virus-neutralising titres (VNTs). As expected, MVvac2-MERS-S(H) and MVvac2-MERS-solS(H) 
                                                             
6 Breeding performed by Dorothea Kreuz, Paul-Ehrlich Institut, using BL-6 background IFNAR-/- mice provided  
   by Prof. Kalinke, TWINCORE and Center for Infection Research, Hannover  
7 Recombinant MERS-S protein for ELISA plate coating was produced and kindly provided by Dr Beissert, Prof.  
   Sahin, TRON GmbH, Mainz, and Dr Hubich-Rau and Prof. Sahin, University of Mainz 
Fig. 14 Vaccination set-up to analyse humoral 
immunity. IFNAR -/-CD46Ge mice were intraperitonally 
vaccinated with 1x105 TCID50 of respective vaccines on 
days 0 and 28 and blood was sampled on day 0, 28, and 
49. 
 
 
0 28 49
Vaccination Boost Final Bleed
d
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(Malczyk et al., 2015, Fig. 3B), but not MVvac2-MERS-N(H) (Fig. 15) provoked an induction of 
MERS-CoV VNTs above detection limit. MVvac2-MERS-S(H), or MVvac2-MERS-solS(H) induced 
VNTs were five- to seven-fold boosted by the second immunisation (167±137 to 847±1012, 
or 96±86 to 640±710 VNT, respectively) (Malczyk et al., 2015, Fig. 3C). In parallel, the 
induction of α-MV nAbs was also tested and revealed anti-MV immunogenicity of MVvac2-
MERS-S(H), MVvac2-MERS-solS(H), MVvac2-CoV-N(H) and MVvac2-ATU(P) (Malczyk et al., 
2015, Fig. 3D-F) (Fig. 15). The vaccines therefore, did not vary in infectivity.  
 
Fig. 15 Analysis of neutralising antibodies. Virus neutralising titers (VNTs) for animals vaccinated on days 
0 and 28 with indicated viruses. Sera were sampled on day 0, 28, and 49. Medium (OptiMEM) or MV backbone 
inoculated (MVvac2-ATU(P)) mice served as controls . VNT were calculated as reciprocal of the highest dilution 
abolishing infectivity of 200 TCID50 of MERS-CoV or 50 pfu of MV. Dots represent single animals (n = 6). 
Horizontal line represents mean per group. Y axis starts at detection limit. All mice at detection limit had no 
detectable VNT. 
To analyse whether the induction of nAbs depends on the replication of the vaccine viruses, 
mice were vaccinated with the same amounts of live or UV-inactivated MVvac2-MERS-S(H). 
In contrast to the replication-competent MVvac2-MERS-S(H), the UV-inactivated vaccine 
neither induced α-MERS-CoV nAbs, nor α-MV nAbs. This indicates that the induction of 
humoral immune responses required active replication of MV-derived vaccines (Fig. 16). 
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Fig. 16 VNTs induced by UV-inactivated or replicating MV-MERS-S. Virus neutralising titers (VNTs) for 
animals vaccinated on days 0 and 28 with indicated viruses. Sera were sampled on day 0, 28, and 49. Medium 
(OptiMEM) or MV backbone inoculated (MV vac2-ATU(P)) mice served as controls. VNTs were calculated as 
reciprocal of the highest dilution abolishing infectivity  of 200 TCID50 of MERS-CoV or 50 pfu of MV. Dots 
represent single animals (n = 4). Horizontal line represents mean per group.  Y axis starts at detection limit. 
All mice at detection limit had no detectable VNT. Mann-Whitney-test (unpaired values); *,P<0,05.  
To further investigate whether MV-derived vaccines against H7N9 are also capable of 
inducing humoral immune responses in vivo, sera of vaccinated mice were tested for the 
presence of H7N9-specific, or H7N9 nAbs. 
 
3.3.2. Induction of humoral immune responses by MV-H7 or  
MV-N9 
Here, vaccination with either MVvac2-H7(P) or MVvac2-N9(P), but not with MVvac2-ATU(P), 
tended to induce α-H7N9 binding Abs, determined by an immune peroxidase monolayer 
assay (IPMA) (Fig. 17). Abs triggered by MVvac2-H7(P), but not by MVvac2-N9(P) or MVvac2-
ATU(P), moreover inhibited the haemagglutination of A/Puerto Rico/8/1934 H7N9, as 
determined in haemagglutination inhibition assay (HAI) (Fig. 17). Contrary to expectation, 
antibodies induced by either MVvac2-N9(P) or MVvac2-H7(P) inhibited the neuraminidase 
activity of A/Puerto Rico/8/1934 H7N9, as determined by enzyme-Linked Lectin Assay 
(ELLA). This indicates that α-HA Abs affect the NA cleavage of sialic-acids when binding H7 
complexed with N9 on the surface of virus particles (Fig. 17). Both IPMA and HAI titres of 
MVvac2-H7(P) were boosted 1.5-fold (4667±1633 to 7555±4352 IPMA titers, or 167±82 to 
240±88 HI titers); the IPMA titre of MVvac2-N9(P), 3.3-fold (2535±1631 to 8001±5631 IPMA 
titers) by the second vaccination. However, the 50% NA inhibitory concentration (IC50) for 
most mice, proved to be beyond the upper limit of detection (>640) after the first 
immunisation, so boosting could, consequently, not be observed. Interestingly, H7N9-
specific Abs (on d28 and d49) were abortive in one MVvac2-N9(P) vaccinated mouse (mouse 
599) and IPMA titres (on d49; d28 not tested) were 32-fold lower, compared to other mice. 
Thus mouse 599 was likely not responsive to vaccination. 
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Fig. 17 Induction of H7N9-specific antibodies.  Blood of mice vaccinated on days 0 and 28 with indicated 
viruses was sampled on day 0, 28 and 49. Sera were analyzed for total  H7N9-binding Abs, hemagglutination 
inhibiting titers (HAI-Titers) and neuraminidase inhibiting titers (NAI) . Medium (OptiMEM) or MV backbone 
inoculated (MVvac2-ATU(P)) mice served as controls. Total α-H7N9 Abs were determined as the reciprocal of 
the highest serum dilution staining A/Puerto Rico/8/1934 H7N9 infected cells in IPMA. HAI-Titers were 
calculated as the highest serum dilution abolishing the hemagglutinat ion properties of H7. Neuraminidase 
Inhibition was calculated as the 50% NA inhibitory concentration (IC 50) after incubation of A/Puerto 
Rico/8/1934 H7N9 with mice sera in ELLA. Dots represent single animals (n = 6). Horizontal line represents 
mean per group. Y-axis starts at detection limit.  All mice at detection limit had no detectable titers. Mann-
Whitney-test (unpaired values); *, P<0.05; **, P<0.01.  
The capacity of MVvac2-H7(P), or MVvac2-N9(P) Abs to prevent infection by A/Puerto 
Rico/8/1934 H7N9 was tested in a neutralisation assay. As expected, MVvac2-H7(P), but not 
MVvac2-N9(P), or MVvac2-ATU(P), induced high amounts of nAbs, which were 1.5-fold 
boosted by a second immunisation (573±270 to 933±310 VNT) (Fig. 18). Consistent with 
the data obtained for the putative MERS-CoV vaccines, MVvac2-H7(P), MVvac2-N9(P) and 
MVvac2-ATU(P), did not differ in the induction of α-MV nAbs (Fig. 18). However, as for H7N9 
specific Abs, α-MV nAbs were abortive in mouse 599, indicating that this individual mouse 
was generally non-responsive to MV vaccination. 
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Fig. 18 Induction of H7N9 neutralising antibodies. Blood of mice vaccinated on days 0 and 28 with indicated 
viruses was sampled on day 0, 28 and 49. Sera were analyzed for H7N9 neutralising antibodies (nAbs) and MV 
nAbs. Medium (OptiMEM) or MV backbone inoculated ( MVvac2-ATU(P)) mice served as mock. Virus neutralising 
titers (VNTs) were calculated as the reciprocal of the highest serum dilution totally neutralising infectivity of 
100 TCID50 A/Puerto Rico/8/1934 H7N9 or 50 pfu of MV. Dots represent single animals (n = 6). Horizontal 
line represents mean per group. Y-axis starts at detection limit. All mice at detection limit had no detectable 
VNT. Mann-Whitney-test (unpaired values); *, P<0.05; **, P<0.01  
To summarise, recombinant MVs encoding antigens of MERS-CoV and H7N9 were shown to 
induce humoral immune responses directed against the inserted antigens. Moreover, MVs 
expressing receptor binding antigens appeared to induce Abs that were capable of 
neutralising the corresponding virus. 
             
3.4. Analysis of cellular immunity 
3.4.1. Generation and characterisation of transgenic cell lines 
The requirement for most effective pre-pandemic vaccines against some viruses, like 
influenza viruses (75), often includes the induction of cellular immunity, in addition to 
humoral immune responses. However, no commercial assays to analyse induced T cell 
responses are usually available for emerging pathogens making the establishment of 
appropriate assays mandatory.  
To this end, this PhD thesis aimed to produce transgenic DC cell lines which stably 
expressed the antigens encoded by the vaccines, in order to re-stimulate respective antigen-
specific T cells ex vivo. An antigen-expressing suspension cell line, EL-4, needed to be 
generated to serve as target cells in a CTL killing assay. For that purpose, lentiviral vectors 
(LVs) transferring genes encoding for the marker gene GFP and the antigens MV-N, MERS-
S, MERS-N, H7 or N9, linked by an IRES sequence, were generated during this thesis. These 
vectors were then used to transduce the DC cell lines JAWSII, DC2.4, or DC3.2, so that these 
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cells expressed the respective antigen and, simultaneously, GFP for visual confirmation of 
successful transduction.  
To produce LVs, 293T cells were transfected with cloned transfer vector plasmids pCSCW2-
MERS-S-IRES-GFP, pCSCW2-MERS-N-IRES-GFP, pCSCW2-H7-IRES-GFP, pCSCW2-N9-IRES-
GFP, or pCSCW2-MV-N-IRES-GFP, in addition to a packaging construct pCMVΔR8.9 and 
envelope (VSV-G) expression plasmid pMDG.2. The transfection resulted in an expression 
of GFP and the inserted antigens (Fig. 19A, Fig. 20B-E), indicating that both were 
simultaneously translated. After transduction of DC cell lines and EL-4 cells using LVs 
purified from supernatants of triple-transfected 293T cells, bulk populations of transduced 
cells (bulk) were enriched to GFP expression using a cell sorter. Moreover, individual cell 
clones were separated by limiting dilution, and single cell clones showing the highest GFP 
expression were chosen for further characterisation (Fig. 19).  
 
Even though the stable integration of all antigens into the genome of transduced cells was 
confirmed by PCR (Fig. 20A), neither MERS-S (Fig. 20C), H7 (Fig. 20D) nor N9 (Fig. 20E) 
were detectable by western blot using a polyclonal rabbit serum, or neuraminidase 
activation assay for detection of N9. The expression of MERS-N was detectable in JAWSII 
and DC3.2, but not in EL-4 or DC2.4 cells (Fig. 20B).  
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Fig. 19 GFP expression of 
transfected cells and selected 
cell clones. (A) Fluorescence 
microscopy pictures of 1x107 293 
T cells transfected with 17.5 µg of 
respective pCSCW2-Antigen-
IRES-GFP transfer vector, 6.23 µg 
pMD2.G, and 11.27 µg 
pCMVΔR8.9 to produce LVs 
[HIVMV-N-IRES-GFP(VSV-G)] (MV-N), 
[HIVMERS-N-IRES-GFP(VSV-G)] (MERS-
N), [HIVMERS-S-IRES-GFP(VSV-G)] 
(MERS-S), [HIVH7-IRES-GFP(VSV-G)] 
(H7), or [HIVN9-IRES-GFP(VSV-G)] 
(N9).  (B) EL-4, JAWSII, DC2.4, 
and DC3.2 cells were transduced 
with purified respective LVs. 
Single cell clones were obtained 
by limiting dilution. The 
expression of GFP was validated 
by flow cytometry. Red, Antigen 
specific cell clones revealing the 
highest GFP expression; black 
untransduced cells. 
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Fig. 20 Integration of antigen-encoding genes and determination of antigen expression by  transduced 
DC cell lines or EL-4 cell line.  (A) Integration of respective antigen-encoding genes into the genome of 
transduced single cell clones of EL-4, JAWSII, DC2.4 or DC3.2 was determined by PCR amplification. PCR 
amplification of isolated DNA was performed using antigen-specific forward and revers primers. DNA 
fragments were separated by gel electrophoresis . Expected bands: MERS-N: 1.24 kbp; MERS-S: 4.06 kpb; H7: 
1.68 kpb, N9: 1.43 kbp. Expression of (B) MERS-N, (C) MERS-S and (D) H7 was determined by immunoblot 
using (B,C) α-MERS-CoV or (D) α-H7N1 rabbit serum. Expression of (E) N9 was tested by neuraminidase assay. 
Depicted are single cell clones with highest GFP expression except of 1 Bulk culture, or 2MERS-N#5. 
Untransduced cells served as negative controls (NC). Arrows indicate specific bands. * 293T cells were 
transfected with respective pCSCW2-Antigen-IRES-GFP transfer vectors as positive control.  
However, MV-N in JAWSIIGreen-MV-N was detected by western blot analysis; and, as 
expected, expression shown to correlate with GFP fluorescence intensity (Fig. 21A). A 
correlation between antigen and GFP expression was, moreover, confirmed by western blot 
analysis of transgenic JAWSII, which expressed the model antigen ovalbumin (Ova)8 (Fig. 
21B).  
 
Fig. 21 Correlation between antigen and GFP expression. (A)α-Ova or, (B) α-MV-N immunoblot of JAWSII 
single cell clones transgenic for (A) Ova or (B) MV-N. Cells were previously transduced with respective LVs 
and single cell clones obtained by limiting dilution. Untransduced cells served as mock. 293T cells transfected 
with respective pCSCW2-Antigen-IRES-GFP transfer vectors as positive control (PC). Arrows indicate specific 
bands. Expression of GFP was determined by flow cytometry. 
                                                             
8 Generated and characterized by Bianca Bodmer during her diploma thesis, Paul-Ehrlich-Institut, Langen 
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Consequently, GFP fluorescence intensity was taken as correlate of antigen expression and 
cell clones exhibiting the highest GFP expression used for re-stimulation of T cells in 
subsequent experiments. Since the respective antigens were integrated into the genome of 
transduced cell clones, the respective abortive proof of antigen expression was attributed 
to expression below detection limit of western blot or neuraminidase activation assay. 
 
3.4.2. Induction of cellular immune responses by prospective 
MV-MERS vaccines 
Subsequently, this thesis aimed to investigate whether these antigen-transgenic DC cell 
lines were suitable to re-stimulate antigen-specific T cells that were induced by vaccination. 
For that purpose, 21 days after booster vaccination, splenocytes were isolated from mice 
vaccinated with MVvac2-ATU(P), MVvac2-MERS-S(H), MVvac2-MERS-solS(H), or  
MVvac2-MERS-N(H). 
Splenocytes labelled with CFSE were first re-stimulated with respective transgenic bulk 
JAWSIIgreen cells to test whether T cells among splenocytes proliferated upon antigen 
stimulation. This would be indicated by a decreasing CFSE signal (Fig. 22 A). In fact, 
CD3+CD8+ T cells (Malczyk et al., 2015, Fig. 5A), but not CD3+CD4+ T (Fig. 22 B) cells of mice 
vaccinated with MVvac2-MERS-solS(H) (29±20% of CD3+CD8+ T cells; 3.8±1.9% of CD3+CD4+ 
T cells) or MVvac2-MERS-S(H) (41±12% of CD3+CD8+ T cells; 3.4±1.4% of CD3+CD4+ T cells) 
specifically, proliferated upon re-stimulation with JAWSIIGreenMERS-S. By contrast, 
JAWSIIGreen-MERS-N (Fig. 22 B) cells neither triggered proliferation of CD3+CD8+ 
(0.9±0.34%) nor of CD3+CD4+ T cells (1.4±0.4%) isolated from mice vaccinated with MVvac2-
MERS-N(H). MERS-S or MERS-N specific proliferation was not detectable in control mice, as 
expected. 
 
Fig. 22 Induction of MERS-S-specific T memory cells. Proliferation of splenocytes from mice vaccinated on 
days 0 and 28 with indicated viruses and isolated 21 d after booster immunization. Medium (OptiMEM) or MV 
backbone inoculated (MVvac2-ATU(P)) mice served as controls. CFSE-labeled splenocytes were co-cultured with 
bulk cultures of transduced JAWSII DC lines transgenic for respective antigen or untransduced controls (NC) 
for 6 days. (A) Percentages of CD8+ or CD4+ T cells with low CFSE were determined by flow cytometry. Low 
CFSE signals indicates proliferation in the samples. (B) Results for splenocytes of vaccinated mice are 
displayed individually and trend between paired unstimulated and re -stimulated samples is outlined. 
Splenocytes of control mice were pooled.  
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Fig. 23 Proliferation of T cells upon 
re-stimulation with positive 
controls. Proliferation of splenocytes 
from mice vaccinated on days 0 and 
28 with indicated viruses and isolated 
21 d after booster immunization. 
Medium (OptiMEM) or MV backbone 
inoculated (MVvac2-ATU(P)) mice 
served as controls. CFSE labeled 
splenocytes were re-stimulated with 
10 µg/ml ConA or MV bulk antigens 
for 6 days. Medium served as mock. 
Percentages of CD8+ or CD4+ T cells 
with low CFSE were determined by 
flow cytometry. Low CFSE signals 
indicates proliferation in the samples. 
Results for splenocytes of vaccinated 
mice are displayed individually and 
trend between paired unstimulated 
and re-stimulated samples is 
outlined. Splenocytes of control mice 
were pooled. 
 
CD3+CD8+ T cells were, in general, responsive to re-stimulation with Concanavalin A (ConA) 
(Fig. 23 A) and CD3+CD4+ T cells of all MV vaccinated to re-stimulation with MV bulk 
antigens. These results demonstrated that abortive MERS-N specific proliferation of T cells 
was neither attributable to non-responsiveness of T cells nor to a general failure of 
vaccination (Fig. 23 B).  
  
Consequently, the ability of MERS-S or MERS-N-specific T cells to secrete antiviral IFN-γ or 
to exert effector T cell responses as alternative correlates of T cell activation were tested in 
the next steps. Since most effector T cells are 
normally detectable a few days after pathogen 
exposure (Fig. 14), splenocytes of vaccinated mice 
were isolated four days after booster vaccination 
for subsequent experiments (Fig. 24). In addition, 
transgenic single cell clones, rather than bulk 
populations of transgenic JAWSII, DC2.4 and 
DC3.2 clones, were selected as defined antigen-
specific DC cell-populations for re-stimulation.   
Consistent with T cell proliferation, a MERS-S-specific re-stimulation of splenocytes from 
mice vaccinated with MVvac2-MERS-S(H) or MVvac2-MERS-solS(H) by MERS-S-transgenic 
JAWSII, DC2.4, or DC3.2 resulted in a significantly enhanced IFN-γ secretion compared to 
control mice (JAWSIIGreen-MERS-S: approx. 2,400 versus 200 spot forming cells (SFC) / 106 
splenocytes) (Malczyk et al., 2015, Fig. 4). Moreover, MERS-N-transgenic JAWSII and DC2.4 
cells provoked an IFN-γ secretion by splenocytes isolated from mice vaccinated with MVvac2-
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Fig. 24 Vaccination set-up for analysis of 
cellular immunity. IFNAR -/-CD46Ge mice 
were intraperitonally vaccinated with 
1x105  TCID50 of respective vaccines on days 
0 and 28 and splenocytes isolated 4 d after 
boost immunization.  
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Fig. 25 α-MERS-N cellular 
immune responses. 
Splenocytes were isolated 
4 d after boost 
immunization and 
analyzed for IFN-γ 
secretion by ELISpot. For 
antigen-specific recall, 
splenocytes were co-
cultured with single cell 
clones of (A) JAWSII-
MERS-N, DC2.4 MERS-N, or 
DC3.2-MERS-N (red 
colums) at a ratio 1:10 for 
36h. Re-stimulation with 
(B) 10 mg/ml, MV bulk 
antigen (black columns), 
10 mg/ml ConA (red 
columns) or (C) JAWSII-
MV-N (blue columns) were 
used as control stimuli. 
Medium (unst.) or 
untransduced cells (NC) 
served as negative controls 
(white columns). Depicted 
are means ± SD (n = 6). 
Students T test (unpaired 
between different mouse 
groups; paired between 
values of one group); *, 
P<0.05; **, P<0.01. 
 
MERS-N(H) (298±213, or 237±244 SFC/ 106 splenocytes, respectively), but not in control 
mice (vector control 54±29, or 21±25 SFC/ 106 splenocytes, respectively). This 
demonstrates the ability of the vaccine to induce MERS-N-specific T cell responses (Fig. 
25A). Nevertheless, the numbers of IFN-γ secreting cells induced by re-stimulation with 
MERS-N-transgenic DCs were at least five-fold lower compared to those induced by MERS-
S in T cells of respectively vaccinated groups (Malczyk et al., 2015, Fig. 4). This reduced 
activity of splenocytes of MVvac2-MERS-N(H) vaccinated mice were not attributed to general 
activity of splenocytes since responsiveness to ConA or MV bulk antigen stimulation was 
comparable to other groups (Fig. 25B). Differences did also not become evident after re-
stimulation with JAWSIIgreenMV-N cells (Fig. 25B).  
 
As already demonstrated for humoral immunity (Fig. 16), no IFN-γ was secreted by 
splenocytes from mice vaccinated with UV-inactivated MVvac2-MERS-S(H) and subsequently 
stimulated by JAWSIIGreen-MERS-S cells (Fig. 26). This data reveals that induction of 
considerable cellular immune response by MVvac2-MERS-S(H) depends on replication of MV-
derived vaccines.  
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Fig. 26 Cellular immunity induced 
by UV-inactivated or replicating 
MV-MERS-S. Splenocytes of mice 
vaccinated on days 0 and 28 with 
indicated viruses were isolated 21 d 
after boost immunization and 
analysed for IFN-γ secretion by 
ELISpot. For recall of T cells, 
splenocytes were stimulated with 10 
mg/ml Ova257-264peptide (NC)(black 
circles), MV bulk antigens (green 
circles), ConA (red circles), or co-
cultured with single cell clones of 
JAWSII-MERS-S (blue diamonds), 
JAWSII-MV-N (red diamonds) or 
untransduced cells (black diamonds) 
for 36h. Dots represent single 
animals (n = 4). Horizontal line 
represents mean per group. Students  
T test (unpaired between different 
mouse groups; paired between 
values of one group);  *, P<0.05; **, 
P<0.01. 
 
 
Finally, to monitor CTL effector responses of reactive T cells after vaccination with MVvac2-
MERS-S(H), MVvac2-MERS-solS(H), or MVvac2-MERS-N(H), the killing of respective antigen-
expressing EL-4 cells was tested in the next step.  
In contrast to the T cells of control mice, those induced by MVvac2-MERS-S(H), or MVvac2-
MERS-solS(H)- vaccination specifically, killed MERS-S-expressing target EL-4 cells (Malczyk 
et al., 2015, Fig. 5C). However, T cells of MVvac2-MERS-N(H) vaccinated animals did not 
exhibit CTL effector responses against MERS-N-expressing cells (Fig. 27). This absence of 
MERS-N but also MV-N-specific killing in the presence of respectively reactive T cells (Fig. 
25) indicated that those antigen-specific T cells did not exhibit detectible CTL responses in 
the killing assay that had been performed.  
 
Fig. 27 CTL effector responses. Splenocytes, isolated 4 d after boost vaccination, were cocultured with 
untransduced JAWSII or with single cell clones of JAWSII-MERS-S, JAWSII-MERS-N or JAWSII-MV-N for 6 days. 
Activated CTLs were co-cultured with respective EL-4-Antigen target cells (Antigen) and EL-4red control cells 
(NC) at indicated E:T ratios for 4 h. Number of living cells was determined by flow cytometry and ratio of 
living target to non-target cells (Antigen:NC) calculated. Depicted are means ± SD  (n = 6). Statistics: a linear 
curve was fitted for antigen, versus  the log-transformed effector-target ratio (E:T). The P values for 
differences in slopes were calculated. ns, not significant; *** P<0.001. 
This chapter demonstrates the suitability of transgenic DC cell lines, like JAWSII, DC2.4, or 
DC3.2 to re-stimulate antigen-specific T cell responses, as shown for three distinct antigens: 
MV-N, MERS-S, and MERS-N. Using these transgenic DC cell lines, the capacity of MV-derived 
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
0
500
1000
1500
2000
2500
3000
3500
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
+ - + - + - + - + - + -
0.124 ** ***
DC2.4 CoV-N
MVvac2-
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
Op
tiM
EM
AT
U(
P)
M
ER
S-
N(
H
)
Op
tiM
EM
AT
U(
P)
M
ER
S-
N(
H
)
Op
tiM
EM
AT
U(
P)
M
ER
S-
N(
H
)
0
2
4
600
800
1000
NC
UV
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
0
500
1000
1500
2000
2500
3000
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
0
500
1000
1500
2000
2500
3000
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
0
500
1000
1500
2000
2500
3000
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
0
500
1000
1500
2000
2500
3000
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
M
ER
S-
S(
H
) U
V
M
ER
S-
S(
H
)
0
500
1000
1500
2000
2500
3000
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
M
ER
-S
(H
) U
V
M
ER
S-
S(
H)
M
ER
-S
(H
) U
V
M
ER
S-
S(
H)
M
ER
S-
S(
H)
 U
V
M
ER
S-
S(
H)
M
ER
S-
S(
H)
 U
V
M
ER
S-
S(
H)
M
ER
S-
S(
H)
 U
V
M
ER
S-
S(
H)
M
ER
S-
S(
H)
 U
V
M
ER
S-
S(
H)
M
ER
S-
S(
H)
 U
V
M
ER
S-
S(
H)
M
ER
S-
S(
H)
 U
V
M
ER
S-
S(
H)
0
500
1000
1500
2000
2500
3000
S
p
o
ts
 p
e
r 
1
x
1
0
6
 s
p
le
n
o
cy
te
s
NC
ConA
MV Bulk
untransduced
MV-N
MERS-S
S1165 1 µM
S1165 10 µM
unst. ConA MV bulk untransd. MV-N MERS-S 
JAWSII
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
2.0
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
2.0
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
:1 5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
2.0
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
2.0
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
6
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
E:T
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
S(H)
A
n
ti
g
e
n
:N
C
solS(H)
E:T
1:
1
5:
1
20
:1
0
1
2
3
4
5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
E:T
1:
1
5:
1
20
:1
0.0
0.5
1.0
1.5
OptiMEM
ATU(P)
N(H)
A
n
ti
g
e
n
:N
C
S(H)
solS(H)
***
ns
ns
V
ia
b
le
ta
rg
e
t
ce
ll
ra
ti
o
A
n
ti
g
e
n
:N
C
EL-4-MERS-S EL-4-MERS-N EL-4-MV-N
RE SU L T S  
 
 41 
recombinant vaccines encoding either MERS-N or MERS-S as extra transgene cargo, to 
induce T cell responses was demonstrated. MERS-S was shown to be more immunogenic 
than MERS-N, in that it induced four- to five-fold higher numbers of IFN-γ secreting antigen-
specific T cells. Also, antigen-specific T cell proliferation and CTL effector responses were 
detectable for MERS-S, but not for MERS-N.  
 
3.4.3. Comparison of re-stimulation capacity of transgenic JAWSII 
to peptides 
To further strengthen the evidence that transgenic DC cell lines are suitable for antigen-
specific re-stimulation of vaccine-induced T cells, we aimed to compare the capacity of 
transgenic JAWSIIGreenOva cells9 (3.4.1) for recall of Ovalbumin (Ova)-specific T cells to that 
of immunodominant peptides specific for CD8+ or CD4+ T-cell responses (SIINFEKL OVA257-
264 or OVA323-339, respectively). For this purpose, we utilized Ova-specific purified pan T cells, 
which were separated from frozen splenocytes. These splenocytes originated from mice, 
which were previously vaccinated with a lentiviral protein-transfer vector transferring the 
model antigen Ova to APCs (Ova-PTVs). Four days after booster vaccination these 
splenocytes were initially isolated, and directly after isolation examined for numbers of 
Ova-specific IFN-γ secreting cells in an ELISpot-assay using OVA257-264, OVA323-339 or 
recombinant Ova proteins for Ova-specific recall. Upon initial examination, it was found that 
splenocytes of IFNAR-/- mice vaccinated with VSV-G-pseudotyped Ova-PTV HIV-
OvaKatushka(VSV) 10  contained significant numbers of IFN-γ secreting cells (>600/106 
splenocytes), which, however, became evident irrespective of the stimuli used for antigen-
specific recall (Uhlig et al., 2015, Fig. 7B). To identify the reason for unspecific activity of T 
cells, pan T cells were consequently separated from other splenocytes by magnetic bead 
sorting and co-cultured with untreated bone-marrow-derived mDCs or mDCs pulsed with 
OVA257-264, OVA323-339, or recombinant Ova. Interestingly, the baseline level of T cells from 
HIV-OvaKatushka(VSV) vaccinated mice was five-fold reduced when pooled untouched pan T 
cells were examined for IFN-γ producing cells in an ELISpot assay (Uhlig et al., 2015, Fig. 
8A). When the APC-containing retentate of these mice was co-cultured with splenocytes of 
OT-I (transgenic TCR specific for MHCI restricted epitope OVA257-264), OT-II (transgenic TCR 
specific for MHCII restricted epitope OVA323-339) or BL/6 wt mice, 15-fold more IFN-γ 
secreting cells were detected among splenocytes of OT-I mice compared to BL/6 wt mice 
(Uhlig et al., 2015, Fig. 8C). This results indicated that the APCs of vaccinated mice were still 
                                                             
9 Generated by Bianca Bodmer during her diploma thesis, Paul-Ehrlich-Institut, Langen 
10 Vaccination performed by Dr Uhlig, Paul-Ehrlich-Institut, Langen 
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Fig. 28 Comparison of JAWSIIGre en-
MERS-S cells to peptide S1165. 
Splenocytes of mice vaccinated on days 
0 and 28 with indicated viruses were 
isolated 21 d after boost immunization 
and analysed for IFN-γ secretion by 
ELISpot. For recall of T cells, 
splenocytes were stimulated with 1 
µMor 10 µM S1165 peptide or co-
cultured with single cell clones of 
JAWSII-MERS-S (blue diamonds),for 
36h. Dots represent single animals  
(n = 4). Horizontal line represents mean 
per group. Students T test (paired 
between values of one group).  
 
presenting Ova peptides and thereby activating Ova-specific, (here CD8+) T cells, four days 
after vaccination by lentiviral PTVs.  
Anyway, during examination of pan T cells, numbers IFN-γ secreting cells activated by 
JAWSIIGreenOva were similar to those induced by 5 µg/ml OVA257-264 (Uhlig et al., 2015, Fig. 
8A) indicating that antigen-specific re-stimulation of T cells by transgenic DC cell lines can 
be as effective as re-stimulation by immunodominant, antigen-peptides loaded onto 
primary DCs. In this setting, re-stimulation by JAWSII cells was, moreover, comparable to a 
stimulus specific for CD8+ T but not CD4+ T cells. These results were later confirmed as the 
meanwhile characterized MERS-CoV peptide S1165, which represent an immunodominant 
MHCI restricted MERS-CoV epitope, was compared to JAWSIIGreen-MERS-S cells. Here, 
numbers of re-stimulated IFNγ-secreting T cells among splenocytes did not significantly 
differ from those induced by JAWSIIGreen-MERS-S, irrespective if 1 µM or 10 µM of S1165 
were used for re-stimulation (Fig. 28). 
Thus, these results, demonstrated that the re-
stimulating properties of transgenic DC cell lines 
can be comparable to re-stimulation by 
immunodominant peptides. The powerful cellular 
immune responses induced by particularly MVvac2-
MERS-S(H) and MVvac2-MERS-solS(H) and are hence 
most likely not attributed to stimulation properties 
of transgenic DC cell lines. As a consequence, those 
can be used especially when these peptides are not 
available; and production of recombinant antigens, 
hardly possible.  Therefore, transgenic DC cell lines 
were also utilized to test the properties of MVvac2-
H7(P), and MVvac2-N9(P) to induce cellular immune 
responses, as already demonstrated for MV-based 
vaccines against MERS-CoV. 
 
3.4.4. Induction of cellular immune responses by MV-H7 or  
MV-N9 
For that purpose, splenocytes of respectively vaccinated mice were isolated four days after 
boost vaccination (Fig. 24) and antigen-specific T cells re-stimulated by antigen-encoding  
Here, an H7-specific recall of splenocytes from MVvac2-H7(P) vaccinated mice resulted in a 
significant number of IFN-γ secreting T cells (358±141 SFC/ 106 after re-stimulation with 
JAWSIIGreen-H7), whereas hardly any IFN-γ secreting splenocytes were obtained from mice 
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injected with OptiMEM (JAWSIIGreen-H7: 23±26 SFC / 106 splenocytes) or vector control 
groups (JAWSIIGreen-H7: 63±44 SFC/ 106 splenocytes). Statistically significant differences 
between MVvac2-H7(P) vaccinated mice and vector control mice became evident for 
JAWSIIGreenH7, DC2.4GreenH7 and DC3.2GreenH7 respectively, indicating that H7-specific 
immunity was not attributable to a specific cell line (Fig. 29A).   
IFN-γ secreting T cells were also abundant among splenocytes of mice vaccinated with 
MVvac2-N9(P) (JAWSIIGreen-N9: 518±304 SFC/ 106 splenocytes), while lower numbers of IFN-
γ secreting T cells were found among splenocytes of medium (JAWSIIGreen-N9: 147±123 
SFC/ 106 splenocytes) or vector control (JAWSIIGreen-N9: 246±157 SFC/ 106 splenocytes) 
treated mice. However, these differences in T cell activation also became evident if 
untransduced DCs were used for recall, indicating that activity of splenocytes from MVvac2-
N9(P) vaccinated mice was attributable rather to DC co-culture than to N9-specific re-call 
(Fig. 29B). Nevertheless, comparable reactivity of these splenocytes in general, and 
comparable responsiveness of mice to MV vaccination were confirmed by unspecific recall 
with ConA (Fig. 29C) or MV-specific recall with MV bulk antigens (Fig. 29 C) or JAWSIIGreen-
MV-N cells (Fig. 29D), respectively.  
 
Fig. 29 Secretion of IFN-γ after H7- or N9-specific re-stimulation of splenocytes. IFN-γ ELISpot analysis 
of murine splenocytes isolated 4 d after boost immunization. (A) H7 or (B) N9 specific T cells were detected 
after co-culture with with single cell clones of JAWSII, DC2.4 or DC3.2 dendritic cell lines transgenic for H7 or 
N9 (red colums). Restimulation with (C) 10 mg/ml MV bulk antigen (black columns), 10 mg/ml ConA (red 
columns) or (D) JAWSII-MV-N (blue columns) were used as control stimuli. Medium (unst.) or untransduced 
cells (NC) served as negative controls (white columns). Depicted are means ± SD (n = 6). Students T Test 
(unpaired values between different groups , paired values of one animal group);  *, p<0.05; **, p<0.01; ***, 
p<0.001; ****, p<0.0001.  
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However, although MVvac2-H7(P) was potent to induce H7-specific T-cell responses in an 
IFN-γ ELISpot assay, cytotoxic activity against H7-, or MV-N-encoding target cells could not 
be demonstrated (Fig. 30).  
 
Fig. 30 α-H7 CTL effector responses. Splenocytes, isolated 4 d after boost vaccination, were cocultured with 
untransduced JAWSII or with single cell clones of JAWSII-H7, or JAWSII-MV-N for 6 days. Activated CTLs were 
co-cultured with respective EL-4-Antigen target cells (Antigen) and EL-4red  control cells (NC) at indicated E:T 
ratios for 4 h. Number of living cells was determined by flow cytometry and ratio of living target to non-target 
cells (Antigen:NC) calculated. Depicted are means ± SD  (n = 6). Statistics: a linear curve was fitted for antigen, 
versus the log-transformed effector-target ratio (E:T). The P values for differences in slopes were calculated. 
ns, not significant. 
Thus, this part of the work demonstrated that MVvac2-H7(P) induced H7-specific cellular 
immune responses which are characterised by a secretion of antiviral IFN-γ. By contrast, 
NA-specific cellular immune responses were not detectable in mice vaccinated with MVvac2-
N9(P) vaccine.  
 
3.5. Analysis of protection capacity of MV-MERS-S  
MV-derived vaccines against two distinct viruses, MERS-CoV and H7N9, were potent in 
inducing humoral (see 3.3.2) and cellular immunity (see 3.4.2, and 3.4.4) in vivo. To finally 
characterise whether those immune responses were protective against the respective 
pathogen, MV-derived vaccines against MERS-CoV were tested in an appropriate challenge 
model. Since MVvac2-MERS-S(H) and MVvac2-MERS-solS(H) induced MERS-CoV nAbs as well 
as strong MERS-S-specific cellular immune responses, these constructs were used as 
preceding vaccines to be tested.  
Thus, in two independent experiments, 5 mice per group (n=10) were vaccinated with 
medium (mock control), MVvac2-ATU(P) (vector control), MVvac2-MERS-S(H), or MVvac2-
MERS-solS(H) in a prime-boost-set-up (Fig. 14). Since mice are naturally not susceptible to 
MERS-CoV infection (51), the respiratory tracts of mice were transduced with mCherry 
marked adenoviral vectors encoding the human DPP4 gene (AdV-hDPP4) on day 6311. Due 
to the expression of huDPP4, the entry receptor of MERS-CoV, mice become susceptible and 
                                                             
11 Performed by Dr Kupke with support of Dr Jörg Schmidt, Dr Vergara-Alert and Dr Eickmann of Prof. Becker’s    
    group, University of Marburg, in collaboration with Dr Herold, University of Gießen 
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were subsequently infected on day 68. Lungs of infected mice were isolated on day 7212 and 
analysed for MERS-N RNA copy numbers, titres of infectious virus and signs of 
inflammation, as determined by histological examination after haematoxylin and eosin 
(H&E) staining (Fig. 31).    
Indeed, the vaccination with MVvac2-MERS-
solS(H) or MVvac2-MERS-S(H) resulted in a 
reduction of viral copy numbers compared to 
medium inoculated mice (9,649±3,045 to  
51±32, or 74±60 MERS-CoV genome copies/ng 
RNA, respectively) which was significant for 
MVvac2-MERS-solS(H) (p=0.0329), and close to 
significance (p=0.057) for MVvac2-MERS-S(H) 
(Malczyk et al., 2015, Fig. 6A). Although titres 
of infectious MERS-CoV were generally low, 
the results corresponded to qRT-PCR data. 
Here, a vaccination with MVvac2-MERS-solS(H) resulted in a three-fold (868±692 to 318±198 
TCID50), reduction of viral titres compared to the medium control (Malczyk et al., 2015, Fig. 
6B). For MVvac2-MERS-S(H), the reduction was seven-fold (868±692 to 122±136 TCID50). 
However, completely negative PCR results and undetectable viral titres were observed for 
40% of challenged mice, indicating that they were not infected by MERS-CoV. Lack of 
infectivity was attributable to failed transduction by AdV-hDPP4 in 37% of affected mice, 
while the reason for lack of infectivity in the remaining mice remains so far unclear. 
However, the groups did not generally vary in mCherry loads, indicating that the reduction 
of MERS-CoV RNA copy numbers and titres after vaccination with MVvac2-MERS-solS(H) or 
MVvac2-MERS-S(H) was not due to low transduction efficiency (Malczyk et al., 2015, Fig. 6C).  
Histopathological examination of infected lungs revealed that the lung tissues of control 
animals (OptiMEM and MVvac2-CoV-ATU(P)) showed areas of inflammation which were 
accompanied by a positive MERS-CoV-S immunostaining 13 , indicating pathology that 
correlates with infection. By contrast, inflammation and MERS-S expression were clearly 
reduced in animals vaccinated with MVvac2-MERS-S(H) or MVvac2-MERS-solS(H) (Malczyk et 
al., 2015, Fig. 7). Expression of mCherry, as a control for successful transduction, generally 
did not vary between the groups, (Malczyk et al., 2015, Fig. 7), but correlated with a lack of 
MERS-CoV infectivity in some mice, as already indicated by mRNA expression levels.  
                                                             
12 Conducted by Dr Kupke and colleagues 
13 Conducted by Dr Kupke and colleagues 
Fig. 31 Set-up for MERS-CoV challenge. 
IFNAR -/-CD46Ge mice were vaccinated on days 
0 and 28. Mice were intranasally transduced 
with 2.5x108 pfu AdV-DPP4 on day 63 and 
challenged with 7x104 TCID50  MERS-CoV on day 
68. Lungs of vaccinated mice were isolated on 
day 72. 
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Taken together, these results demonstrate that the powerful humoral and cellular immune 
responses induced by vaccination with MVvac2-MERS-S(H) and MVvac2-MERS-solS(H) do 
indeed protect vaccinated mice from MERS-CoV challenge. This protection was not only 
demonstrated by a reduction of viral loads in the lung tissues of MERS-CoV infected mice, 
but also by a reduction of relevant clinical signs of disease.  
 
3.6. Analysis of the impact of pre-existing anti-measles 
immunity on the efficacy of MV-MERS-S 
Since most human beings are vaccinated against measles as infants, pre-existing nAbs have 
long been suspected to counteract the efficacy of MV-derived vaccine vectors. Consequently, 
the final aim of this thesis was to analyse the impact of pre-immunity on the induction of 
humoral and cellular immune responses directed against MERS-CoV by generated MV-
MERS vaccines.  
For this purpose, IFNAR-/-CD46Ge mice were pre-immunised once (1xATU(P)) or twice 
(2xATU(P)) with MVvac2-ATU(P) to induce MV immunity, or else inoculated with medium as 
a control. Three months after pre-vaccination, the animals were vaccinated with MVvac2-
MERS-S(H) in a prime-boost set-up as used for naïve mice. Sera were collected on days 0, 
28, 49, 147, 168 and 189, and analysed for the presence of α-MV and α-MERS-CoV nAbs at 
each time point. Splenocytes isolated on day 189 were examined for IFN-γ secretion upon 
MERS-S specific re-stimulation by peptide S1165 or by JAWSIIgreenMERS-S cells.  
As expected, α-MV nAbs were boosted by each immunisation and were thus significantly 
higher in twice pre-immunised mice compared to once pre-immunised mice at the time 
point of vaccination with MVvac2-MERS-S(H) (1,072±649 versus 420±244 VNTs). Consistent 
with previously published data (164, 33), a single pre-immunisation had no effect on α-
MERS-CoV nAbs titres compared to naïve mice (18.3±14.7 versus 15±14.1 VNTs) (Malczyk 
et al., 2015, Fig. 3). By contrast, twice pre-vaccinated animals revealed no detectable α-
MERS-CoV nAbs when vaccinated afterwards with MVvac2-MERS-S(H) (Fig. 32). However, 
titres even in naïve animals were unexpectedly low, when compared to previous 
experiments.  
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Fig. 32 Humoral immune responses in 
the presence of pre-existing 
immunity. Mice were once or twice pre-
vaccinated with 1x105 TCID50 MVvac2-
ATU(P). Control mice were treated with 
OptiMEM. 147 and 168 days after the 
initial vaccination all mice were 
vaccinated with 1x105 TCID50 MVvac2-
MERS-S(H) in a prime-boost set-up. 
Mouse sera sampled on day 0, 28, 49, 
147, 168 and 169 were analysed for 
virus neutralising titers (VNT). VNTs 
were calculated as reciprocal of the 
highest dilution abolishing infectivity of 
200 TCID50 of MERS-CoV or 50 pfu of MV. 
Y axis starts at limit of detection. 
Depicted are Means ± SD (n = 4-7); 
Students T Test (unpaired values 
between different groups); *, p<0.05.  
 
 
 
Next, the impact of pre-existing α-MV immunity on MVvac2-MERS-S(H)-induced antigen-
specific cellular immune responses was considered. Here, splenocytes of all mice were 
responsive to MV-specific re-stimulation (MV bulk antigens and JAWSIIGreen-MV-N) as 
expected. However, no significant differences in MV-specific cellular immunity became 
evident between the groups, even though those differed in the quantity of MV 
immunisations. Considering MERS-S specific immunity in naïve mice, the numbers of IFN-γ 
secreting cells after re-stimulation of splenocytes with JAWSIIGreen-MERS-S cells or 10 µM 
S1165 were high and comparable to previous experiments (Fig. 28) (JAWSIIGreen-MERS-S: 
1,509±467 versus 1,644±625 SFC/106 splenocytes). This indicates that general 
responsiveness of mice to vaccination with MVvac2-MERS-S(H) was as usual. However, 
MERS-S specific immune responses were approximately 20-fold reduced if mice were once 
or twice pre-vaccinated (JAWSIIGreen-MERS-S:  1,509±467 versus 93.6±83.5 or 83.8±41.6 
SFC /106 splenocytes, respectively). These results imply that pre-immunity directed against 
MV significantly affects the induction of MERS-S specific cellular immunity by MVvac2-MERS-
S(H). However, although this impact is quite considerable, numbers of MERS-S specific IFN-
γ secreting cells (S1165 or JAWSIIGreen-MERS-S) were still significantly higher compared to 
respective control stimuli, even in twice pre-immunised mice (untransduced JAWSII: 
19.4±15.8 or 27±17.6 SFC /106 splenocytes in once or twice pre-vaccinated mice, 
respectively) (Fig. 33). This indicates preservation of basal immunogenicity also in animals 
with significant pre-formed MV immunity. 
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Fig. 33 Cellular immune responses in the presence of pre -existing MV immunity. Mice were once or twice 
pre-vaccinated with 1x105 TCID50 of MVvac2-ATU(P). Control mice were treated with OptiMEM. 147 and 168 
days after the initial vaccination all mice were vaccinated with 1x10 5 TCID50 MVvac2-MERS-S(H) in a prime-
boost set-up. Splenocytes of mice were isolated on day 189 and analyzed for IFN-γ secretion by ELISpot assay. 
For antigen-specific recall, splenocytes were co-cultured with single cell clones of JAWSII-MERS-S, JAWSII-
MV-N (red circles) or stimulated with 10 µM S1165, 10 µg/ml MV bulk antigens or 10 µg/ml ConA for 36h. 
Medium or untransduced cells  (untransd.) served as negative control (NC). Dots represent single animals (n = 
4-7). Horizontal line represents mean per group.  Students T Test (unpaired values between different groups, 
paired values of one animal group);*, p<0.05 **, p<0.01; ***, p<0.001; ****, p<0.0001. 
Thus, even though pre-formed MV immunity was shown to considerably affect antigen-
specific cellular immune responses induced by a MV-derived vaccine, effects on induced 
humoral immune responses, at least in once-pre-vaccinated mice, seem to be marginal. 
Therefore, the contribution and thresholds of both processes on the protection efficacy of 
the vaccine have to be elucidated in further experiments. These experiments will allow an 
appropriate evaluation of the effects of pre-existing immunity of the vaccines efficacy.  
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4. DISCUSSION 
Our limited experience with new pathogens allows for the undetected spread of newly-
emerged, highly pathogenic viruses by worldwide travel and trade. Prevention of larger 
outbreaks therefore relies on further investigation into viral pathomechanisms that would 
provide a basis for the development of pre-pandemic anti-viral drugs and vaccines. Success 
of the latter is emphasised by the eradication of smallpox by 1980 (92), but also by the high 
levels of protection efficacies (up to 99%) (123) of vaccines against, for example, measles, 
hepatitis A, and polio.  
Infections with the 2012 newly-discovered MERS-CoV resulted in an alarming case fatality 
rate of about 35% (297). This pathogen is thus an appropriate example of an emerging 
highly pathogenic virus. Extensive research on interactions of SARS-CoV with the human 
immune system (180, 334, 249, 48) provides us with some insight into pathogenicity and 
immune evasion strategies of human coronaviruses. However, immune responses induced 
by MERS-CoV, as well as the mechanisms mediating protection, were unknown directly after 
its emergence. Therefore, an efficient protection from MERS-CoV-induced epidemics 
requires the production of pre-pandemic vaccines, but also, in parallel, an investigation of 
MERS-CoV’s interaction with the immune system. This acquired knowledge might 
consequently be applied to further improve antiviral drugs and vaccine strategies. 
 
4.1. pDCs as potent source of type I and III IFNs upon infection 
with MERS-CoV  
The observation that some patients who failed to promote type I IFN production upon 
MERS-CoV infection (91) suffered from a more severe disease, indicates a correlation of 
innate immune responses with progress of the disease. However, human epithelial cells (46, 
147, 330), macrophages (325) and bronchial and lung tissue samples from healthy donors 
cultured ex vivo (46) failed to secrete type I IFNs upon MERS-CoV infection. Consistent with 
these publications, we could demonstrate that MERS-CoV was not capable of triggering type 
I and III IFNs in most human immune cells, including macrophages, B cells, and human 
monocyte-derived DCs (MDDCs). By contrast, the secretion of IFN-β, IFN-λ, and particularly 
IFN-α by plasmacytoid dendritic cells (pDCs), helped identify pDCs as a potent source of 
type I IFNs in response to MERS-CoV by the human immune system. The identified 
mechanisms involved in infection of pDCs and induction of type I IFN responses are 
summarised in Fig. 34: 
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Fig. 34 Model for MERS-CoV-induced 
infection and type I IFN secretion in 
human pDCs. The figure schematically 
depicts the life cycle of MERS-CoV in 
human pDCs. MERS-CoV most likely enters 
pDCs after binding to DPP-4 and 
subsequent endocytosis. Amplification of 
viral RNA and expression of viral protein 
takes place after release of the replication 
machinery into the cytosol. Further steps 
of assembly, budding or release of viral 
particles are inhibited.  Viral ssRNA is 
sensed via TLR7 in the endosome resulting 
in the expression of particularly IFN-α. 
Replication intermediates like dsRNA are 
sensed by unknown mechanisms, which 
results in the production of IFN-β.  Written 
in bold letters and greenly edged are 
treatments which were experimentally 
conducted by Scheuplein et al . , 2015. 
Questions marks indicate supposed 
mechanisms, which remain to be 
investigated (239)      
 
 
MERS-CoV was shown to initially infect pDCs via binding to DPP-4 and subsequent 
endosomal uptake. Amplification and transcription of viral RNA likely takes place after 
release of the viral replication machinery into the cytosol. The sensing of MERS-CoVs RNA 
by PRRs in the endosomes thereby induces secretion of type I and III IFNs, particularly IFN-
α. Secretion of IFN-β is likely to be mediated by sensing of amplified MERS-CoV dsRNA after 
release of the viral replication machinery into the cytosol in addition. However, MERS-CoV 
failed to fully replicate in pDCs, which indicates that further steps during viral assembly, 
budding, or release are blocked after transcription and amplification of viral RNA.  
Besides giving insights into viral replication, our results appear important in unravelling 
potential factors of MERS-CoV-induced severe pathogenicity. Several reports demonstrated 
that type I IFNs play a significant role in the clearance of various viruses like CCHFV (24), 
chikungunya virus (CHIKV) (234) or measles virus (MV) (189). Our findings, combined with 
previously published results (46, 147, 325, 330), question the role that the considerable, 
but exclusively pDC-mediated type I IFN production might have in humans. In fact, MERS-
CoV replication in vitro has been shown to be highly sensitive to treatment with IFN-α in 
ng/ml concentrations (89, 298) indicating that the amounts secreted by pDCs might be 
relevant. However, while the production of type I and III IFNs may be a cause of suppressed 
MERS-CoV replication in pDC cell culture, its relevance in vivo remains to be investigated in 
animal models or clinical studies. 
Regarding other viruses, IFN production by pDCs has been demonstrated to be responsible 
for clearance of respiratory syncytial virus (RSV) (253, 282), vesicular stomatitis virus 
(VSV) (264) or murine cytomegalovirus (MCMV) (264) in mice (264). However, at high viral 
doses, the role of pDCs in MCMV clearance, for example, has been negligible. This may have 
been due to the low numbers of pDCs at the sites of viral replication (264). Interestingly, 
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MERS-CoV infections and especially those with severe outcome, are mostly found in the 
elderly (6), who are known to have fewer and less functional pDCs (131, 245). 
Consequently, decline of type I IFN production by pDCs in elderly patients might be a 
correlate of severe disease and would suggest that pDCs play a significant role in MERS-CoV 
clearance.  
On the other hand, severe pathogenicity of some viruses like influenza subtype H5N1 (134) 
or human enterovirus (EV71) (285), is characterised by immunopathogenicity based on 
overshooting cytokine responses (148). The latter is also considered to be a cause of SARS-
CoV-induced severe inflammation of lung tissue (45). Accordingly, SARS-CoV infected 
patients, who suffered from a more severe outcome and were more likely to succumb to 
disease (41), exhibited elevated levels of pro-inflammatory cytokines in the serum (303).  
A potential cause of this postulated immunopathogenicity is assumed to exist in delayed 
type I IFN responses accompanied by rapid replication of the virus (149). In infected mice, 
both factors — secretion of type I IFNs and considerable replication of SARS-CoV —
synergistically resulted in a vast secretion of immunopathogenic pro-inflammatory 
cytokines by recruited inflammatory monocyte-macrophages (IMMs) (45). Delayed type I 
IFNs responses are assumed to be mediated, particularly if the immediate secretion of type 
I IFN by infected cells is inhibited. This has been observed for coronaviruses that evade 
cytosolic RLR sensing, like SARS-CoV or mouse hepatitis virus (MHV) (149).  
While SARS-CoV, like MERS-CoV, tends to suppress type I IFNs in human epithelial cells, 
macrophages (329) and cDCs (44, 329); human pDCs have also been identified as potent 
producers of IFN-α/β upon SARS-CoV infection (45). The exclusive capability of pDCs to 
secrete type I IFNs was assumed to result in potent, but delayed IFN-I secretion in mice 
infected with SARS-CoV and thus likely in immunopathogenicity (149).  
Type I IFN production by pDCs upon infection with ssRNA viruses is mostly mediated 
through the sensing of viral ssRNA via TRL7 (13, 205). In contrast, non-haematopoetic cells 
are known to secrete IFN-β exclusively and macrophages and cDCs mostly (in addition to 
TLR-3 in the endosomes) (13) after sensing of viral dsRNA by cytosolic MDA-5 (long dsRNA) 
(265) or RIG-I (phosphorylated ssRNA, short dsRNA) (265). Consistent with the findings of 
previous publications, we demonstrated that the secretion of IFN-α (138, 174), IFN-β (232), 
and IFN-λ (205) by pDCs depends on recognition of viral RNA by TLR-7 in the endosomes. 
Interestingly, immune evasion strategies proposed for MERS-CoV mostly assume 
interference with the sensing of dsRNA by cytolic RLR (298) or RLR-induced signalling 
pathways (15, 249). By implication then, it would be probable to suppose that type I IFN by 
pDCs might be unimpaired as a consequence of ssRNA sensing via TLR-7. By contrast, RLR- 
mediated sensing of RNA is known to play a subordinate role in pDCs (240). It has so far 
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only been shown for some negative-sense RNA viruses like human respiratory syncytial 
virus (hRSV) (121) or VSV (18), which enter the cell via the plasma membrane. For other 
viruses, like influenza viruses (73), type I IFN secretion tends to be independent of viral 
replication. In our study, secretion of IFN-β, but not IFN-α or IFN-λ by pDCs was shown to 
depend on live virus and hence, the presence of replication intermediates like dsRNA, in the 
cytosol. Whether expression of IFN-β upon MERS-CoV infection is mediated via RLR sensing 
remains to be investigated. 
Nevertheless, the fact that type I IFN responses are restricted to pDCs (44) taken together 
with the similarity of symptoms in both SARS-CoV and MERS-CoV (320), indicates that 
immunopathogenicity may also play a role for MERS-CoV. In line with this argument, Zhou 
et al. previously observed that MERS-CoV induces the secretion of large amounts of pro-
inflammatory cytokines like IL-12 and IFN-γ and chemokines like IP-10, CXCL-10 or 
RANTES in human macrophages (325). Moreover, infiltration of macrophages and 
neutrophils into infected lung tissue was observed in MERS-CoV-infected patients (105, 
320), rhesus macaques (192), and also in MERS-CoV susceptible mice (172, 280). Whether 
this infiltration of immune cells and pathogenicity is associated with potentially delayed 
type I IFN secretion by pDCs, as proposed for SARS-CoV, remains to be investigated. 
However, then, regulation of type I IFN production by pDCs could be considered as potential 
target of antiviral therapy. 
In any event, an effective vaccine, inducing protective adaptive immune responses, would 
be beneficial, especially in at-risk patients. Consequently, this thesis aimed to produce and 
characterise such a potential pre-pandemic vaccine to protect against the highly-pathogenic 
MERS-CoV. 
 
4.2. MV-MERS-S is an efficient vaccine to protect against  
MERS-CoV 
A putative vaccine against MERS-CoV or similar emerging infections should be safe, 
immunogenic, rapidly available and its production should be cost efficient. For this purpose, 
replication-competent measles virus (MV) constitutes a promising tool, since it is based on 
an efficient vaccine with a remarkable safety profile (102, 238). Moreover, an established 
rescue system (218) not only enables the fast generation of recombinant MV clones from 
DNA plasmids; but also, the insertion of open reading frames (ORFs) encoding for foreign 
antigens into MV's genome. For this reason MV has already been utilised as a vaccine 
platform protecting against MV and a wide variety of other foreign pathogens (69, 164, 248) 
as described in 1.5 (Tab. 2).  
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To characterise whether MV also constitutes an appropriate vaccine platform against 
MERS-CoV, we generated recombinant viruses which expressed the full-length surface 
protein spike (MERS-S) of MERS-CoV and a truncated version of MERS-S lacking the 
transmembrane domain (MERS-solS). Comparable to other so-far developed vaccines  
(Tab. 3), replication-competent MV-MERS-S and MV-MERS-solS14 induced potent antibody 
responses capable of neutralising infectivity of MERS-CoV. However, although we aimed to 
induce stronger humoral immune responses by generation of MV-MERS-solS, VNTs 
provoked by this vaccine were similar; and MERS-S-specific Abs, just slightly higher than 
those induced by MV-MERS-S. Interestingly, a DNA vaccine encoding MERS-S lacking the 
transmembrane (TM) domain (MERS-SΔTM) did even induce significantly lower titres of 
nAbs than MERS-S (283). For SARS-S, where a similar phenomenon has been observed 
(313), conformational  alteration of the soluble spike protein and thereby induction of Abs 
which do not efficiently bind to native SARS-S was supposed to be the putative cause (313). 
Such alterations might also apply for MERS-solS and affect the conformation of the MERS-
RBD, thereby resulting in less functional MERS-CoV- neutralising Abs. 
Although most experimental vaccines rely on full-length MERS-S and are thus comparable 
to our vaccine approach, methodological differences in Ab titre determination makes direct 
comparison a challenge. However, VNTs induced by MVA-MERS-S (255) and Ad5.MERS-S 
(144) were calculated as the reciprocal of the highest dilution absolutely neutralising MERS-
CoV infectivity and are hence, at least based on methodology, comparable to our vaccines. 
Considering that 103-fold fewer viral particles than MVA and 106-fold fewer than Ad5 were 
applied in our study, MV-MERS-S still induced robust VNTs (Tab. 3). That aside, it should be 
noted that MVA and Ad5-induced immune responses were tested in Balb/c wt mice, 
whereas IFNAR-/-CD46Ge mice on a C57BL/6(BL/6) background were used for examination 
of MV-MERS-S. While Balb/c mice are predominantly characterised by a Th2-mediated (and 
thus humoral) immune response, Th1- and hence, cellular immunity prevails in BL/6 mice 
after vaccination (34, 182, 237). Furthermore, vaccine-induced Ab production by B cells (94, 
55) may also be influenced by the abortive effects of IFNAR signalling (see 1.2) (119, 127, 
240) in IFNAR-/-CD46Ge.  
Focusing on cellular immunity, T cell responses have so far been demonstrated for DNA 
(195) and VLPs (281) in non-human primates; and recombinant RBD (157), DNA (195), 
MVA (280), Ad5/Ad45 (107) and MV (172), in mice (Tab. 3).  
  
                                                             
14 MVvac2-MERS-S(H) and MVvac2-MERS-S(H) for simplification termed MV-MERS-S and MV-MERS-solS 
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Tab. 3 Experimental MERS-CoV vaccines. *clinical trial started; underlined, assays comparable to MV-
MERS-S or MV-MERS-solS; grey, not tested. 
Vaccine 
platform 
Construct Pre-clinical development Reference 
  
Immunogenicity Protection 
 
Life-
attenuated 
recMERS-CoV 
 
 
(5) 
Subunit Full lenght S 
trimers  
Mice (Balb/c): 
 Humoral (VNTs) 
 
(50)  
RBD fused 
with human FC 
Mice (Balb/c): 
 Humoral (VNTs)  
 Cellular (IFNγ ICS) 
Rabbits 
 Humoral (VNTs) 
Mice (Balb/c): 
 reduced viral titers  
(below detection limit after 
vaccination) 
(170, 171, 
322) 
Truncated 
RBD 
Mice (Balb/c): 
 Humoral (MERS-S1 Abs, VNTs)  
 Cellular (IFNγ -ELISpot: approx. ca. 
200 SFC/106 splenocytes, cytokines) 
 
(80, 157, 
188) 
MERS-CoV 
VLPs  
Rhesus macaques: 
 Humoral (MERS-S-RBD Abs, VNTs)  
 Cellular (IFNγ / IL-4 ELISpot) 
 
(281)  
DNA* Full length 
MERS-S 
Mice (C57BL/6): 
 Humoral (MERS-S Abs, VNTs)  
 Cellular (IFNγ -ELISpot: approx.  
3,000 SFC/106 splenocytes; IFNγ-, 
TNF-α and IL-2 ICS) 
Rhesus macaques: 
 Humoral (MERS-S- Abs, VNTs)  
 Cellular (IFNγ ELISpot/ICS, TNF-α 
and IL-2 ICS) 
Dromedary camels: 
 Humoral (MERS-S Abs, VNTs) 
Rhesus macaques:  
 reduced viral loads 
 reduced clinical signs 
(195) 
Mice (Balb/c): 
 Humoral (MERS-S1 Abs, VNTs)  
Rhesus macaques: 
 Humoral (MERS-S-RBD Abs, VNTs)  
 Cellular (IFNγ / IL-4 ELISpot) 
Rhesus macaques:  
 reduced clinical signs 
(283) 
MERS-S1, 
MERS-SΔTM 
Mice (Balb/c): 
 Humoral (MERS-S1 Abs, VNTs)  
 
(283) 
Rec. 
vectors 
Ad5.MERS-S or 
S1 
Mice (Balb/c): 
 Humoral (MERS-S RBD Abs, VNTs: 
MERS-S: approx. 1,500, MERS-S1 
approx. 2,048)  
 
(144) 
Ad5/ Ad45 S Mice (Balb/c): 
 Humoral (MERS-S RBD Abs, VNTs)  
 Cellular (IFNγ -ELISpot: approx. ca. 
400 SFC/106 splenocytes, cytokines) 
 
(107) 
MV-S/ MV-solS Mice (IFNAR-/-CD46Ge BL/6): 
 Humoral (MERS-S Abs, VNTs: approx. 
840)  
 Cellular (IFNγ ELISpot: approx. 2,000 
SFC/106 splenocytes, Proliferation, 
CTL response) 
Mice: 
 reduced viral loads 
(130- -190-fold) 
 reduced viral titers 
(5- -13-fold reduction) 
 reduced clinical signs 
(172) 
MVA-MERS-S Mice (Balb/c):  
 Humoral (VNTs: approx. 1,500)  
 Cellular (IFNγ -ELISpot: approx.  
1,500 SFC/106 splenocytes) 
Dromedary camels: 
 Humoral (mucosal, VNTs)  
Mice (Balb/c): 
 reduced viral loads  
(50- -700-fold reduction) 
 reduced clinical signs 
dromedary camels: 
 reduced excreted infectious 
virus 
 reduced excreted viral RNA 
transcripts 
(108, 255, 
280) 
RABV-MERS-
S1 
Mice (Balb/c):  
 Humoral (MERS-S1 Abs, VNTs)  
Mice (Balb/c): 
 reduced viral loads  
(390-fold reduction) 
 reduced viral titers  
(below detection limit after 
vaccination) 
(299) 
VRP-MERS-S Mice (Balb/c): 
 Humoral (protective sera, titers not 
shown)  
 
Mice: 
 reduced viral titers 
(below detection limit after 
vaccination) 
(324) 
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Taking into consideration the numbers of IFN-γ secreting T cells among splenocytes, the 
expression of MERS-S by DNA (195), MVA (280), and MV (172) induced the most potent 
cellular immune responses (Tab. 3). However, in contrast to other studies, T cell responses 
induced by MV-MERS-S and MV -MERS-solS, were detected after co-cultivation of 
splenocytes with MERS-S expressing DC cell lines for antigen-specific recall. Nevertheless, 
T cell responses re-stimulated by these cell lines were comparable to those reactivated by 
the immunodominant MERS-CoV peptide S1165 (324) as also demonstrated for Ova 
expressing cells. Thus, transgenic DC cell lines were shown to be a suitable alternative for 
antigen-specific recall without intensive knowledge of immunodominant peptides and the 
time-consuming production of recombinant proteins. By application of these cell lines, T 
cells of MV-MERS-S and MV-MERS-solS vaccinated mice – as only vaccines so far –were 
additionally shown to respond to MERS-S specific recall by antigen- specific proliferation of 
CD8+ T cells and CTL effector responses. CTL effector responses may be critical for 
protection as demonstrated for a number of viruses like influenza (223) or CMV (38).  
With regards to studies of protection efficacy, the lack of susceptibility of mice to MERS-CoV 
infection (49) was overcome by i. n. transduction with AdV-hDDP-4. Mice treated this way 
became susceptible to infection by expression of the MERS-CoV entry receptor (324) and 
could then be used to test the efficacy of different experimental vaccines against MERS-CoV 
(280). Using this method, protection efficacy in Balb/c mice has been demonstrated for 
recombinant MERS-S RBD fused with human FC (322), as well as the vector-based vaccines 
Venezuelan equine encephalitis virus replicon particles encoding MERS-S (VRP-MERS-S) 
(324), MVA- MERS-S (280) and RABV- MERS-S1 (299) (Tab. 3). 
However, in contrast to Balb/c mice, 40% of IFNAR-/-CD46Ge mice used in our study were 
not susceptible to MERS-CoV infection, even though AdV-hDDP-4 transduction in 60% of 
these mice was efficient. The reasons for lack of MERS-CoV susceptibility in the remaining 
mice is so far not understood, but indicates that AdV-hDDP-4-transduced  
IFNAR-/-CD46Ge mice do not appear to be an optimal model for characterisation of 
protection efficacy by MV-based vaccines against MERS-CoV. Nevertheless, despite the 
drop-out rate, significant differences in viral loads, reduced infectious titres and, most 
importantly, reduction of clinical signs between control and MERS-S-vaccinated became 
evident. Thus far, MV-based MERS-CoV vaccines are one of only six different experimental 
vaccines that have showed robust protection efficacy in appropriate animal models  
Remarkably, experimental MVA-MERS-S (109) and DNA vaccine encoding full-length MERS-
S induced humoral immune responses in dromedary camels (195), the suspected natural 
reservoir of MERS-CoV (108, 179). A reduced shedding of MERS-CoV as demonstrated for 
MVA-MERS-S vaccinated camels (109) might then prevent transmission of MERS-CoV to 
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humans if dromedary camels are vaccinated. Such veterinary use of MV-based vaccines 
seems quite unlikely, certainly initially, since efficacy of protection depends on active 
replication of rMV in the vaccinated host, as demonstrated (Fig. 16, Fig. 26). However, 
dromedary camels can be infected with Peste des petits ruminants (PPR) (139) or 
Rinderpest virus (RPV) (72), two close relatives of MV. Interestingly, camel kidney cells 
have also been shown to be susceptible in vitro, at least under certain circumstances, to MV 
infection (183). Moreover, the MV vaccine is, in principle, able to induce immune responses 
in non-human species such as dogs (11) or cattle, where it is has been shown to protect 
calves against RPV challenge (215). Thus, it might be considered to test the immunogenicity 
of MV-MERS vaccines in camels.    
As a first step, though, clinical trials have been started, or are in the planning stages, in order 
to analyse the efficacy of experimental vaccines in man (184). Among potential vector-based 
vaccines, inactivated RABV or replication-competent MV as platform, have the advantage of 
being based on vaccines historically known to be efficient and safe for use in humans (102, 
238, 294). On the other hand, already-implemented vaccination in patients carries with it 
the potential risk that pre-existing immunity might reduce the efficacy of these vaccine 
platforms.  
Considering the effects of pre-formed MV immunity in mice, we observed that single-pre-
vaccination with pure MV vaccine did not impair MV-MERS-S-induced nAb titres in a 
preliminary experiment. This observation is consistent with previously published results, 
where the induction of respective pathogen-specific Abs by MV-HIV (164) or MV-CHIKV 
vaccines (33) was also not affected by single-pre-vaccination of mice with an empty MV 
vaccine strain. However, neither the effects on induced cellular immune responses, nor the 
effects of double-pre-vaccination, have yet been tested so far. Here, we observed that MERS-
S-specific cellular immune responses were significantly reduced if mice were pre-
vaccinated once or twice with pure MV vaccine. Whether these reduced, yet still detectible 
T cell responses, and still induced MERS-CoV nAbs are protective against MERS-CoV, 
remains to be analysed. Interestingly, residual MV-CHIKV-induced CHIKV-specific immune 
responses in mice pre-vaccinated once prior, did prove protective against CHIKV challenge 
(33). Thus, if nAbs are a correlate of protection, as they are for CHIKV (33), then humoral 
immune responses, at least in once-pre-vaccinated mice, might be sufficient for protection, 
even if T cell responses are significantly reduced. Indeed, there are indications for a 
correlation between humoral immunity and protection since passively transferred sera 
from VRP-MERS-S immunized mice were shown to be protective (324).  
Keeping in mind that VNTs in this single experiment were unusually low, a reduction of 
MERS-CoV nAbs to titre levels below detection after double-pre-vaccination might, on the 
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contrary, be of relevance. However, it has to be noted that mice were vaccinated with MV-
MERS only two months after boost pre-vaccination and hence, at time points of high MV nAb 
titres. In the light of biological relevance, humans would be vaccinated years after initial MV 
vaccination and consequently, at time points of lower nAb titres, which are known to 
decrease over time (65, 66). In line with this argument, a recant phase-I clinical trial has 
impressively demonstrated that MV-CHIKV was potent in inducing α- CHIKV Abs in measles 
pre-immune patients (219). Here, immunogenicity of a MV-based vaccine was not only 
transferred from mice to men, but also shown to be indeed unaffected by pre-existing 
immunity. Thus, whether the used pre-vaccination set-up is an appropriate model to display 
the physiological situation in man, remains to be tested in a clinical trial. 
Taken together, we could demonstrate that MV-MERS-S and MV-MERS-solS are efficient 
experimental vaccines that are capable of triggering protective MERS-CoV specific humoral 
and cellular immunity in vivo. Besides the five other experimental vaccines that have so far 
demonstrated protection efficacy, these, consequently, merit testing as vaccines against-
MERS-CoV in clinical trials.  
Vaccination targeting MERS-S is likely to be successful, since circulating MERS-CoV stains 
represent one single serotype (194), indicating that MERS-S has so far not undergone 
significant amino acid changes. Nevertheless, already-described mutations in MERS-CoVs 
glycoproteins (143, 146, 169) do indicate the potential for antigenic variations in future. A 
positive selection of escape mutants would therefore make a supportive vaccination 
prudent. These mutants would have to be of unaffected or even enhanced virulence; and the 
vaccination would need to be based on usually more conserved nucleocapsid proteins. 
Given these possibilities, this thesis also aimed to characterise an alternative MV-derived 
vaccine encoding MERS-N. 
 
4.3. MV-MERS-N as alternative vaccine against MERS-CoV 
Although the glycoprotein spike is the primary target of prophylactic vaccines against 
coronaviruses, targeting the coronavirus nucleocapsid protein (N) of, for example, SARS-
CoV (145, 161), mouse hepatitis virus (MHV) (260), or avian infectious bronchitis virus 
(IBV) (239) has also been shown to induce potent cellular immune responses in vivo. For 
IBV, N-specific immune responses induced by Semliki Forest virus (SFV) vector (239) or 
recombinant fowl poxvirus (rFPV) (318) encoding IBV-N have proved to be even protective 
against IBV challenge in chickens.  
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By generating MV-MERS-N15, we demonstrated that a potential vaccine candidate against 
MERS-CoV targeting MERS-N was also potent to induce antigen-specific cellular immunity. 
Here, the immune response was comparable to that of MV-N or H7-specific cellular 
immunity, although still significantly lower than those triggered by MV-MERS-S or MV-
MERS-solS. Notably, besides considerable MERS-S-specific IFN-γ secretion by T-cells, 
MERS-S was additionally the only antigen which triggered proliferation and CTL effector 
responses when testing splenocytes of immunised mice. This indicates a remarkably strong 
immunogenicity of MERS-S, particularly to induce CD8+ T cell responses. Interestingly, most 
immunodominant H2b-restricted T epitopes that were recognised by MERS-CoV-induced 
CD8+ T cells of BL/6 mice, were located in the S; but not N, protein (324). This observation 
might explain the considerable MERS-S specific CTL-responses in IFNAR-/- CD46Ge mice 
(BL/6 background). By contrast, at least one epitope of MERS-N, N214, was shown to be 
immunodominant in Balb/c mice (324). Therefore, results might look different in these 
mice, that have another peptide-presenting haplotype. Nevertheless, detection of MERS-N 
specific IFN-γ secreting T cells among splenocytes of MV-MERS-N immunized mice indicates 
that MERS-N indeed includes immunodominant H2b-restricted epitopes. Whether these are 
recognized by CD8+ or CD4+ T cells and whether the observed immunogenicity or potential 
immunogenicity in other models is relevant for protection though, should be tested as a next 
step.  
In conclusion, then, this weaker immunogenicity in comparison to MERS-S might be a bias 
resulting from the animal model, but might still be due to peptide presentation by the 
transgenic DC cell lines, and so warrants further investigation. Nevertheless, MV-MERS-N 
could serve as an alternative or supportive vaccine approach against MERS-CoV. Both 
MERS-N and MERS-S could even be co-expressed by recombinant MV to induce neutralising 
Abs, as well as cellular immunity by targeting a conserved nucleoprotein. 
 
4.4. MV as vaccine platform against other highly pathogenic 
viruses like H7N9 or CCHFV 
To further utilise MV and analyse its properties as a vaccine platform against highly 
pathogenic viruses other than MERS-CoV, this thesis also aimed to generate MV-derived 
vaccines against the avian influenza virus H7N9 and Crimean-Congo haemorrhagic fever 
virus (CCHFV).  
                                                             
15  MVvac2-MERS-N(H) for simplification termed MV-MERS-N 
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Insofar as MVs targeting MERS-CoV are concerned, recombinant vaccines encoding antigens 
of those viruses have the potential to be rapidly rescued; and the expression of most 
antigens in cells infected with respective vaccines confirmed. However, the so far 
unsuccessful detection of the glycoprotein Gn of CCHFV demonstrates that in vitro 
examination of vaccines against pathogens that are not yet well characterized can be 
challenging. The failure to detect preGn, even in an inactivated CCHFV lysate used as a 
positive control, was, in this instance, most likely due to the unsuitability of the two 
antibodies used to bind preGn under denaturing conditions in western blot analysis, as has 
already been described (26).  
With regards to replication of MV-H7N9 and MV-CCHFV vaccines, the insertion of respective 
antigen encoding genes had no effect on propagation of MV-H7, MV-N9 and 16 of 18 MV-
CCHFV constructs. However, two vaccines, MVvac2-CCHFV-solGn(P) and particularly MVvac2-
CCHFV-G-FL(P), revealed instances of impaired replication. The considerable size of the 
inserted CCHFV-M segment (5.4 kb) might be a factor here. It may somehow interfere with 
the growth of MVvac2-CCHFV-G-FL(P), even though insertions of approximately 4 kb 
appeared to have no impact, as shown for full-length spike proteins of  SARS-CoV (161) or 
MERS-CoV (172). Interestingly, interference in both cases was only observed when 
additional gene cassettes were inserted into a position proximal to the promotor (post P) 
and not in post H position. However, while insertions upstream of  the N gene are known to 
affect growth of recombinant MV in some cases (221), insertion into positions distal to the 
N gene should normally not be problematic. Nevertheless, expression of antigens by the post 
P position of MV is higher compared to positions distal to the promotor and potential 
interference of expressed antigens, consequently stronger (27). Such interference might be 
exerted by toxicity of the antigens on infected cells, as described for MVs expressing ecto 
domains of dengue (31), thereby affecting replication of the vaccine. However, toxicity of 
CCHFV glycoproteins has not been described thus far (26, 307). Another possibility might 
entail interference of membrane-bound proteins, like those encoded by MVvac2-CCHFV-G-
FL(P), with, for example, viral assembly by competition with MV glycoproteins, as described 
for an MV encoded fusion protein (F) of mumps virus (MuV) (287). Moreover, the complex 
processing machinery of CCHFV glycoproteins (230) could also somehow interfere with the 
replication cycle of MV. However, this needs to be investigated further.  
In the case of CCHFV-solGn, interference might be due to a misfolded protein with altered 
characteristics caused by truncation. Indeed, abortive localisation to the Golgi-apparatus 
and hence, expression of a misfolded protein has been described for Gn constructs lacking 
the mucin-like and P35 region of preGn (26). Although abortive localisation to the Golgi-
apparatus hence predicts altered folding for both MV-CCHFV-Gn and MV-CCHFV-solGn, the 
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additional truncation of the transmembrane might also result in altered characteristics such 
as, for example, toxicity. However, the exact effects of such constructs remain open to 
question and warrant further investigation.  
Thus, although most MV-CCHFV constructs expressed the inserted antigens without causing 
any effects on the vaccines replication, further in vitro analysis is required to select the most 
promising CCHFV vaccine candidates for testing in vivo. Since an experimental MVA vaccine 
encoding both glycoproteins (encoded by full-length CCHFV-M segment) has been shown to 
induce protective humoral and cellular immunity (40, 77) in vivo, MVvac2-CCHFV-G-FL, might 
also prove to be a promising vaccine candidate. Immune responses against the more 
conserved nucleocapsid protein of CCHFV (116), which  were not protective in the case of 
MVA (77), could, moreover, support the efficacy of MVvac2-CCHFV-G-FL for example.  This 
could result in increased cross-protection against the seven different CCHFV strains (71). 
In contrast to MV-CCHFV, the immunogenicity of MV-H7 and MV-N916 has already been 
demonstrated in vivo during this thesis. Here, both vaccines induced considerable titres of 
H7N9 binding Abs, while Abs that completely neutralised H7N9 A/Shanghai/2/2013-
A/PR/8/34 infectivity were detectible after vaccination with MV-H7, but not with MV-N9. 
Induction of nAbs by MV-H7 was expected, since α-HA Abs induced by vaccination may 
hinder HA – the receptor binding protein of influenza viruses – from  binding to sialic acids 
and consequently prevent viral entry (242). Influenza NA, by contrast, is responsible for 
virus particle release by removal of bound sialic acids from the cell and virus surface (141, 
241, 266, 301). Hence, induced Abs binding NA prevent removal of sialic acids by NA, which 
results in increased aggregation of viruses on the cell surface (266, 301). Even though these 
Abs are not completely neutralising in terms of their effect, the aggregation of particles may 
result in reduced shedding of viral particles and thereby help to mediate protection in vivo 
(235). Indeed, α-N9 Abs induced by N9 expressing vaccinia virus (rVac-N9 NA) were shown 
to reduce the replication of H7N9 in vitro (130).  
Although the effects of MV-N9-induced Abs on replication of H7N9 have so far not been 
tested, they did show evidence of being able to inhibit the enzymatic functionality of N9 to 
cleave sialic acid. This demonstrated inhibition of enzymatic functionality will most likely 
result in aggregation of viral particles (266, 301) and consequently, reduced replication 
(130). Surprisingly, Abs induced by MV-H7 also inhibited the NA-specific activity of H7N9 
A/Shanghai/2/2013-A/PR/8/34. This NA inhibition by α-HA Abs is likely attributable to 
the steric hindrance of H7N9 A/Shanghai/2/2013-A/PR/8/34 NA by Abs bound to the HA, 
a mechanisms already described elsewhere (57, 142).  
                                                             
16 MVvac2-H/(P) and MVvac2-N9(P) for simplification termed MV-H7 and MV-N9 
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Although protection against many viruses such as SARS-CoV (261, 313) is mediated by 
antibodies, influenza viruses are known to continuously evade neutralising Abs by antigenic 
shift (point mutations in the glycoproteins) and drift (exchange of genomic segments 
against other subtypes) (75). Thus, Abs induced by vaccines often do not protect against 
escape mutants. By contrast, cellular immunity mediates higher cross-protection against 
other influenza subtypes (95, 177, 291) and was generally shown to be important for 
recovery from influenza viruses like H3N2 or H1N1 - at least in animal experiments (23). In 
line with this observation, the induction of cytotoxic T cell responses also appears to 
correlate with reduced H7N9 pathogenicity in human patients (288).  
In addition to Abs neutralising H7N9, MV-H7 was shown to induce H7-specific cellular 
immune responses, which were characterised by a H7-specific IFN-γ secretion from isolated 
spleen cells. These detected T cell responses might hence increase the likelihood of the 
vaccine to be protective (288). However, although splenocytes from MV-N9-vaccinated 
mice contained more IFN-γ secreting cells than those of control mice, these responses were 
not restricted to re-stimulation by N9-expressing DCs but also provoked by untransduced 
DC cell lines. Even though DC cell lines also provoked a slight unspecific IFN-γ response by, 
for example, MERS-N or H7-specific T cells, background responses were approximately 
three-fold higher for T cells of MV-N9-vaccinated mice. This observation indicated that 
unspecific re-stimulation correlated with immune responses induced by this specific 
vaccine.  Interestingly, MVvac2-N9(P) exhibited a slightly more stable replication than other 
viral vaccines generated during the course of this thesis. Thus, it might be possible that viral 
proteins may still be present among splenocytes due to the longer persistence of MVvac2-
N9(P) in the spleen. In Uhlig et al. we demonstrated that APCs isolated four days after 
vaccination with Ova-transferring PTVs are still capable of activating Ova-specific T cells. 
These results indicated that presentation of Ova-peptides was still ongoing at this time-
point of splenocyte isolation (286). This being the case, further expressed viral proteins 
might be taken up by DCs, thereby resulting in an unspecific re-call of virus-specific T cells. 
This could also be an explanation for the generally high background stimulation of DC3.2 
cells, which are known to be potent in their expression of exogenous antigen (253). Further 
investigation concerning this long presentation of antigens but also regarding possible 
influences of DC cell-lines in this example seems therefore to be worthwhile. 
Even though both MV-H7 and MV-N9 induced humoral responses, with at least MV-H7 
showing evidence of cellular immune responses, as yet, protection by these vaccines has not 
been tested. Already though, several published experimental vaccines, including VLPs (216, 
236), DNA (314) and MVA (154) have shown efficacy in protecting ferrets (216, 154) and 
mice (216, 236, 314) from challenge with H7N9 by induction of H7-specific immune 
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responses. Considering humoral immune responses, HAI titres of about 18-40 are normally 
associated with 50% infection risk in human patients (82, 118, 212). Titres of 160 were 
even shown to reduce the likelihood of infection with influenza H3N2 by 95 % (212). 
Experimental DNA or VLP vaccines, targeting H7 as antigen, induced HI titres of approx. 60 
(216), 50 (236) and 150 (314), respectively, and were protective in mice. Hence, HI titres of 
about 200 induced by MV-H7 are also likely to be protective against H7N9 challenge. 
Moreover, cellular immunity induced by MV-H7 is comparable to T cell responses provoked 
by a protective DNA vaccine (400/106 splenocytes vs. 500/106 splenocytes) and might be a 
further indicator for protection.  
Thus, this PhD thesis has demonstrated that MV-derived vaccines have the potential to be 
used as vaccines against highly pathogenic viruses like H7N9 of the Orthomyxoviridae or 
CCHFV of the Bunyaviridae family. Taken together, the data suggests that vaccine-derived 
MV has the potential to become a promising vaccine platform that may be applied as a first 
line of defence against different emerging, highly pathogenic viruses. 
 
4.5. Conclusion 
This thesis contribution towards the development of potential vaccines against emerging 
infections by providing insights into the pathomechanisms of a highly pathogenic emerging 
virus, as well as establishing the appropriate assays needed to test the immunogenicity of 
vaccines in vivo, and by outlining a potential vaccine platform derived from recombinant 
measles viruses. To summarise:  
Interaction of MERS-CoV with innate immune cells: We identified pDCs as a remarkably 
potent but exclusive source of antiviral type I and type III IFNs (233). Here, we uncovered 
the mechanisms of viral entry, as well as the replication and sensing of viral RNA essential 
in the production of type I and III IFNs by infected pDCs. These results may serve as a basis 
from which to analyse the protective properties of pDCs as well as their role as a potential 
pathomechanism of MERS-CoV. Such knowledge might prove essential for future antiviral 
drug development or vaccine design focusing on pDCs as potential targets.  
Setting up a system to re-stimulate T cells ex vivo and to analyse T cell responses: We 
established set-ups for vaccination and immunological assays in order to analyse cellular 
immune responses (172, 276). The application of transgenic DC cell lines, which stably 
express full-length ORFs of antigens, was found to be suitable for the re-stimulation of 
antigen-specific T cells for five different antigens induced by two different vaccine 
platforms. Hence, it was established from this work that transgenic DC cell-lines allow for 
D I SC U S S IO N  
 
 63 
the re-stimulation of T-cells without any need for deeper knowledge of immunodominant 
peptides or the availability of recombinant proteins.  
Generation and characterisation of vaccine-derived MV as pre-pandemic vaccine platform: 
We generated MV-derived vaccines against emerging infections, which were characterised 
as follows:   
1. Rapid production of vaccines against three viruses belonging to three distinct 
families Coronaviridae, Orthomyxoviridae and Bunyaviridae  
2. Insertion of antigen-encoding ORFs up to 5 kb and expression of full-length antigens 
in infected cells 
3. Induction of humoral immune responses by MVvac2-H7(P), MVvac2-N9(P),  
MVvac2-MERS-S(H) and MVvac2-solS(H) 
4. Induction of cellular immune response by MVvac2-H7(P), MVvac2-MERS-N(H),  
MVvac2-MERS-S(H) and MVvac2-solS(H) 
5. Protection efficacy as demonstrated against MERS-CoV challenge in mice. 
These findings, when combined with already published data, serve to demonstrate that MV 
is a promising vaccine platform that may be used against various viruses. These include DNA 
viruses like HBV (Hepadnaviridae) (248), but also RNA viruses like HIV (Retroviridae) (164), 
WNV (Flaviviridae) (32) or the demonstrated MERS-CoV (Coronaviridae) (172) and H7N9 
(Orthomyxoviridae). All these vaccines have the advantage of being expressed in the 
backbone of a long-term applied, efficient, and safe vaccine. 
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ABSTRACT
TheMiddle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 as the causative agent of a severe respiratory
disease with a fatality rate of approximately 30%. The high virulence andmortality rate prompted us to analyze aspects of MERS-
CoV pathogenesis, especially its interaction with innate immune cells such as antigen-presenting cells (APCs). Particularly, we
analyzed secretion of type I and type III interferons (IFNs) by APCs, i.e., B cells, macrophages, monocyte-derived/myeloid den-
dritic cells (MDDCs/mDCs), and by plasmacytoid dendritic cells (pDCs) of human andmurine origin after inoculation with
MERS-CoV. Production of large amounts of type I and III IFNs was induced exclusively in human pDCs, which were signifi-
cantly higher than IFN induction by severe acute respiratory syndrome (SARS)-CoV. Of note, IFNs were secreted in the absence
of productive replication. However, receptor binding, endosomal uptake, and probably signaling via Toll-like receptor 7 (TLR7)
were critical for sensing of MERS-CoV by pDCs. Furthermore, active transcription of MERS-CoVN RNA and subsequent N pro-
tein expression were evident in infected pDCs, indicating abortive infection. Taken together, our results point toward dipeptidyl
peptidase 4 (DPP4)-dependent endosomal uptake and subsequent infection of human pDCs byMERS-CoV. However, the repli-
cation cycle is stopped after early gene expression. In parallel, human pDCs are potent IFN-producing cells uponMERS-CoV
infection. Knowledge of such IFN responses supports our understanding of MERS-CoV pathogenesis and is critical for the
choice of treatment options.
IMPORTANCE
MERS-CoV causes a severe respiratory disease with high fatality rates in human patients. Recently, confirmed human cases have
increased dramatically in both number and geographic distribution. Understanding the pathogenesis of this highly pathogenic
CoV is crucial for developing successful treatment strategies. This study elucidates the interaction of MERS-CoV with APCs and
pDCs, particularly the induction of type I and III IFN secretion. Human pDCs are the immune cell population sensingMERS-
CoV but secrete significantly larger amounts of IFNs, especially IFN-a, than in response to SARS-CoV. Amodel for molecular
virus-host interactions is presented outlining IFN induction in pDCs. The massive IFN secretion upon contact suggests a critical
role of this mechanism for the high degree of immune activation observed duringMERS-CoV infection.
In 2012 a novel human betacoronavirus associated with severerespiratory disease emerged in Saudi Arabia (1). Due to its geo-
graphic distribution, this new virus was classified as Middle East
respiratory syndrome coronavirus (MERS-CoV) (2). MERS-CoV
is associated with high fatality rates (3, 4), and case numbers glob-
ally have increased to 909 laboratory-confirmed cases with 331
fatalities (as of 21 November 2014 [http://www.who.int/csr/don/
21-november-2014-mers/en/]). In parallel, the geographic distri-
bution has expanded (4).MERS-CoV is the second emerging CoV
with severe pathogenicity in humans within 10 years after the
severe acute respiratory syndrome coronavirus (SARS-CoV) that
infected approximately 8,000 people worldwide during its spread
in 2003 (5). Human-to-human transmissions have been reported
for MERS-CoV, but transmissibility seems to be inefficient (6, 7).
MERS-CoV persists in animal reservoirs, i.e., dromedary camels
(8), and transmission events between camels and contact persons
have been reported (7–10). Thus, MERS-CoV infection of men
has zoonotic origins, similar to SARS-CoV, but unlike SARS-CoV,
where bats have been identified as the original virus reservoir, bats
have been reported to host only closely related viruses of MERS-
CoV (11).However, the only small-animalmodel developed so far
involves type I interferon receptor (IFNAR)-deficient mice ex-
pressing human dipeptidyl peptidase 4 (huDPP4; CD26), the en-
try receptor of MERS-CoV (12), in the lung after intranasal ad-
ministration of huDPP4-expressing adenoviral vectors (13).
MERS-CoV causes symptoms in humans similar to those of
SARS-CoV infection, such as severe pneumonia with acute respi-
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ratory distress syndrome, leukopenia and lymphopenia (14), sep-
tic shock, and multiorgan failure. A special feature of MERS-CoV
infection is that it can cause renal complications whichmay end in
renal failure (15). The unusual tropism of MERS-CoV has been
related to the wide tissue distribution of DPP4, e.g., on renal epi-
thelial cells or leukocytes (16).
MERS-CoV replication is sensitive to type I and type III inter-
ferons (IFN) in vitro (17, 18), and macaques can be protected by
administration of IFN-b in combination with ribavirin (19).
However, a benefit of IFN-b treatment could not be confirmed in
five severely ill human patients in whom disease had presumably
progressed too far (20, 21). Sensitivity of MERS-CoV to IFNs in-
dicates that innate immunity and IFN secretion are critical param-
eters for the outcome of MERS-CoV infection. Type I IFNs, par-
ticularly IFN-b, can be produced by most stromal cell types upon
viral infection. Indeed, MERS-CoV actively suppresses type I IFN
production in a variety of infected cell types, such as primary
airway epithelial cells (18, 22). Additionally, professional antigen-
presenting cells (APCs) are an important source of type I IFNs
upon recognition of pathogen-associated molecular patterns
(PAMPs) (23). Particularly, plasmacytoid dendritic cells (pDCs)
have been shown to secrete large amounts of IFN-a after contact
with virus (e.g., HIV-1 [24] or SARS-CoV [25]). Type I IFNs have
a significant bystander effect on uninfected neighboring cells by
inducing an antiviral state, activating innate immune cells, and
priming adaptive immunity. On the other hand, over shooting
secretion of IFN can result in cytokine dysregulation and immune
pathogenesis (26).
To analyze the role of primary innate immune cells, especially
their IFN secretion levels duringMERS-CoV infection, we inocu-
lated a range of professional APCs and pDCswithMERS-CoV.No
type I or type III IFNs were produced by murine myeloid DCs
(mDCs), pDCs, or peritoneal exudate cells (PECs) after contact
with MERS-CoV. Most interestingly, this was also the case for all
human APC cell types, which did not react to MERS-CoV with
IFN secretion. Human pDCs, however, produced large amounts
of IFN-a and IFN-b and moderate amounts of IFN-l upon con-
tact with MERS-CoV without virus amplification. The observed
IFN induction was dependent on the availability of the MERS-
CoV receptor DPP4, endosomal maturation, or partially on
PAMP recognition via Toll-like receptor 7 (TLR7) and correlated
with de novo expression of MERS-CoV N protein. The large
amounts of type I IFNswhich are secreted by pDCs duringMERS-
CoV infection suggest that type I IFNs hold a key position in
MERS-CoV infection.
MATERIALS AND METHODS
Cell lines and viruses. Vero cells (ATCC CCL-81) and BHK-21 cells (C-
13) (ATCC CCL-10) were purchased from the ATCC (Manassas, VA,
USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Lonza, Cologne, Germany) supplementedwith 2mMglutamine and 10%
fetal bovine serum (FBS; Biochrom, Berlin, Germany) at 37°C in a humid-
ified atmosphere containing 6% CO2 for no longer than 6 months of
culture after thawing of the original stock. MERS-CoV (EMC/2012) (14)
and SARS-CoV (strain Frankfurt-1) (27) were propagated in Vero cells.
Titers were determined by 50% tissue culture infection dose (TCID50)
titration on Vero cells (28). Virus stocks were stored in aliquots at280°C.
Inactivated MERS-CoV was generated by UV inactivation (120,000 mJ/
cm2 UV light [254 nm] for 90 min) (Stratalinker UV Cross-linker; Strat-
agene, La Jolla, CA) of 0.1 ml of virus suspension in 48-well plates on ice.
Thogoto virus, an influenza-like orthomyxovirus inducing type I IFNs in
murine mDCs, lacking an elongatedmatrix protein [THOV(DML)] (29),
and vesicular stomatitis virus M2 (VSV-M2) (30), a variant of VSV with
defects inM protein functionality that induces high IFN responses in cells
(31), were propagated on BHK-21 cells and titrated via plaque assay on
Vero cells as described previously (30).
Isolation and generation of humanprofessional antigen-presenting
cells and pDCs. Human peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll (Biochrom) density gradient centrifugation from
buffy coats (Blutspendedienst, Frankfurt am Main, Germany) or citrate-
blood samples of anonymized healthy human volunteers. Human B cells
were purified by negative selection using a B-Cell IsolationKit II (Miltenyi
Biotec, Bergisch Gladbach, Germany) and cultured as described before
(32). Monocytes were purified by positive selection using CD14
MicroBeads (Miltenyi Biotec). For generation of monocyte-derived DCs
(MDDCs), 23 105 CD141monocytes were cultured in 96-well flat-bot-
tom tissue culture plates using X-VIVO 15 medium (Lonza) in the pres-
ence of granulocyte-macrophage colony-stimulating factor (GM-CSF;
1,000 U/ml) (CellGenix, Freiburg, Germany) and interleukin-4 (IL-4;
1,000 U/ml) (CellGenix) for 5 days (33). For generation of GM-CSF-
derived (M1) macrophages, monocytes were cultured in X-VIVO 15 me-
dium supplemented with 10 ng/ml GM-CSF. For macrophage colony-
stimulating factor (M-CSF)-derived (M2) macrophage generation,
monocytes were cultured in RPMI 1640medium containing 10% FBS, 10
mM L-glutamine, 0.5 mM penicillin-streptomycin (PAA Laboratories,
Egelsbach, Germany), 0.1mMnonessential amino acids (Biochrom), and
30 ng/ml M-CSF (R&D Systems, Wiesbaden-Nordendstadt, Germany)
(34). Untouched human plasmacytoid dendritic cells (pDCs) were iso-
lated by negative selection from PBMCs using a plasmacytoid dendritic
cell isolation kit (Miltenyi Biotec) and cultured in RPMI 1640 medium
(Biowest, Nuaillé, France) containing 10% fetal calf serum (FCS; Lonza),
10 mM L-glutamine, and 100 ng/ml recombinant IL-3 (R&D Systems).
For subsequent experiments, all APCs were seeded at a density of 2.5 3
105 APCs/well, and pDCswere seeded at a density of 23 104 pDCs/well in
96-well plates in 200 ml of medium.
Generationofmurineprofessional antigen-presenting cells.Murine
bone marrow-derived myeloid dendritic cells (mDCs) and plasmacytoid
dendritic cells (pDCs) were generated from bone marrow cells isolated
from femurs and tibias of sacrificed 6- to 10-week-old C57BL/6Nmice by
differentiation with GM-CSF (R&D Systems) or Flt-3L (R&D Systems)
for 8 days, as described before (35). Peritoneal exudate cells (PECs) were
isolated from sacrificed 6- to 10-week-old C57BL/6Nmice by flushing out
cells from the abdominal cavity with 5 ml of phosphate-buffered saline
(PBS) and seeding at 2 3 105 cells/ml in 200 ml of RPMI 1640 medium
(Biowest).
Virus growth kinetics. Vero cells, APCs, or pDCs were infected at a
multiplicity of infection (MOI) of 0.01 or 5. Cells were washed once at 1 h
postinfection (hpi) and incubated in the respective cell culture medium.
At the time points indicated in the figures, cell-free supernatants were
sampled and stored at280°C. Titers were determined by TCID50 titration
on Vero cells as described above.
Analysis of type I and III interferon secretion. Innate immune cells
were inoculated with MERS-CoV, SARS-CoV, or UV-inactivated MERS-
CoV. VSV-M2 (MOI of 0.1), THOV (MOI of 0.1), CpG 2216 (5 mg/ml),
or CpG 2006 (5 mg/ml) (Invitrogen Life Technologies) (36) was used as a
control. Cell-free supernatantwas collected at 24 hpi and stored at280°C.
Supernatants of human cells were analyzed for secreted IFNs using a hu-
man IFN-a enzyme-linked immunosorbent assay (ELISA) (Mabtech AB,
Nacka Strand, Sweden), human IFN-b ELISA (R&D Systems), human
IL-29 (IFN-l1) ELISA (eBioscience, Frankfurt, Germany), or a human
IL-6 DuoSet ELISA development system (R&D Systems) according to the
manufacturers’ instructions. Supernatants of murine cells were analyzed
using a mouse IFN-a or mouse IFN-b ELISA (PBL Biomedical Laborato-
ries, Piscataway, NJ) kit. To inhibit endosomal maturation or TLR7 sig-
naling, pDCs were preincubated for 30 min at 37°C with 5 mM chloro-
quine (Sigma) or 5.6 mM inhibitory oligonucleotide (ODN) IRS661
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(Invitrogen Life Technologies), respectively, and infected with MERS-
CoV (MOI of 1) in the presence of inhibitors. To inhibit receptor binding
of MERS-CoV, pDCs were preincubated for 30 min at 37°C with the
recombinant receptor binding domain (RBD) consisting of residues 358
to 588 of the MERS-CoV spike protein (S) or with IgG1-Fc control pro-
tein (40 ng/ml) (37) before infection (MOI of 1).
qRT-PCR.A total of 23 104 pDCswere infectedwithMERS-CoV (MOI
of 3) andwashed oncewithmedium at 1 hpi. Total RNAof infected cells was
isolatedusing anRNeasyPlusminikit (QIAgen,Hilden,Germany) according
to the manufacturer’s instructions. Isolated RNA (10 ml) was subjected to
quantitative reverse-transcription PCR (qRT-PCR) using a SuperScript III
Platinum OneStep qRT-PCR System (Invitrogen Life Technologies) with
primers N2-Forward and N2-Reverse and probe N2-Probe (labeled 5= with
6-carboxyfluorescein and 3= with Black Hole Quencher 1) as described pre-
viously (38)utilizinganABI7900HTFastReal-TimePCRSystem(Invitrogen
Life Technologies). The amplification protocol was as follows: RT at 50°C for
30min, initial denaturationat 95°C for2min, andPCRconsistingof 40cycles
at 95°C for 15 s and 55°C for 1min, with a final elongation at 55°C for 5min.
Datawerenormalized tocellularglyceraldehyde-3-phosphatedehydrogenase
(GAPDH) mRNA, which was quantified using a SuperScript III Platinum
SYBR green OneStep qRT-PCR System (Invitrogen Life Technologies) with
primersGapdH fwd (5=-GGCGATGCTGGCGCTGAGTAC-3=) andGapdH
rev (5=-TGGTCCACACCCATGACGA-3=) for human GAPDH and
mGAPDHfwd(5=-CACCAACTGCTTAGCCCC-3=) andmGAPDHrev(5=-
TCTTCTGGGTGGCAGTGATG-3=) for murine GAPDH. The amplifica-
tion protocol was as follows: 50°C for 30 min and 95°C for 15 min,
followed by 40 cycles of 94°C for 15 s, 56°C for 1 min, 72°C for 30 s, and
95°C for 15 min. The normalized change in the cycle threshold (CT)
value [DCT 5 CT(MERS vRNA) 2 CT(GAPDH mRNA), where vRNA is viral
RNA] thus describes the difference between threshold cycle numbers
for qRT-PCR signals of viral RNA and cellular mRNA for a given
sample. Therefore, the lower theDCT, the higher is the relative amount
of vRNA in the sample. Due to exponential amplification of DNA
during PCR, differences (n) between DCT values were converted to
x-fold ratios using the formula x 5 22n, assuming optimal amplifica-
tion for all samples.
Immunoblotting. For detection of CoVNprotein expression, 53 104
pDCs were incubated withMERS-CoV (MOI of 3) and washed once with
medium at 1 hpi or 8 hpi. For blocking experiments, cells were preincu-
bated with the respective blocking agents as described above or with hu-
manDPP4/CD26 affinity-purified polyclonal antibody (R&DSystems) or
goat IgG control (R&D Systems) (40 mg/ml) (12) for 30 min at 37°C
before infection. Subsequently, washed pDCs were lysed and subjected to
immunoblot analysis as described previously (39). MERS-CoVN protein
was detected using polyclonal rabbit anti-MERS-CoV serum (1:1,000)
with donkey horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG(H1L) (1:10,000) (Rockland, Gilbertsville, PA); b-actin was detected
by mouse monoclonal anti-b-actin antibody (AC-15; 1:5,000) (ab6276;
Abcam, Cambridge, United Kingdom) with HRP-conjugated rabbit anti-
mouse secondary antibody (Invitrogen Life Technologies). Pierce ECL 2
Western blotting substrate (Thermo Scientific) on Amersham Hyperfilm
ECL (GE Healthcare) was used for detection of specific bands.
Flow cytometry analysis. Flow cytometry was performed on an LS-
RII-SORP fluorescence-activated cell sorter (FACS; BD, Heidelberg, Ger-
many), and data were analyzed using FACSDiva, version 6.1.3, or FCS
Express, version 3 (De Novo Software, Los Angeles, CA). Cells were
stained and analyzed as described previously (39) using the following
antibodies: murine anti-human CD26-phycoerythrin (PE) (BA5b; Bio-
legend, San Diego, CA), murine anti-human CD14-fluorescein isothio-
cyanate (FITC) (M5E2; BD), murine anti-human CD19-PE (HIB19; BD
Bioscience),murine anti-humanCD123-PE (9F5; BDBioscience), ormu-
rine anti-human DC303-allophycocyanin (APC) (BD Bioscience) ac-
cording to the manufacturers’ instructions. Fc block was performed with
Gammagard (1.25 mg/m; Baxter, Deerfield, IL). Viability was checked by
Fixable Viability Dye eFluor 780 (eBioscience).
RESULTS
Analysis of type I IFN secretion inmurine immune cells.Due to
the sensitivity of MERS-CoV to IFNs and the important role of
innate immune cells in pathogen recognition and IFN secretion,
we were interested in which innate immune cell subsets produce
type I or type III IFNs upon contact with MERS-CoV. Therefore,
type I IFN secretion by murine APCs and pDCs inoculated with
MERS-CoV was analyzed first. Murine PECs (mainly macro-
phages), mDCs, or pDCs were inoculated with MERS-CoV or
SARS-CoV. FormurinemDCs and PECs, THOV(DML) served as
a positive control for IFN secretion (29). Murine pDCs were in-
oculated with CpG 2216 oligonucleotide to test the cells’ reactiv-
ity. All murine immune cells revealed robust IFN-a and IFN-b
responses to the adequate positive controls but no induction of
type I IFN after contact with MERS-CoV or with SARS-CoV (Fig.
1A). Next, viral replication of MERS-CoV in murine APCs was
FIG 1 Inoculation of murine cells with MERS-CoV. (A) Type I IFN secretion by murine immune cells. Cells were inoculated with MERS-CoV (MOIs as
indicated), SARS-CoV, or the indicated positive controls. Single dots, individual experiments; horizontal lines, means. IFNs weremeasured at 24 hpi. b.d., below
detection. Limits of detection were 12.5 pg/ml for IFN-a and 15.6 pg/ml for IFN-b. (B) Growth kinetics of MERS-CoV on Vero cells or murine APCs (MOI of
0.01). Indicated cell types were inoculated with virus, and sampled supernatants were titrated. Filled symbols, MERS-CoV; open symbols, SARS-CoV;L, PECs;
Œ, mDCs;h, pDCs. Values are means of three independent experiments; error bars indicate standard deviations. conc, concentration.
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controlled since inhibition of type I IFN production in MERS-
CoV-infected cells has been described previously (17), potentially
decoupling replication from IFN secretion. Productive viral rep-
lication in immune cells was quantified by titration of the super-
natant of inoculated cells to detect released infectious progeny
virus (Fig. 1B). Two days postinfection, permissive Vero cells pro-
duced high peak titers of 5 3 106 TCID50s/ml and 1 3 10
7
TCID50s/ml ofMERS- and SARS-CoV, respectively (Fig. 1B, panel
i). In contrast, no infectious virus considerably above the limit of
detection (13 102 TCID50s/ml) was detected in the supernatants
of any murine cell population for both MERS- and SARS-CoV
(Fig. 1B, panel ii).
Interferon production by human APCs upon contact with
MERS-CoV. AlthoughMERS-CoV did not induce any reactivity in
murine immune cells, reactivity of human immune cells seemed not
too unlikely as SARS-CoV exhibited such a pattern of IFN induction
(25). Therefore, we analyzed next if and which human innate im-
mune cell subset(s) produces type I or type III IFNsupon inoculation
with MERS-CoV. Human B cells, M1 and M2 type macrophages,
MDDCs, andpDCswere inoculatedwithMERS-CoVorSARS-CoV.
As positive controls for IFN secretion,M1 andM2macrophages and
MDDCswere inoculated with VSV-M2 (30), B cells were inoculated
with the B cell-stimulating CpG oligonucleotide CpG2006 (40), and
pDCs were inoculated with pDC-stimulating CpG oligonucleotide
CpG2216 (41). Untreated cells served as mock controls. Human B
cells, M1 macrophages, M2 macrophages, and MDDCs did not se-
crete type I or type III IFNs upon inoculation with MERS-CoV, de-
spite being responsive to appropriate stimuli (Fig. 2A). General
responsiveness of B cells was confirmed by IL-6 secretion after stim-
ulation with CpG 2006 (Fig. 2D) (40). In contrast, human pDCs
secreted large amounts of IFN-a, IFN-b, or IFN-l (up to 40, 0.3, or
0.1 ng/ml, respectively) upon contact with MERS-CoV (Fig. 2A),
with the highest secretion at an intermediateMOI of 1. Interestingly,
this did not correlate with rates of infection. pDCs inoculated with
increasing MOIs of MERS-CoV revealed an approximately linear
correlation of viral RNA detectable in infected pDCs, as determined
by calculating the normalized DCT values of qRT-PCR analysis and
converting the detected differences into fold changes (Fig. 2B). The
FIG 2 Inoculation of human immune cells with MERS-CoV. (A) Type I and III IFN secretion by human immune cells. Human cells were inoculated with
MERS-CoV (MOIs indicated), SARS-CoV (MOI of 1), or the indicated positive control (CpG 2006, VSV-M2, or CpG 2216). Supernatants were sampled at 24
hpi, and secreted IFNs were determined by specific ELISAs. (B) Isolated RNA was used for qRT-PCR. MERS RNA signals were normalized to cellular GAPDH
mRNA [DCT5CT(MERS RNA)2CT(GAPDHmRNA)].DCT values and respectively calculated x-fold amounts of RNAnormalized to anMOI of 0.1 were determined.
(C) Titers of MERS-CoV or SARS-CoV (control) in human immune cells (APCs) infected at an MOI of 0.01 or on pDCs infected at an MOI of 5. (D) IL-6
secretion by human B cells upon inoculation with stimulating CpG 2006. Supernatants were sampled at 24 h after inoculation with CpG 2006, and secreted IFNs
were determined by ELISA. Individual donors are displayed as single dots, and horizontal lines indicate means. Limits of detection were 7 pg/ml for IFN-a, 50
pg/ml for IFN-b, and 8 pg/ml for IFN-l. b.d., below detection; filled symbols, MERS-CoV; open symbols, SARS-CoV;L, B cells;o, M1 macrophages;p, M2
macrophages;Œ, MDDCs;h, pDCs. Growth in human APCs (MOI of 0.01) (i, left), or in human pDCs (MOI of 5) (ii, right) was determined. Values are means
of three independent experiments; error bars indicated standard deviation. *, P, 0.05.
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largest amounts of secreted IFNs at anMOI of 1were about 8-, 4-, or
1.5-fold higher, respectively, than IFN levels measured after inocula-
tion with SARS-CoV (5 ng/ml IFN-a, 0.07 ng/ml IFN-b, and 0.07
ng/ml IFN-l). In addition, responses of human pDCs to CpG 2216
(8.6 ng/ml IFN-a, 600 pg/ml IFN-b, and 80 pg/ml IFN-l) were re-
markably less strong than toMERS-CoV but clearly detectable (41).
MERS-CoV replication in human innate immune cells. To
analyze whether production of IFNs corresponds to productive rep-
lication of MERS-CoV in the respective human innate immune cell
subsets, we inoculated cells withMERS-CoVand SARS-CoVat a low
MOI of 0.01. Productive viral replication was quantified by titration
of the supernatant of inoculated cells to detect released infectious
progeny virus (Fig. 2C). Similar to findings with murine APCs (Fig.
1B, panel ii), no infectious virus considerably above the limit of de-
tection (13102TCID50s/ml)wasdetected in the supernatants of any
human cell population for both MERS- and SARS-CoV (Fig. 2C).
Thus, no productive replication of MERS-CoV in APCs and pDCs
became evident after infection at a low MOI. Since replication of
MERS-CoV inM1macrophages orMDDCs after infection at a high
MOI has been reported (42, 43), human pDCs were additionally in-
fected at anMOI of 5 to test, if, e.g., putative antiviral cellular restric-
tion factors may be overcome by infection at high MOIs, and infec-
tious virus in supernatantswas titrated. A slowly decreasing titerwith
an initial set point (1 hpi) of 23 104 TCID50s/ml was detected in the
supernatant (Fig. 2C, panel ii). This indicates only inefficient replica-
tion ofMERS-CoV in pDCs in our hands even after inoculation at a
highMOI. Thus, IFN secretion by pDCs is not linked to virus ampli-
fication.
Inhibition of IFN production by pDCs upon MERS-CoV
contact.Next, we aimed to study the recognition ofMERS-CoV in
human pDCs. Therefore, human pDCs were inoculated with UV-
inactivated MERS-CoV particles (corresponding to an MOI of 1
before inactivation).
UV-inactivated MERS-CoV induced secretion of similar
amounts of IFN-a (50 ng/ml) and IFN-l (0.06 ng/ml) but signif-
icantly reduced amounts of IFN-b (0.08 ng/ml) compared to val-
ues with untreated MERS-CoV (Fig. 3A to C). These results indi-
cate the requirement for replication-competent virus particles
(even if no productive replication was evident in pDCs) to induce
IFN-b secretion, whereas IFN-a and IFN-l are induced by repli-
cation-defective virus particles as well, as evident by similar differ-
ences in induction betweenUV-inactivated and untreatedMERS-
CoV compared to mock controls.
To determine the route of MERS-CoV cell entry necessary for
viral replication, we first analyzed the role of the virus receptor
DPP4. Analysis of DPP4 surface expression by flow cytometry
indicated surface expression of DPP4 on human pDCs (Fig. 4A).
Indeed, preincubation of human pDCs with the receptor binding
domain (RBD) of MERS-CoV (37) to block active MERS-CoV
entry reduced secretion of IFNs by pDCs. Secretion of IFN-a was
reduced 10-fold (3 ng/ml versus 30 ng/ml), that of IFN-b was
reduced 26-fold (0.03 ng/ml versus 0.8 ng/ml), but that of IFN-l
was reduced only slightly (37 pg/ml versus 43 pg/ml) compared to
levels in control-treated cells (Fig. 3D to F). For IFN-l the impact
of one outlier data point with high IFN-l secretion within this
experiment influenced the data. In an additional data set, RBD
FIG 3 Dissecting type I and III IFN induction in human pDCs. Impact of different parameters on IFN induction in pDCs after inoculation ofMERS-CoV (MOI
of 1). (A to C) Live virus. pDCs were incubated with UV-inactivated virus (UV) or live virus (MERS-CoV). (D to F) Entry receptor. Infection was performed in
the presence or absence of the MERS-CoV S receptor binding domain (RBD) or IgG1-Fc control protein (Ctrl). (G to I) Endosomal maturation. Infection was
performed in the presence of chloroquine. (J to L) TLR recognition. Infection was performed in the presence of TLR7 inhibitor (IRS661). IFNs were sampled at
24 hpi.Mock andMERS-CoV data for live virus experiments are the same as displayed in Fig. 2.Mock, uninfected cells; sham, infected but untreated cells. Single
dots, individual donors; horizontal lines, means. *, P, 0.05; **, P, 0.01; ns, not significant.
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blocked IFN-l, again, for each of the three studied donors (Fig.
4C). However, also after stimulation by CpG2216 the secretion of
all IFNs was strongly reduced in the presence of RBD protein (1.5
ng/ml versus 150 ng/ml IFN-a, ,50 pg/ml versus 0.16 ng/ml
IFN-b, 4 pg/ml versus 40 pg/ml IFN-l), indicating general im-
mune-suppressive properties of the RBD protein (Fig. 4C).
Toevaluate ifMERS-CoVparticles are endocytosedand ifMERS-
CoV is recognized in the endosome, endosomal maturation and,
thus, the endosomal route of entry and IFN induction (44) were in-
hibited by chloroquine. Of note, 24 h after cotreatment with chloro-
quine or RBD and MERS-CoV, viability of pDCs was not impaired
(Fig. 4B).When pDCs were infected withMERS-CoV (MOI of 1) in
the presence of chloroquine, the secretion of IFNs was reduced by
factors of 11 for IFN-a (5 ng/ml versus 55 ng/ml), 35 for IFN-b (0.6
ng/ml versus 0.016 ng/ml), and 2.3 for IFN-l (60 pg/ml versus 140
pg/ml) (Fig. 3G to I). These data indicate that the endosomal route is
critical for sensing of MERS-CoV infection by human pDCs. Since
viralRNAcanbe recognizedas aPAMPin the endosomesofpDCsby
TLR7, we inhibited TLR7 via the inhibitory ODN IRS661. IFN-a
production was 1.5-fold decreased upon TLR7 inhibition (15 ng/ml
versus 25 ng/ml) compared to infection in the presence of a nonin-
hibiting control oligonucleotide. IFN-b production was 3-fold de-
creased (0.25 ng/ml versus 0.73 ng/ml), and IFN-l production was
2-fold decreased upon TLR7 inhibition (36 pg/ml versus 77 pg/ml)
(Fig. 3J to L). Thus, secretion of all IFNs analyzed was reduced upon
inhibitionofTLR7.Thesedata indicate involvementofTLR7 in sens-
ingMERS-CoVRNA and in IFN induction uponMERS-CoV infec-
tion of pDCs.
Transcription of MERS-CoV N RNA in infected pDCs. Even
though no significant productive viral replication was observed,
initial steps of viral infection and replication may take place in
pDCs and could be responsible for triggering cytosolic pattern
recognition receptors (PRRs). To analyzeMERS-CoV infection of
pDCs, onset of viral transcription was monitored by qRT-PCR
ofNproteinRNA in infected pDCs. For this purpose, total RNAof
human pDCs infected with MERS-CoV (MOI of 3) was isolated,
and amounts of MERS-CoV N RNA was quantified at 1 hpi and 6
hpi and normalized to cellular housekeeping gene mRNA
(GAPDH) (Fig. 5A). The relative amount of N RNA increased
from 1 hpi to 6 hpi by 14-fold, indicating onset of viral gene tran-
scription. In line with IFN-blocking experiments, only a minimal
increase in relative N RNA levels was detected when human pDCs
were pretreated with chloroquine (1.2-fold) or when murine
pDCs were used as the substrate (no increase) (Fig. 5A).
Expression of MERS-CoV nucleocapsid protein in infected
human pDCs. To back up mRNA expression data, the onset of
viral protein translation was monitored by immunoblot analysis
FIG 4 CD26 expression and functionality of human pDCs. (A) Expression of
MERS-CoV receptor DPP4 on human pDCs. pDCs were stained with anti-
DPP4 antibody and analyzed via flow cytometry. ITC, isotype control anti-
body. (B) Viability of pDCs of three different donors (D1 to D3) treated with
inhibitors. pDCs were treated as indicated. At 24 hpi, cells were stained for
viability and analyzed via flow cytometry. Dead, cells killed by osmotic shock.
(C) Block of CpG 2216-induced IFN secretion byMERS-CoV RBD. Secretion
of the indicated IFNs was determined in the presence or absence of theMERS-
CoVS receptor binding domain (RBD)or IgG1-Fc control protein (Ctrl) upon
MERS-CoV infection or the DPP4-independent stimulus CpG 2216. IFNs
were sampled at 24 hpi. Single dots, individual donors; horizontal lines,means.
b.d., below detection.
FIG 5 Infection of human pDCs byMERS-CoV. (A) Quantification of viral N
RNA in human or murine pDCs by qRT-PCR in the presence or absence of
chloroquine, normalized to cellular GAPDHmRNA [DCT5CT(MERS vRNA)2
CT(GAPDH mRNA)] at indicated time points after inoculation. (B to D) Immu-
noblot analysis of N protein expression in murine pDCs (B) or human pDCs
(C and D) after inoculation with MERS-CoV (MOI of 3). pDCs of three dif-
ferent donors (D1 to D3 and D4 to D6) were infected in the presence of
blocking anti-DPP4 serum (DPP4), the receptor binding domain of MERS-
CoV S protein (RBD), or respective controls (Ctrl) or with UV-inactivated
(UV) or live MERS-CoV in the presence (Chl) or absence (sham) of chloro-
quine. Cells were lysed at the indicated time points and subjected to analyses.
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of viral N protein expression in infected pDCs. For this purpose,
human pDCs were infected with MERS-CoV (MOI of 3), and N
protein expression was checked (Fig. 5C and D). As expected, no
CoVNproteinwas detected inmurine pDCs (Fig. 5B) and human
pDCs at 1 hpi (Fig. 5C and D). However, at 8 hpi CoV N protein
expression was clearly demonstrated in human pDCs, indicating
the onset of viral gene expression in infected human pDCs. In
contrast, using polyclonal anti-DPP4 antibody or the RBD,
MERS-CoVNprotein expression was decreased in comparison to
that in the respective control, indicating infection of pDCs via
DPP4 (Fig. 5C). Moreover, when human pDCs were inoculated
with UV-inactivated MERS-CoV, no expression of N protein was
detected, thus indicating that intact viral genomes are crucial for
N protein expression (Fig. 5D). In addition, inhibition of endo-
somal maturation was accompanied by considerably less N pro-
tein expression in infected cells at 8 hpi (Fig. 5D). Therefore, ex-
pression of MERS-CoV N depends on receptor binding and
endosomal maturation, arguing for the endosomal pathway as a
primary route of MERS-CoV entry into human pDCs.
DISCUSSION
Our data reveal that primary humanpDCs produce large amounts
of type I and type III IFNs in response to MERS-CoV infection.
Sensing depends on receptor availability, endosomal uptake, and,
at least partially, functionality of TLR7. Moreover, we detected
expression of MERS-CoV NmRNA and protein in the absence of
progeny virus, suggesting unproductive infection of human
pDCs. Similar to data obtained upon SARS-CoV infection, secre-
tion of IFNs was exclusively found in pDCs (25), but the amounts
of IFNs induced by MERS-CoV were significantly higher.
In parallel, stimulation with CpG 2216 also resulted in lower,
but clearly detectable, amounts of IFNs. Thereby, integrity of
pDCs can be assumed since the amounts of secreted IFNs were
comparable to those in previously published data (25, 41) consid-
ering the fact that in the present study only one-third the amount
of pDCs was used and that IFN-containing supernatants were
harvested after 24 h.
When human B cells, macrophages, or MDDCs were inocu-
lated with MERS-CoV, no type I or III IFNs were detected in the
supernatant of infected cells. In line with these data, Zhou et al.
(42) could not detect upregulation of type I IFN mRNA upon
infection of human macrophages. Also in infected human
MDDCs, only minor induction of IFN-a mRNA was detected,
and no induction of IFN-bmRNA synthesis was detected (43).
In contrast, large amounts of IFN-a were detected when hu-
man pDCs were inoculated with MERS-CoV. IFN-a can be in-
duced in pDCs after recognition of PAMPs in the endosome, e.g.,
via TLR7 (45). In our experiments, secretion of IFN-a was
strongly inhibited by chloroquine treatment. Indeed, chloroquine
is an inhibitor of endosomal maturation and can inhibit IFN pro-
duction induced by viruses (e.g., HIV) via PRRs within the endo-
some (46). When the endosomal PRR of pDCs for viral RNA,
TLR7, was inhibited, secretion of IFN-a also decreased. Taken
together, these data argue for endosomal recognition of MERS-
CoV and potentially recognition via TLR7 in mature endosomes
of pDCs. The pattern of IFN-l secretion by human pDCs after
MERS-CoV inoculation followed that of IFN-a, as expected, since
IFN-l is induced by stimuli similar to those that induce IFN-a
(47).
IFN-b was also secreted in significant amounts by human
pDCs upon MERS-CoV inoculation. IFN-b can be induced after
recognition of PAMPs by cytosolic PRRs such asMDA-5 or RIG-I
(48). Indeed, we demonstrated the onset of viral gene expression
in human pDCs. In line with this, UV inactivation ofMERS-CoV,
which damages the viral genome and thereby inhibits transcrip-
tion and amplification of viral RNA, significantly reduced IFN-b
secretion, but secretion of IFN-a or IFN-l remained on similar
levels. Thus, cytoplasmic recognition of viral replication interme-
diates seems to be responsible for IFN-b induction. However,
MERS-CoV-induced IFN-b secretion was also blocked by chloro-
quine, an effect that cannot be explained if we postulate direct viral
entry across the plasma membrane after contact of the viral spike
glycoprotein S with its receptor CD26/DPP4, as assumed for
MERS-CoV entry into lung epithelial cells (49). To use this entry
pathway, MERS-CoV S has to be activated by cellular exopepti-
dases; mainly, transmembrane protease serine 2 (TMPRSS2) has
been demonstrated to be responsible for cleavage during MERS-
CoV entry into Calu-3 cells (49). In contrast, we demonstrate that
endosomal maturation is crucial forMERS-CoV entry into pDCs.
Interestingly, uptake of MERS-CoV via the endosomal route has
already been described as an alternative pathway for entry into,
e.g., Vero cells (49). Here, lysosomal proteases such as cathepsin L
are required to activate the MERS-CoV S protein (50), but their
activity depends on endosomal maturation (51). Hence, chloro-
quine-mediated inhibition of IFN-b secretion by pDCs after con-
tact withMERS-CoV argues for receptor-mediated endocytosis of
MERS-CoV particles and activation of MERS-CoV S protein by
endosomal proteases, such as cathepsin L, finally resulting in cy-
tosolic entry of MERS-CoV across the endosomal membrane. In-
deed, expression of mRNA and MERS-CoV N protein was con-
siderably decreased in the presence of chloroquine, indicating
chloroquine-mediated inhibition of infection.
Furthermore, we blocked cell attachment of MERS-CoV to
pDCs by blocking DPP4 with recombinant viral RBD. Block of
receptor binding led to a significant reduction of IFN production
following virus inoculation. However, CpG-stimulated IFN in-
duction was blocked by recombinant RBD as well, indicating the
immune suppressive properties of theMERS-CoVRBD in human
pDCs. DPP4 is described as an activating receptor on T lympho-
cytes (52–54), but its function inDCs has thus far been linked only
to T cell stimulation (55). Thus, the reasons for the eventually
immune-suppressive properties of the RBD remain to be eluci-
dated. Nevertheless, the remarkable inhibition of N protein ex-
pression by both RBD and anti-DPP4 serum indicates the neces-
sity of DPP4 as an entry receptor for endocytotic uptake and
subsequent infection on human pDCs. Receptor-dependent en-
docytosis as an uptake pathway for MERS-CoV may also explain
the absence of IFN induction in murine pDCs after contact with
the virus. In contrast to humanDPP4,murine DPP4 is no suitable
receptor for promoting infection with MERS-CoV (56). Thus,
lack of binding of MERS-CoV to murine DPP4 should reduce
endosomal uptake of virus particles, thereby reducing the amount
of PAMPs which can be sensed by PRRs, resulting in strongly
reduced IFN induction in murine pDCs.
To summarize the data, a model explaining the mechanism
how of MERS-CoV induces type I IFN in human pDCs may be
proposed (Fig. 6).MERS-CoVbinds to its entry receptorDPP4 on
the surface of pDCs, triggering receptor-mediated endocytosis of
viral particles. In the mature endosome, MERS-CoV RNA is
sensed by TLR7, inducing IFN-a secretion. Furthermore, MERS-
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CoV spike proteins become cleaved by endosomal proteases dur-
ing or after endosome maturation. This cleavage allows fusion of
viral and endosomal membranes, causing release of the viral ge-
nome into the cytoplasm. In the cytoplasm, expression of viral
proteins starts. We hypothesize that MERS-CoV RNA replication
intermediates are recognized by cytosolic PRRs, resulting in full-
blown induction of IFN-b. However, assembly or release of new
progeny viral particles is impaired by yet unknownmechanisms in
stages subsequent to viral gene expression. This absence of signif-
icant MERS-CoV replication in pDCs in contrast with the virus’s
replication in MDDCs (43) or macrophages (42) may be ex-
plained by the significant (biological and functional) differences
between pDCs and other DC subsets (57). In line with this hy-
pothesis, influenza A virus replication was also demonstrated in
mDCs but shown to be blocked at postentry steps in pDCs (58).
Entry receptors are crucial for MERS-CoV recognition by
pDCs, and lack of functional entry receptors in mice leads to lack
of IFN production in murine cells. Meanwhile, it has been shown
that murine DPP4 cannot be used as aMERS-CoV entry receptor;
as demonstrated by expression of humanDPP4 inmouse lungs via
adenoviral vectors, this is sufficient to gain (partial) susceptibility
to MERS-CoV infection (13).
Moreover, type I (59) and type III (17) IFNs inhibit MERS-
CoV replication in vitro. A characteristic feature of type I IFNs is
that effects are seen at small concentrations. In previous studies
replication of MERS-CoV was inhibited by type I and III IFNs in
different cell types in vitro already starting at a ng/ml concentra-
tion range (17, 59, 60). The IFN-a levels obtained in the experi-
ments surpassed such amounts at least 40-fold; thus, the amounts
of IFNs produced by pDCs upon MERS-CoV infection can be
supposed to be relevant. The release of type I and III IFNs may
protect against MERS-CoV-induced pathogenicity. It is therefore
counterintuitive that MERS-CoV induces significantly higher se-
cretion of IFNs than SARS-CoV when infecting pDCs, but clini-
cally recordedMERSpatients having aworse prognosis than SARS
patients (5). However, secretion of extraordinarily large amounts
of type I IFNs can result in aberrant immune activation. Zhou et
al. already speculated that an induced cytokine storm could be the
reason for the severity of illness on the basis of large amounts of
proinflammatory cytokines and chemokines such as IL-12 or
FIG 6 Model for MERS-CoV-induced type I IFN secretion in human pDCs. The figure schematically depicts the life cycle of MERS-CoV in human pDCs and
events triggering secretion or infection of type I IFNs. Successful inhibition of IFN secretion at single steps is indicated. Inhibitors or proteins which have been
analyzed are depicted in bold. Question marks point out steps during assembly or release of viral particles, the block of which could be responsible for absence
of significant viral replication in pDCs. a, anti.
Scheuplein et al.
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IP-10 secreted by human macrophages upon MERS-CoV infec-
tion (42). In human SARS patients, aberrant IFN-stimulated gene
expression and cytokine responses, compared to those of healthy
individuals, were indeed observed (61). Patients that had such
kinds of hyperimmune activation were more likely to succumb to
the infection (62). Furthermore, the severity of SARS correlated
with large amounts of inflammatory cytokines in serum (63), and
symptoms of disease became usually worse after virus clearance
(64). For these reasons, immune-mediated pathogenesis has been
proposed for SARS-CoV infection (62). Whether such a patho-
mechanism also applies toMERS and whether pDCs are really the
major source of IFNs in such a setting remain to be demonstrated
in further studies. However, the up to 8-fold-enhanced IFN type I
secretion uponMERS-CoV infection compared to SARS-CoV in-
fection might then hint at overshooting immune reactions being
potentially one factor for the higher mortality rate observed in
MERS patients.
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Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform
and Induce a Strong Antigen-Specific Cytotoxic T Cell Response
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ABSTRACT
To induce and trigger innate and adaptive immune responses, antigen-presenting cells (APCs) take up and process antigens. Ret-
roviral particles are capable of transferring not only genetic information but also foreign cargo proteins when they are geneti-
cally fused to viral structural proteins. Here, we demonstrate the capacity of lentiviral protein transfer vectors (PTVs) for tar-
geted antigen transfer directly into APCs and thereby induction of cytotoxic T cell responses. Targeting of lentiviral PTVs to
APCs can be achieved analogously to gene transfer vectors by pseudotyping the particles with truncated wild-type measles virus
(MV) glycoproteins (GPs), which use human SLAM (signaling lymphocyte activationmolecule) as a main entry receptor. SLAM
is expressed on stimulated lymphocytes and APCs, including dendritic cells. SLAM-targeted PTVs transferred the reporter pro-
tein green fluorescent protein (GFP) or Cre recombinase with strict receptor specificity into SLAM-expressing CHO and B cell
lines, in contrast to broadly transducing vesicular stomatitis virus G protein (VSV-G) pseudotyped PTVs. Primary myeloid den-
dritic cells (mDCs) incubated with targeted or nontargeted ovalbumin (Ova)-transferring PTVs stimulated Ova-specific T lym-
phocytes, especially CD81 T cells. Administration of Ova-PTVs into SLAM-transgenic and control mice confirmed the observed
predominant induction of antigen-specific CD81 T cells and demonstrated the capacity of protein transfer vectors as suitable
vaccines for the induction of antigen-specific immune responses.
IMPORTANCE
This study demonstrates the specificity and efficacy of antigen transfer by SLAM-targeted and nontargeted lentiviral protein
transfer vectors into antigen-presenting cells to trigger antigen-specific immune responses in vitro and in vivo. The observed
predominant activation of antigen-specific CD81 T cells indicates the suitability of SLAM-targeted and also nontargeted PTVs as
a vaccine for the induction of cytotoxic immune responses. Since cytotoxic CD81 T lymphocytes are a mainstay of antitumoral
immune responses, PTVs could be engineered for the transfer of specific tumor antigens provoking tailored antitumoral immu-
nity. Therefore, PTVs can be used as safe and efficient alternatives to gene transfer vectors or live attenuated replicating vector
platforms, avoiding genotoxicity or general toxicity in highly immunocompromised patients, respectively. Thereby, the poten-
tial for easy envelope exchange allows the circumventing of neutralizing antibodies, e.g., during repeated boost immunizations.
Vaccination is the administration of one ormore immunogens,the vaccine, into patients to trigger antigen-specific adaptive
immune responses to prevent (prophylactic vaccination) or to
treat (therapeutic vaccination) disease. Vaccines can be classified
into several subtypes. Among these are live attenuated replicating
vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, or
recombinant vector vaccines (for review, see reference 1). Well-
known live attenuated vaccines are, e.g., those against measles (2)
or mumps (3). These vaccines replicate but have been attenuated
to become apathogenic. The immune responses triggered by live
attenuated vaccines are similar to those induced by the pathogenic
form of the microbe (4, 5) and involve both the cellular and hu-
moral arms of the immune system. However, attenuated replicat-
ing pathogens may carry an inherent risk of reversion to the pa-
rental virulent form by in vivo passaging during vaccination, as
observed for the Sabin strain used as a polio vaccine (6), or may
still be pathogenic in highly immunocompromised patients (7),
depending on the respective degree of attenuation of the vaccine
strains. On the other hand, inoculation of solely proteinaceous
antigens (such as the hepatitis B virus vaccine [8]) or antigen-
encoding genes (as a DNA vaccine) is regarded as safe but rela-
tively inefficient (9).
As an alternative to such vaccines, the genes encoding an anti-
gen can be transferred into cells and thereby presented to the
immune system by using recombinant vaccine vectors. For that
purpose, an attenuated vector is utilized as a carrier for the anti-
gen-encoding sequences of another pathogen. Thereby, they are
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sound triggers of immune responses due to stimulation of innate
immunity by the pathogen-associated molecular patterns
(PAMPs) of the vector backbone’s structure. This vaccine subtype
is relatively easy to generate and tomanipulate; heterologous pro-
teins can be encoded, and the vector vaccine’s safety is comparable
to the safety of the chosen vector backbone. Among other vector
backbones tested for such applications are human immunodefi-
ciency virus type 1 (HIV-1)-derived lentiviral vectors (LVs). These
vectors do not replicate but support only a single round of infec-
tion of a target cell. Their potential to reconstitute the pathogenic
parental virus is excluded by the split-vector-genome approach
separating essential components of the virus on at least three dif-
ferent plasmids. Receptor specificity depends on the glycoproteins
(GPs) used for pseudotyping the vector particles. A variety of cell
types can be transduced by LVs, even nondividing cells (10, 11),
but especially myeloid cells reveal a considerable degree of resis-
tance to HIV-1-derived gene transfer due to a postentry block of
replication steps (12). Among these are dendritic cells (DCs) (13),
one of the most potent types of antigen-presenting cells (APCs)
(14). As such, the main function of DCs is to activate naive, anti-
gen-specific T cells upon uptake, processing, and presentation of
antigens in the context of costimulatorymolecules. Besides induc-
ing T cell immune responses, humoral immunity is closely linked
to activation and antigen processing by APCs, especially DCs, ei-
ther by direct B cell-DC interactions (15) or indirectly via activa-
tion of CD41 T helper cells.
Due to the important function of DCs, considerable effort has
beenmade to target the transfer of antigen-encoding sequences to
DCs. Several surface molecules on DCs have been used for target-
ing approaches, e.g., the C-type lectin DC-SIGN interacting with
the Sindbis virus envelope protein used to pseudotype LVs (16).
Also the glycoproteins of the measles virus (MV) strain Edmon-
stonwith its natural tropism for the receptors CD46, nectin-4, and
SLAM (signaling lymphocyte activation molecule), the last ex-
pressed on activated immune cells such as DCs (17), have been
shown to be highly suited for targeting of DCs (18). Moreover,
engineered MV-GPs displaying a single-chain antibody fragment
directed againstmajor histocompatibility complex class II (MHC-
II) have been successfully used for targeting of APCs (19). The
transduced DCs then express the transferred antigen-encoding
genes, process the antigens, present the antigen-derived peptides
on MHC-I and MHC-II, and consequently activate antigen-spe-
cific CD41 and CD81 T cells (20). Consequently, antibody pro-
duction is induced. Usually, the genetic information for the anti-
gen transferred by LVs is stably integrated into the host cells’
genome, potentially causing issues with genomic integrity of the
transduced cells. Alternatively, nonintegrating LVs have been
tested in which a defective integrase prevents genomic integration
of the transferred vector genomes (21). However, a relatively large
amount of vectors or complementation with HIV-2 Vpx has to be
used to overcome the postentry block to gene transfer preventing
antigen expression in situ.
Nevertheless, lenti- and other retroviral vectors transfer not
only their genomes during transduction but also their structural
proteins into the target cell’s cytoplasm. This feature can be uti-
lized to shuttle foreign cargo proteins into transduced cells when
the cargo is genetically fused to the structural vector proteins (22).
This protein transfer is independent from gene transfer and, if a
carefully chosen pretested fusion site is used, does not impair the
genomic integrity of the transduced target cells. Thus, a risk of
insertional mutagenesis by these so-called protein transfer vectors
(PTVs) does not exist. Furthermore, blocks in postentry steps of
genome replication do not impair protein transfer in any way and
thus should be no hindrance for the application of such vectors
under otherwise limiting conditions.
We reasoned that, besides marker proteins or enzymes, PTVs
may be constructed in which antigenic proteins of specific patho-
gens or antigens associated to tumor cells are genetically fused to
the structural vector proteins. In this study, we aimed to evaluate
if lentiviral PTVs could be used as such antigen carriers to induce
antigen-specific immune responses.We assessed the performance
of vectors pseudotyped with GPs of SLAM-tropic wild-type
MVwt323 (here, MVwt) (23) enabling direct targeting of APCs in
comparison to vectors pseudotyped with the standard glycopro-
tein VSV-G, which broadly transduces a large variety of cells but
gives rise to high-titer vector preparations. As proof of principle,
we demonstrated highly selective protein transfer into MVwt re-
ceptor-positive cell lines byMVwt-GP pseudotyped green fluores-
cent protein (GFP)- and ovalbumin (Ova)-transferring PTVs
(GFP-PTVs and Ova-PTVs, respectively), which matched with
gene transfer of cotransduced red fluorescent protein Katushka
(TurboFP635)-encoding vector genomes. Cytoplasmic release of
cargo proteins was confirmed for both tested pseudotypes. Ex vivo
treatment of myeloid DCs (mDCs) with Ova-PTVs resulted in
stimulation of Ova-specific CD81 T lymphocytes, evident by se-
cretion of interleukin-2 (IL-2) and gamma interferon (IFN-g). In
contrast, CD41 T cells were stimulated most by mDCs incubated
with “bald” vector particles, which did not incorporate viral gly-
coproteins and were thus not able to actively enter a target cell. In
vivo, ovalbumin-transferring PTVs triggered a predominantly cel-
lular immune response inmice expressing the respective receptor,
stimulating especially CD81 cytotoxic T cells. Thus, SLAM-tar-
geted PTVs have demonstrated specificity and, as well as nontar-
geted PTVs, efficacy of antigen transfer into primary APCs to trig-
ger antigen-specific immune activation. Since especially CD81 T
cells were activated ex vivo and in vivo, SLAM-targeted PTVs rep-
resent a suitable and, due to the absence of integration, safe vac-
cine especially for inducing cytotoxic immune responses. Since
cytotoxic CD81 T lymphocytes are a mainstay of antitumoral im-
mune responses, SLAM-targeted PTVs could be engineered for
the transfer of specific tumor antigens provoking tailored antitu-
moral immunity.
MATERIALS AND METHODS
Cells. CHO-K1 (ATCC CCL-61), 293T (CRL-11268), HT1080 (CCL-
121), and Raji (CCL-86) cells were purchased from the American Type
Culture Collection (ATCC,Manassas, VA, USA) and cultured for no lon-
ger than 6 months after initial thawing. CHO cells expressing human
SLAM (CHO-hSLAM) (24), CHO-CD46 (25), CHO-Nectin 4 (26), B95a
(27), and HT1080-Cre (28) are described elsewhere. CHO-K1, CHO-
CD46, CHO-Nectin 4, 293T, HT1080, and HT1080-Cre cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) (PAA, Cölbe, Germany) and 2 mM L-Gln.
Geneticin (Life Technologies, Darmstadt, Germany) was additionally
added for the cultivation of CHO-CD46 (1.2 mg/ml) or CHO-Nectin 4
(0.5 mg/ml) cells. Raji and CHO-hSLAM cells were maintained in RPMI
1640 medium supplemented with 10% FBS, 2 mM L-Gln, and, for CHO-
hSLAM cells, 0.5 mg/ml Geneticin. CHO-K1-blue, CHO-hSLAM-blue,
and Raji-blue cells were generated by stable transduction with VSV-G
pseudotyped HIV-1-derived lentiviral vectors encoding an expression
cassette for a floxed cerulean gene (LeGO-Cer2, plasmid 27338; Addgene)
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(29). Single clones were selected by limiting dilution. The cells weremain-
tained as described for the parental cell lines. JAWSII dendritic cells
(ATCC CRL-11904) were purchased from ATCC. JAWSII-Ova are
JAWSII cells stably expressingOva after lentiviral transduction. Bothwere
cultured in minimal essential medium alpha (MEM-a) with ribonucleo-
sides and deoxyribonucleosides (Gibco BRL, Eggenstein, Germany)
supplemented with 20% FBS, 2 mM L-Gln, 1 mM sodium pyruvate (Bio-
chrom), and 5 ng/ml murine granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) (Peprotech, Hamburg, Germany). All cells were
cultured at 37°C with 6% CO2 and 96% humidity.
Plasmids. For cloning of pcHIV1_MA_P_Ova, the 3= end of the ma-
trix (MA) [primers HIVgag-ClaI(1) andMA-Prot(2)] and the 5= end of
capsid (CA) [primers Prot-CA(1) andHIVgag-BaeI(2)] genes were am-
plified by PCR using pCMVDR8.9 as the template. The ovalbumin gene
was amplified by PCR [primersMA-Prot-Ova(1) and CA-Prot-Ova(2)]
with template pET15b-Ova (30). Thereby, the sequence encoding an ad-
ditional HIV-1 protease cleavage site (amino acid sequence VSQNYPI
VQN) was inserted between the matrix and Ova genes with primers MA-
Prot(2) and MA-Prot-Ova(1). The three resulting PCR fragments were
joined by primer extension PCR (31) using primers HIVgag-ClaI(1) and
CA-Prot-Ova(2). Primer sequences and detailed PCR protocols are
available upon request. PCR products were ligated into pCR2.1-TOPO
(Life Technologies), resulting in pCR2.1HIV1_MA_P_Ova, and the ab-
sence of mutations was confirmed by sequencing (Eurofins MWG
Operon, Ebersberg, Germany). To enable directed cloning, the 3= end of
pCR2.1HIV1_MA_P_Ova was elongated by a 1.64-kb gag fragment ob-
tained from NsiI-cleaved pcDNA3.GP1GFP.4xCTE (22, 32) to yield
pCR2.1-gag-Ova.NsiI. The desired sequence from the resulting plasmid
was cloned via ClaI and SbfI with the intended insert orientation into
pcDNA3.GP1GFP.4xCTE to yield pcHIV1_MA_P_Ova.
To generate pcHIV1_MA_P_Cre, pUC18 (Life Technologies) was lin-
earized by BamHI/EcoRI, and blunt endswere generated byKlenowfill-in
to yield pUC18-mod. The cargo protein-encoding cassette was isolated
from pcHIV1_MA_P_GFP (identical to pcHIV1_MA_P_Ova with GFP
instead ofOva sequence) via EcoRV/EcoRI and inserted into pUC18-mod
to yield pUC18-gag/pol-P. BamHI/AvaI restriction sites flanking the
cargo sequence were introduced by PCR (primers GGS-linker 1 P fwd;
GGS-linker1 P rev; LGG, AvaI fwd; LGG, AvaI rev) to yield pUC18-gag/
pol-P-mod. The cre gene was amplified by PCR with flanking BamHI/
AvaI sites (primers Cre-BamHI fwd and Cre-AvaI rev) using pSEW-Cre
(33) as the template. Primer sequences and detailed PCR protocols are
available upon request. The amplified cre fragment was ligated into
pCR2.1-TOPO (Life Technologies) to yield pCR2.1-Cre-inv and se-
quenced. The cre gene was subsequently cloned into pUC18-gag/pol-P-
mod via AvaI/BamHI to yield pUC18-gag/pol-P-Cre. Finally, the matrix-
Cre-capsid fragment was inserted into pcHIV1_MA_P_GFP via ClaI/SbfI
to yield pcHIV1_MA_P_Cre.
Plasmids pMD.G2 (34), pCG-Hwt323D18 (35), pCG-Fwt323D30
(35), pSEW-TurboFP635 (36), and pCMVDR8.9 (37) have been de-
scribed previously.
Transfection of cells. A total of 7 3 105 293T cells were seeded in
six-well plates (Nunc,Wiesbaden, Germany). The next day, cells (approx-
imately 80% confluent) were transiently transfected with 5 mg of plasmid
DNA using Lipofectamine 2000 reagent (Life Technologies) according to
the manufacturer’s instructions.
Vector production. HIV-1-derived lentiviral vector particles were
produced by transfection of 293T cells as described previously (38). To
produce VSV-G or MVwt-GP pseudotyped PTVs, 3.98 mg of Env expres-
sion plasmid(s) (pMD.G2 or 1.49mg of pCG-Hwt323D18 plus 2.49mg of
pCG-Fwt323D30), 12.73 mg of transfer vector plasmid (pSEW-Tur-
boFP635), and 18.3 mg of packaging plasmid(s) (pCMVDR8.9 and re-
spective cargo protein-encoding constructs in a 1:1 or, for Cre-encoding
constructs, 2:1 ratio) were transfected per T175 flask. Bald particles were
produced by cotransfecting 14.36mg of transfer vector plasmid and 20.64
mg of packaging plasmid(s). Two days after transfection, cell debris was
removed using 0.45-mm-pore-size filters and subsequently concentrated
by ultracentrifugation through a 20% sucrose cushion (100,0003 g, 4°C,
3 h). Pelleted vector particles were resuspended in Opti-MEM (Life Tech-
nologies) and stored in aliquots at280°C.
Lentiviral transductionof cells.For transduction, cells were seeded in
24-, 48-, or 96-well plates (Nunc). The next day, when cells reached 70 to
80% confluence, 250 ml (24-well plates) or 150 ml (48-well plates) of
vector-containingmediumwas added to the cells. In gene transfer experi-
ments, vector-containing supernatant was replaced by normal growth
medium at 6 h posttransduction. Protein transfer was assessed at 4 h
posttransduction, whereas gene transfer was analyzed at 72 h posttrans-
duction.
Lysis of cells. Cells were lysed 48 h after transient transfection or 4 h
after transduction. First, cells were washed once with ice-cold phosphate-
buffered saline (PBS). After transduction with protein transfer vectors,
surface-bound particles were removed by incubation with citric acid buf-
fer (40 mM citric acid [Sigma-Aldrich], 135 mMNaCl, 10 mMKCl) for 2
min at room temperature, where indicated in the text and on the figure.
Then, cells were washed once with ice-cold PBS and lysed with radioim-
munoprecipitation assay (RIPA) lysis buffer (50 mMTris, 150 mMNaCl,
1% NP-40, 0.5% sodium desoxycholate, 0.1% SDS) supplemented with
protease inhibitor cocktail (Roche, Mannheim, Germany). Either 500 ml
or 100ml of RIPA lysis buffer was used per 6- or 48-well plate, respectively.
Immunoblotting. Cell lysates or suspensions of purified vector parti-
cles were denatured using equal volumes of 23 urea sample buffer (200
mM Tris-HCl, 8 M urea, 5% SDS, 0.1 mM EDTA, 0.03% bromophenol
blue, 1.5%dithiothreitol) and incubated for 10min at 95°C. Proteinswere
separated by polyacrylamide gel electrophoresis on 10% SDS-PAGE gels
and blotted onto polyvinylidene difluoride (PVDF)membranes (Hybond
P; GE Healthcare, Freiburg, Germany). The membranes were incubated
with rabbit anti-GFP (1:2,000; Life Technologies), rabbit anti-Cre (1:
20,000; Merck Millipore, Darmstadt, Germany), rabbit anti-chicken
ovalbumin (1:40,000; Novus Biologicals, Cambridge, United Kingdom),
mouse anti-HIV-1 p24 (1:1,000; Gentaur, Aachen, Germany), rabbit an-
ti-MV hemagglutinin protein (MV-H) (1:1,000; clone 606), rabbit an-
ti-MV fusion protein (MV-F) (1:4,000; clone 1034; Abcam, Cambridge,
United Kingdom), rabbit anti-VSV-G (1:2,000), ormouse anti-a-tubulin
(1:50,000; Sigma-Aldrich) primary antibody in 5%milk or horse serum in
TBS-T (50 mM Tris, 150 mMNaCl, pH 7.4, 0.1% Tween 20). As second-
ary antibody, horseradish peroxidase (HRP)-conjugated donkey anti-
rabbit IgG(H1L) (1:10,000; Rockland, Limerick, PA,USA) or rabbit anti-
mouse IgG-IgA-IgM(H1L) (1:10,000; Life Technologies) was used as
appropriate. Probedmembranes were strippedwith Restore PlusWestern
blot stripping buffer (ThermoFisher Scientific,Dreieich,Germany) for 20
min at room temperature and washed once with TBS-T before being
reprobed.
Flow cytometry analysis. Adherent cell lines were detached using
trypsin-EDTA, and DCs were detached by vigorous pipetting. A total of
5 3 105 cells per staining were washed thoroughly with fluorescence-
activated cell sorter (FACS) wash buffer (PBS, 1% FBS, 0.1% NaN3). To
stain DCs, cells were incubated first with Fc-blocking reagent (1:100;
Miltenyi Biotec, Bergisch-Gladbach, Germany) for 15 min at room tem-
perature. Then, antibodieswere added, and sampleswere incubated for 20
min at 4°C in the dark. For flow cytometry, anti-mouse CD11c-allophy-
cocyanin (APC) (1:500; BD, Heidelberg, Germany), anti-mouse CD69-
phycoerythrin (PE)-Cy7, or anti-mouse CD86-Pacific Blue (each 1:100;
BioLegend, London, United Kingdom) was used. After staining, all cells
were washed twice with FACS wash buffer before fixation with 100 ml of
FACS Fix buffer (PBS, 1% paraformaldehyde [PFA]). Cells expressing
fluorophores, e.g., after transduction, were subjected to flow cytometry
after beingwashed thoroughly andfixedwith FACSFix buffer. All samples
were analyzed using an LSRII SORP cytometer (BD). Data were analyzed
using FACSDiva (BD) or FCS Express software (DeNovo Software, Glen-
dale, CA, USA).
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Electron microscopy. At 48 h posttransfection, vector-producing
packaging cells were fixed by addition of 10% (vol/vol) glutaraldehyde to
the culture medium. After a 10-min incubation at room temperature, the
medium was removed, and cells were gently washed twice with PBS with-
out Ca21/Mg21. The fixed cells were stored in PBS lacking Ca21/Mg21 at
4°C until ultrathin sections were prepared as described previously (38). In
short, fixed cells were scraped from the plastic surface and embedded in
agarose. Then, cells were stained and subjected to secondary fixation with
1%osmium tetroxide (Sigma-Aldrich), contrastedwith 2%uranyl acetate
(Merck, Darmstadt, Germany), and finally dehydrated by consecutive use
of 30%, 50%, 70%, 80%, 90%, 96%, and 100% ethanol (EtOH). In a last
step, cells were embedded into epoxy, and ultrathin sections were cut.
Sampleswere placed onFormvar-coatedmesh copper grids (Athene; Agar
Scientific, Essex, United Kingdom) and analyzed with an EM109 trans-
mission electron microscope (Zeiss, Jena, Germany).
NanoSight particle analysis. NanoSight particle analysis of concen-
trated vector particles by a liquid-phase Stokes diffusion particle-tracking
system was performed using a NanoSight NS500 device and NTA2.3 soft-
ware (both, NanoSight, Ltd., Amesbury, United Kingdom). Prior to analysis,
samples were diluted in sterile filtered PBS without Ca21/Mg21 to obtain
suspensions with a particle concentration of 13 107 to 13 109 particles/
ml. The paths of 20 to 40 particles were followed per measurement. Each
sample wasmeasured in triplicate (75 s each) at a constant temperature of
25°C, and themean of the singlemeasurements was calculated. The device
was cleaned thoroughly before and after each measurement.
Generationand transductionofbonemarrow-derivedmyeloidden-
dritic cells.Myeloid dendritic cells (mDCs) were generated by cultivating
bone marrow cells from IFNAR2/2 and IFNAR2/2-SLAMki (where ki is
knock-in) mice in the presence of GM-CSF (100 ng/ml) as described
previously (30). A total of 3.2 3 105 mDCs were seeded per well into
24-well plates and stimulated by addition of 100 ng/ml lipopolysaccharide
(LPS; Sigma-Aldrich) overnight to upregulate SLAM on mDCs of
IFNAR2/2-SLAMki mice (39). Subsequently, mDCs were transduced
with the respective PTVs. For inhibition of transduction using the MV-
specific fusion inhibitor FIP (2-D-Phe-Phe-Gly-OH; Bachem, Bubendorf,
Switzerland) (40), medium containing FIP (200 mM) was added 30 min
before transduction. Inhibitor-supplementedmediumwas used in all fur-
ther steps. mDCs were incubated with protein transfer vectors for 4 h.
Then, transduced mDCs were coincubated with 8 3 105 primary T cells
isolated from splenocytes ofOT-I (41) orOT-II (42)mice bymagnetic cell
separation using CD41 T Cell Isolation Kit II (mouse) or a CD8a1 T cell
isolation kit (mouse) (both, Miltenyi Biotec) and suspended in DC me-
dium (RPMI 1640 medium, 10% FBS, 2 mM L-glutamine, 100 U/ml pen-
icillin, 100 mg/ml streptomycin, 10 mMHEPES, 1 mM sodium pyruvate,
0.1 mM 2-mercaptoethanol). At 24 h and 72 h after addition of T cells,
supernatants of the cocultures were sampled and stored at 220°C for
analysis of secreted cytokines by enzyme-linked immunosorbent assay
(ELISA).
ELISA. Murine IL-2 or IFN-g was quantified with BD OptEIA Set
Mouse IL-2 or BD OptEIA Set Mouse IFN-g (BD Biosciences), respec-
tively, according to the manufacturer’s instructions. Ovalbumin concen-
tration was determined using a chicken egg ovalbumin ELISA kit (Alpha
Diagnostic International, San Antonio, TX, USA); HIV-1 p24 concentra-
tion was determined by an HIV-1 p24 antigen ELISA (Gentaur, Aachen,
Germany) according to the manufacturer’s instructions.
ELISpot assay. Antigen-specific IFN-g secretion of splenocytes in
mice was analyzed using a mouse IFN-g enzyme-linked immunosorbent
spot (ELISpot) assay (Ready-Set-Go! kit; eBioscience). One day before the
assay, MultiScreen-IP filter plates (Merck Millipore) were activated with
70% EtOH and immediately washed three times with sterile water and
once with PBS before further processing was done according to the man-
ufacturer’s protocol. A total of 5 3 105 splenocytes per well were incu-
bated with plain medium (negative control), 10 mg/ml concanavalin A
([ConA] positive control; Sigma-Aldrich), 10 mg/ml recombinant Ova
(30), 5mg/ml of anOva peptide consisting of residues 257 to 264 (Ova257–
264; SIINFEKL), or 5 mg/ml Ova323–339 (ISQAVHAAHAEINEAGR)
(both, Invivogen, Toulouse, France). The plates were subsequently incu-
bated, without movement, for 36 h at 37°C and 6% CO2 in a humidified
incubator. IFN-g-secreting cells were detected according to the manufac-
turer’s instructions. The spots were counted using an ELISpot reader
(Eli.Scan; A.EL.VIS, Hannover, Germany) with the software ELI.Analyse
(A.EL.VIS). Wells with too many spots to be counted were set to 1,500
spots (maximum spot count reliably determined).
Animal experiments. Animal experiments were performed in com-
pliance with the regulations of the German animal protection law. All
animals used were bred in-house at Paul-Ehrlich-Institut, and genotypes
were confirmed by PCR-based genotyping. Six- to 8-week-old IFNAR2/2
(43) or IFNAR2/2-SLAMki (39) mice were injected intraperitoneally
(i.p.) with 200 ml of vector suspension diluted in Opti-MEM adjusted
to a total content of 1 mg of ovalbumin. MVwt-GP pseudotyped HIV-
derived vectors transferring GFP protein and cotransducing the katushka
gene [HIV-GFPKatushka(MVwt)] were normalized by p24 content to
HIV-OvaKatushka(MVwt). Four weeks later, mice were boosted. The ani-
mals were sacrificed on day 32, spleens were harvested, and splenocytes
were isolated by mashing the spleens through a 70-mm-pore-size filter.
After lysis of red blood cells (155 mM NH4Cl, 10 mM Tris, pH 7.5) and
one wash step, splenocytes were either used directly for IFN-g ELISpot
assays or stored at 280°C in freezing medium (90% FBS, 10% dimethyl
sulfoxide [DMSO]) before use.
Statistical analysis. To evaluate the statistical significance between
data sets, statistical analysis was done using the analyzing software Graph-
Pad Prism (GraphPad Software, Inc., La Jolla, CA) with tests indicated in
the respective figure legends.
RESULTS
Generation and characterization of lentiviral protein transfer
vectors. To establish the generation of cargo protein-transferring
particles, VSV-G pseudotyped vector particles were produced us-
ing different ratios of packaging plasmids expressing unmodified
Gag/Pol and a construct where GFP was genetically fused to the C
terminus of the matrix (MA) protein coding region of gag (Fig.
1A). While protein transfer can thus be detected by GFP fluores-
cence, gene transfer into HT1080 cells was monitored in parallel
by packaging of a transfer vector (pSEW-TurboFP635) encoding
the red-fluorescing Katushka protein into these vector particles.
Increasing the amount of gag fused to gfp relative to the amount of
unmodified gag in packaging cells enhanced both the percentage
and mean fluorescence intensity (MFI) of GFP-positive (GFP1)
cells after transduction of target cells, thereby indicating thatmore
GFP had been packaged into protein transfer vector particles (Fig.
1B). However, if only GFP-tagged Gag/Pol was used for particle
production, protein transfer was strongly reduced (Fig. 1B). In-
terestingly, gene transfer by the produced PTVs reciprocally cor-
related with protein transfer, and this correlation was even stron-
ger in terms of theMFI than of the percentage of transduced cells,
indicating multiple transduction events of target cells for “opti-
mal” ratios (Fig. 1B). Thus, the higher the ratio was of Gag-GFP to
Gag expressed during vector production, the lower the gene trans-
fer efficacy of the generated particles was. When solely Gag-GFP
fusion protein was used for particle production, no transducing
particles were generated at all. The optimal relation of protein and
gene transfer was determined in packaging cells transfected with a
1:1 ratio of Gag-GFP/Pol-to-Gag/Pol packaging plasmids [Gag
(-GFP)/Pol] (Fig. 1B). While greater GFP transfer by particles
generated in cells that express more GFP-Gag than Gag is ex-
pected, a reduction in gene transfer by larger amounts of the GFP-
Gag fusion protein may argue for impairment of vector particle
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FIG 1 Optimization of lentiviral protein transfer vector production. (A) Schematic depiction of Gag-cargo/Pol constructs. MA, matrix; CA, capsid; NC,
nucleocapsid; PR, protease; RT, reverse transcriptase; IN, integrase. The arrowhead indicates HIV-1 protease cleavage motif. (B) Titration of Gag/Pol to
Gag-GFP/Pol used for PTV production. VSV-G pseudotyped PTVs transferring the katushka transgene were produced in 293T cells transfected with the
indicated ratios of Gag/Pol to Gag-GFP/Pol packaging constructs. GFP transfer or Katushka expression (gene transfer) by flow cytometry 3 h or 72 h
posttransduction, respectively, was assessed in HT1080 cells after transduction with similar volumes of vector-containing supernatant, analyzed both for
the fraction of positive cells or relative MFI. The maximal fraction of cells positive for protein or gene transfer was normalized to 1. For relative MFI, the
MFI of untransduced cells was set to 1. Values are means 6 standard errors of the means (n 5 3). No GFP, vector lacking GFP cargo; No G/P, vectors
composed of Gag-GFP/Pol only. (C) Particle morphology. Ultrathin sections of 293T cells releasing the indicated PTVs were analyzed by electron
microscopy. Arrows depict disrupted MA layer and irregularities of envelope. Scale bar, 100 nm. (D) Particle size. Analysis of PTV particles produced as
indicated by real-time single-particle tracking analysis. (E and F) Optimization of protein and gene transfer during PTV production for PTVs pseudotyped
by VSV-G (E) or PTVs pseudotyped by MV glycoproteins (F). Vectors harvested from 293T cells transfected with the indicated relative plasmid ratios
(Gag-Pol/Gag-cargo-Pol to Env to transfer vector; ratio A, 1.62:0.87:2.5; ratio B, 2.1:0.7:2.1; ratio C, 2.3:0.5:1.6) were used for transduction of CHO-
hSLAM cells with same volume of PTVs. GFP protein transfer (black) or Katushka gene transfer (white) were assessed by flow cytometry at 3 h or 3 days
after transduction, respectively. Values are means 6 standard errors of the means (n 5 3).
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structure due to the changed steric requirements of the Gag-GFP
polyprotein in these vector particles.
To test this hypothesis, the morphology of PTV particles pro-
duced with only GFP-Gag or with GFP-Gag/Gag in a 1:1 ratio was
characterized by electron microscopy of ultrathin sections of cor-
responding packaging cells. In parallel, purified vector particles
were analyzed in comparison to the respective vector particles
with no additional cargo protein using the NanoSight system.
Electron microscopy revealed no morphological differences be-
tween lentiviral gene transfer vectors and protein transfer vectors
produced with a 1:1 ratio of Gag-GFP/Pol-to-Gag/Pol packaging
plasmids (Fig. 1C). In contrast, fewer particles were detectedwhen
only Gag-GFP/Pol was used for particle production. These parti-
cles also revealed structural abnormalities such as a disruptedMA
layer and the presence of fewer and irregularly arranged envelope
protein complexes (Fig. 1C, right panel).
Real-time single-particle tracking analysis of the three particle
types confirmed the different structure of particles produced with
only Gag-GFP/Pol (Fig. 1D). Gene transfer vectors and PTVs pro-
duced with a 1:1 ratio of packaging constructs did not differ es-
sentially in particle diameter, which was determined to be 125 nm
for both vector types. A few aggregates were detected in both par-
ticle stocks. In contrast, in vector particle stocks produced with
GFP-tagged Gag only, at least four particle populations with di-
ameters of approximately 110 nm, 140 nm, 260 nm, and 355 nm
could be distinguished (Fig. 1D). These data clearly demonstrate
the presence of aggregates and irregularly formed particles when
only GFP-Gag was used for packaging, explaining the lack of
transducing vector particles (Fig. 1B, right column). Therefore, a
1:1 ratio of Gag-GFP/Pol to Gag/Pol packaging constructs was
chosen for the generation of PTV particles in all subsequent ex-
periments.
Finally, the ratio of Gag(-GFP)/Pol packaging plasmids to
transfer vector and envelope expression constructs required for
PTV production was varied, and the resulting particles were ana-
lyzed as described above. When the relative fraction of packaging
plasmids (Gag/Pol and Gag-GFP/Pol) was increased and the frac-
tions of envelope protein (VSV-G or MV-F plus MV-H) and
transfer vector plasmids (pSEW-TurboFP635) were reduced, the
efficacy of gene and protein transfer became affected (Fig. 1E and
F). ForVSV-Gpseudotyped vectors, employing a ratio of 2.3 to 0.5
to 1.6 (sum of Gag/Gag-cargo to Env to vector) (Fig. 1E and F,
ratio C), efficiency of protein transfer by the resulting particles
could be increased from 11.0%6 2.8% to 55.2%6 25.5%, which
was also accompanied by an increase of gene transfer from
74.9%6 34.1% to 95.5%6 3.8% (Fig. 1E). ForMV glycoproteins
(Fig. 1F), the best protein transfer (53.3%6 28.3% positive cells)
was achieved at a ratio of 2.1 to 0.7 to 2.1 (Fig. 1E and F, ratio B),
but gene transferwas slightly reduced to 4%6 1.3% in this setting.
Taken together, these data show a positive correlation between the
amount of packaging plasmids transfected into 293T packaging
cells for vector production and the capability of the originating
particles to transfer cargo proteins. In essence, the greater the
amount of Gag-GFP/Pol and Gag/Pol packaging plasmids that
was transfected for vector production, the greater was the amount
of GFP protein transferred into transduced target cells by VSV-G
pseudotyped vector particles, as expected. For MVwt-GP pseu-
dotyped particles, however, this was less stringent, most likely due
to more complex Env-GP organization. Obviously, the nature of
the glycoproteins codetermines functionality of the respective
pseudotyped PTV particles.
Transfer of different cargo proteins by PTVs. In addition to
PTVs transferring GFP, Cre recombinase- or ovalbumin (Ova)-
transferring PTVs were used in this study. For this purpose, pack-
aging plasmids encoding Cre recombinase or Ova within the gag
open reading frame (ORF) were cloned (Fig. 1A). To assess
whether the cargo proteins encoded by these packaging plasmids
were expressed, Cre orOva expressionwas analyzed in addition to
GFP expression in transfected 293T cells byWestern blot analysis.
In both Cre- and Ova-encoding packaging constructs, an HIV-1
protease site (VSQNY2PIVQN)-encoding amino acid sequence
was inserted between matrix- and cargo protein-encoding DNA
sequences (Fig. 1A). This cleavage site (indicated by the down
arrow) enables release of the respective cargo proteins into the
cytoplasm of transduced cells after fusion of particle and
plasma membranes during cell entry due to processing of the
respective MA-cargo precursor protein during particle matu-
ration. All cargo proteins were efficiently expressed (Fig. 2A to
C) and were detected as fusion proteins within the 55-kDa Gag
polyprotein precursor and/or with the 17-kDa MA protein.
Gag-GFP (82 kDa) andMA-GFP (44 kDa) fusion proteins were
detected in cells transfected with pcDNA3.GP1GFP.4xCTE,
and expression of Gag-Ova (98 kDa) was visible in
pcHIV1_MA_P_Ova-transfected cells, whereas Gag-Cre (93
kDa) and MA-Cre (55 kDa) were detected in lysates of 293T
cells transfected with pcHIV1_Ma_P_Cre. Additionally, the re-
spective released cargo proteins Ova (43 kDa) and Cre (38 kDa)
were detected with the expectedmolecularmasses as well, indicat-
ing functionality of the inserted protease cleavage site. Taken to-
gether, these data demonstrate expression of all Gag-cargo fusion
proteins and release of Ova or Cre recombinase by proteolytic
cleavage during particle maturation.
These plasmids were used for production of PTVs pseu-
dotyped with VSV-G or truncated MVwt glycoproteins, i.e., the
hemagglutinin (H) and fusion protein (F). Vector particles were
produced in 293 T cells and concentrated via ultracentrifugation.
Subsequently, incorporation of cargo proteins into the respective
concentrated vector particles was analyzed byWestern blot analy-
sis (Fig. 2D to F).GFP,Cre, andOvawere detected in purifiedPTV
lysates, indicating efficient incorporation of cargo proteins into
PTV particles. In PTVs generated using Gag-cargo/Pol constructs
with the additional protease cleavage site between MA and cargo,
complete release of Ova frommatrix fusion proteins was observed
(Fig. 2F). Also Cre was completely released from the Gag-Cre
polyprotein, but in addition to free Cre recombinase, degradation
products of the enzyme were also observed (Fig. 2E, lower bands).
If no cleavage site was encoded, the cargo protein was detected as
a fusion protein with MA, as demonstrated for vectors incorpo-
rating the MA-GFP fusion protein (Fig. 2D). Additionally, incor-
poration of the envelope glycoproteins VSV-G, MV-H, or MV-F
correlated with p24 incorporation irrespective of the payload of
the different vector particles (Fig. 2D to F). In contrast, no cellular
cytoplasmic proteins seem to be incorporated into PTVs, as dem-
onstrated by the lack ofa-tubulin in all PTV preparations (Fig. 2G
to I).
To analyze whether incorporation of different cargo proteins
into lentiviral particles causes structural alterations of vectors, the
morphology of PTVs was assessed by electron microscopy of ul-
trathin sections of vector-producing packaging cells. No remark-
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able differences betweenGFPor other protein transfer vectors and
the respective lentiviral gene transfer vectors were observed (Fig.
3). All PTV particles revealed a regularly shaped core structure,
which was indistinguishable between PTVs and gene transfer vec-
tors. However, particles with different envelope proteins could
clearly be discriminated. VSV-G pseudotyped vectors were char-
acterized by a high density of an ordered envelope glycoprotein
shell (Fig. 3B). MVwt-GPs were less abundant on PTV surfaces
(Fig. 3C) but clearly detectable as distinct envelope protein com-
plexes protruding from the particles’ surfaces (marked by arrows)
while such structures were not detectable on bald particles
(Fig. 3A).
Receptor specificity of pseudotyped PTVs.Next, we aimed to
assess receptor specificity, i.e., the tropism of pseudotyped PTVs,
and thereby to analyze their potential for targeting specific cell
types of interest. A receptor-transgenic CHO cell panel expressing
MVwt receptors (CHO-hSLAM and CHO-Nectin 4), controls
(CHO-K1 and CHO-CD46), and naturally SLAM-positive B95a
and Raji cells were used. These cells were transduced in parallel
with GFP-transferring PTVs additionally mediating gene transfer
of the Katushka marker gene at a multiplicity of infection (MOI)
of 1 (all vectors were previously titrated by gene transfer in CHO-
hSLAM cells). As depicted in Fig. 4A and B, flow cytometry re-
vealed specific delivery of GFP by PTVs pseudotyped with MVwt
glycoproteins (MVwt-GP) exclusively into SLAM- or nectin-4-
positive cells, as expected. In parallel, transfer of vector genomes
encoding Katushka was demonstrated into the same cells, which
had been susceptible for protein transfer. In contrast, VSV-G
pseudotyped PTVs revealed the expected broad tropism, as indi-
cated by gene transfer into all CHO lines and humanRaji cells, but
FIG2 Expression of cargo proteins by packaging constructs and efficient incorporation into PTVparticles. (A toC) Expression ofGFP, Cre, orOva by packaging
constructs. Immunoblot analysis was performed of 293T cells left untransfected (2) or transfected with Gag/Pol, the indicated Gag-cargo/Pol packaging
plasmids, or pSEW-Cre (transfer vector encodingCre recombinase). At 48 h after transfection blotswere probed forGFP (A), Cre (B), orOva (C). (D to I) Protein
incorporation into PTVs. PTVparticles produced in 293Tpackaging cells were purified and concentrated by ultracentrifugation from supernatants and subjected
to immunoblot analysis probing for GFP (D), Cre (E), or Ova (F) to detect cargo protein content. Lentiviral gene transfer vectors, pseudotyped with VSV-G
(VSV/2) or MVwt-GPs (MV/2), served as negative controls. All particle preparations were further probed for incorporation of envelope glycoproteins (lower
panels, D to F) or a-tubulin (lower panels, G to I). Lysates of unmodified 293T cells or 293T cells transfected with the indicated Gag/Pol packaging plasmids
served as positive controls, as well as p24 detection in vector preparations (different from those used in the experiments shown in panels D to F). a-Tub,
a-tubulin.
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the protein transfer was significantly less efficient and sometimes
(e.g., in CHO-K1 cells) very scarce. Results in the simian cell line
B95a differed from those in the other analyzed cell lines since gene
transfer was absent in these cells using VSV-G pseudotyped PTVs.
Also gene transfer byMVwt-GP pseudotyped PTVs was drastically
reduced in B95a cells. In contrast, efficient protein transfer espe-
cially usingMVwt-GP pseudotyped PTVs was unimpaired in these
cells. Taken together, analysis of lentiviral GFP-PTVs on receptor-
transgenic CHO and B cell lines revealed specific delivery of cargo
protein by MVwt-GP pseudotyped vectors only into SLAM- and
nectin-4-positive cells, in contrast to broadly transducing VSV-G
pseudotyped vector particles.
PTVsmediate cytoplasmic transfer of their cargoprotein.To
exclude that the observed fluorescence of target cells after trans-
duction by GFP-transferring PTVs was caused by adhesion of the
individual particles to cellular surfaces, we aimed to confirm cell
entry of vectors usingCre recombinase-transferring PTVs in com-
binationwith receptor-transgenic cell lines. These target cells were
modified to incorporate a protein expression cassette for the blue
fluorescent marker protein cerulean (44), in which the cerulean
ORF is flanked byCre recognition sites (Fig. 5A). Thus, expression
of Cre recombinase results in loss of blue fluorescence due to
inactivation of the cerulean ORF by recombination.
Cre indicator cell lines harboring a floxed cerulean cassette but
differing in their receptor status (CHO-K1-blue, SLAM2; CHO-
hSLAM-blue, SLAM1; Raji-blue, SLAM1) were transduced with
Cre PTVs pseudotyped with VSV-G [HIV-CreKatushka(VSV)] or
MVwt-GPs [HIV-CreKatushka(MVwt)] at anMOI of 15 or, as a pos-
itive control, VSV-G pseudotyped Cre gene transfer vectors
[HIVCre(VSV)] at an MOI of 10. Blue fluorescence of transduced
cells and controls was analyzed 2weeks after transduction to allow
fading of fluorescence after inactivation of the cerulean ORF (Fig.
5B). Transduction with HIVCre(VSV) gene transfer vectors resulted
in complete (CHO-K1-blue and CHO-hSLAM-blue) or at least sig-
nificant lossof ceruleanfluorescence (Raji-blue), as expected(Fig. 5B,
right column). Transduction with HIV-CreKatushka(MVwt) PTVs re-
sulted in fading of cerulean fluorescence in a significant fraction of
transduced cells (Fig. 5B, middle and right columns). With the
exception of MV receptor-negative CHO-K1-blue cells, this frac-
tion of cells was bigger than after transduction of the same indi-
cator cell lines by HIV-CreKatushka(VSV) particles. Accordingly,
we observed 0% versus 3.4% loss of fluorescence in CHO-K1-blue
cells, 13.0% versus 3.0% fading of blue fluorescence in CHO-hS-
LAM-blue cells, and 1.9% versus 0.8% inactivation of cerulean
fluorescence in Raji-blue cells after transduction with
HIV-CreKatushka(MVwt) or HIV-CreKatushka(VSV) PTVs. Thus,
HIV-CreKatushka(MVwt) selectively diminished blue fluorescence
in only MVwt receptor-positive indicator cell lines, whereas
HIV-CreKatushka(VSV) led to inactivation of cerulean fluorescence
in all three cell lines, independent of the presence of SLAM. These
data thus confirmed cytoplasmic release of functional proteins
into transduced cells and confirmed the receptor specificity of the
generated PTVs.
SLAM-targeted transfer of ovalbumin is feasible by
MVwt-GPpseudotyped PTVs. Since the final aim of this study has
been the analysis of the suitability of PTVs for use in vaccines, the
immunologically well-characterized protein ovalbumin (Ova)
was chosen as a model antigen for subsequent analyses. As de-
scribed above for GFP-PTVs, the target receptor specificity of
Ova-PTVs was determined using the same cell panel expressing
the different receptor(s) of interest. Althoughwewere aware of the
challenge in using a small quantity of transferred protein, i.e., 723
fg of Ova per transducing unit (TU) in HIV-OvaKatushka(MVwt)
vector preparations as determined by ELISA (data not shown),
lysates of cells transduced with Ova-PTVs were subjected to anti-
Ova immunoblot analysis. Analysis of lysates of transduced cells
revealed clearly detectable Ova signals in receptor-positive CHO-
hSLAM, B95a, and Raji cells transduced with MVwt pseudotyped
Ova-PTVs (Fig. 4C). These signals were still detectable after citric
acid buffer treatment (to remove surface-bound particles) of
transduced cells before lysis, thus indicating that Ova was trans-
ferred into the cytoplasm of the transduced target cells, as ex-
pected. Moreover, selective Katushka transgene expression, as de-
tected by flow cytometry analysis, confirmed transduction of the
SLAM-positive cells by HIV-OvaKatushka(MVwt) (Fig. 4D). In
contrast, in cell lysates obtained from cells transduced by
HIV-OvaKatushka(VSV) vectors at the same MOI, no Ova was de-
tectable byWesternblot analysis.Gene transfer, however,wasobserved
for all HIV-OvaKatushka(VSV)-transduced cells, except, again, for the
monkey cell line B95a (Fig. 4D). In conclusion, receptor-dependent
transductionwas demonstrated also forOva-PTVs.
Ex vivo transduction ofmurinemDCswithOva-PTVs. In the
next step, myeloid dendritic cells (mDCs) were generated from
bone marrow of MV receptor-negative IFNAR2/2 and receptor-
positive IFNAR2/2-SLAMki mice (parental strain of both,
C57BL/6) as prototypic antigen-presenting cells (APCs) (Fig. 6A).
PTVs, especially those targeted to APCs, may constitute a well-
suited agent for the induction of APC-initiated immune responses
due to their ability to transfer antigenic protein into these cells.
However, activation of APCs requires additional costimulation.
As PTVs are derived from virus particles, interaction of PTVs with
APCs might stimulate APCs per se. Thus, stimulation of APCs by
PTVs was analyzed 24 h after transduction by analysis of expres-
sion of the activationmarkers CD69 andCD86 onmDCs.None of
the tested PTVs induced upregulation of CD69 or CD86 in trans-
FIG 3 Analysis of vector particle morphology by electron microscopy. Ultra-
thin sections of 293T packaging cells transfected to produce GFP-PTV parti-
cles harboring no envelope glycoproteins (Bald/GFP) (A), GFP-PTV or lenti-
viral gene transfer particles pseudotyped with VSV-G (VSV/GFP and VSV/2,
respectively) (B), orGFP-PTVor lentiviral gene transfer particles pseudotyped
with MVwt-GPs (MV/GFP and MV/2, respectively) (C) were analyzed by
electron microscopy. Representative pictures of each vector particle type are
shown. Arrows point at envelope glycoprotein complexes. Scale bar, 100 nm.
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duced mDCs (Fig. 6B) despite the general responsiveness of those
cells, as demonstrated by the addition of LPS (Fig. 6B).
To assess the immune-stimulatory capacity of mDCs trans-
duced by Ova-PTVs, transduced mDCs were cocultured with
Ova-specific CD81 or CD41 T cells isolated from spleens of T cell
receptor (TCR)-transgenic mice (OT-I or OT-II mice, respec-
tively) (Fig. 6A). Stimulation of T cells was assessed by quantifying
the secretion of IL-2 or IFN-g (Fig. 6C and D). CD81 T cells were
stimulated to secrete only IL-2 and IFN-g in coculture with
IFNAR2/2 mouse-derived mDCs preincubated with endotoxin-
depleted recombinant Ova or HIV-OvaKatushka(VSV) PTVs.
Preincubation of mDCs with HIV-OvaKatushka(bald),
HIV-OvaKatushka(MVwt), or GFP-PTVs [HIV-GFPKatushka(MVwt) and
HIV-GFPKatushka(VSV)] did not induce activation of OT-I T cells.
Similarly, CD81 Ova-specific T cells were stimulated by
IFNAR2/2-SLAMki mDCs preincubated with recombinant Ova
or HIV-OvaKatushka(VSV). However, IL-2 and IFN-g release was
additionally detected forOT-I cells in coculture withmDCs trans-
duced byHIV-OvaKatushka(MVwt) PTVs. Thus, PTVs pseudotyped
with MVwt-GPs revealed highly selective transduction of SLAM-
positive APCs only. Cytokine secretion was also dependent on the
number of infectiousHIV-OvaKatushka(MVwt) particles as IFN-g release
correlated with theMOI (Fig. 6C). In line with these data, activation of
CD81 T cells by mDCs transduced with HIV-OvaKatushka(MVwt) was
completely ablated upon addition of the fusion-inhibiting peptide
FIP (data not shown), which inhibits MVwt-GP-mediated mem-
brane fusion. These data indicate GP-mediated transfer of the
cargo protein into the cytosols of mDCs by PTVs. Obviously,
transferred cargo proteins were proteasomally processed and pre-
sented on MHC-I molecules via the endogenous antigen presen-
tation pathway. Interestingly, the amount of secreted IL-2 in co-
cultures of cytotoxic T cells with HIV-OvaKatushka(VSV)- or
HIV-OvaKatushka(MVwt)-transduced mDCs was comparable to the cy-
tokine level released by CD81 T cells in culture with mDCs incu-
bated with 50 mg of recombinant Ova, albeit only approximately
230 ng of protein was transferred by PTVs. Thus, transduction of
mDCs by PTVs is significantly more efficient in stimulating anti-
gen-specific T cells than incubation with purified protein.
In contrast to the efficient activation of CD81 T cells by mDCs
transduced with pseudotyped PTVs, CD41 T cells were most
vigorously stimulated by mDCs when incubated with
HIV-OvaKatushka(bald) vector particles without envelope GPs, irrespec-
tive of receptor status (Fig. 6D). Moreover, also MVwt-GP pseu-
dotyped PTVs [HIV-OvaKatushka(MVwt)] triggered activation of
Ova-specific CD41 T cells when MV-receptor-negative mDCs
(from IFNAR2/2 mice) were incubated with these vectors
FIG 4 Receptor specificity of GFP and Ova protein transfer by PTV particles.
(A and B) Receptor-dependent transduction of cell lines by GFP-PTVs.
Transgenic CHO cells expressing either MVwt receptors (CHO-hSLAM and
CHO-Nectin 4), MV vaccine strain receptor (CHO-CD46), or no receptors
(CHO-K1) or naturally SLAM-expressing B95a and Raji cells were mock
transduced (negative control, NC), or transduced with concentrated GFP-
PTV, pseudotypedwith VSV-G (V) orMVwt-GPs (M), at anMOI of 1. Protein
and gene transfer were monitored at 3 h or 3 days posttransduction for the
fraction of positive cells or relativeMFI. Values aremeans6 standard errors of
themeans (n5 3). (C andD)Receptor-dependent transduction of cell lines by
Ova-PTVs. Cell lines as described for panel A were transduced with Ova-PTVs
at an MOI of 1 and subjected to immunoblot analysis at 3 h posttransduction
(C). MC indicates citric acid buffer treatment 3 h after transduction with
HIV-OvaKatushka(MVwt). Katushka fluorescence was analyzed at 72 h post-
transduction by flow cytometry (D). Values are means (n 5 2). Statistical
significance was determined by a two-tailed unpaired Student’s t test.
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(Fig. 6D). Together, these data indicate endocytotic uptake of vec-
tor particle-associated Ova in the absence of the corresponding
cell entry receptor, followed by MHC class II presentation, as ex-
pected for the classic route for receptor-independent internaliza-
tion by antigen presentation.
Immunogenic properties of Ova-PTVs in vivo.After demon-
stration of the immune-stimulatory properties (especially activa-
tion of CD81 T lymphocytes) of PTVs in vitro, nontargeted
VSV-G- and SLAM-targeted MVwt-GP pseudotyped PTVs were
analyzed in vivo for induction of cytotoxic antigen-specific im-
mune responses. For this purpose, IFNAR2/2 and IFNAR2/2-
SLAMki mice were inoculated with HIV-OvaKatushka(bald),
HIV-GFPKatushka(MVwt), HIV-OvaKatushka(MVwt), and
HIV-OvaKatushka(VSV), as well as with recombinant Ova or with
medium (mock control). The amount of particles administered
i.p. was adjusted to 1 mg of Ova per injection. The particle
number of HIV-GFPKatushka(MVwt) was normalized to that of
HIV-OvaKatushka(MVwt) by capsid protein (p24) content. Mice
were primed and boosted 4 weeks later. Four days after boosting, the
animals were sacrificed, and splenocytes were isolated (Fig. 7A).
Then, the number of antigen-specific T cells among splenocytes of
vaccinatedmice was determined by IFN-g ELISpot analysis.
No IFN-g-secreting splenocytes were found in IFNAR2/2
mice injected with Opti-MEM (mock), recombinant Ova, HIV-
FIG 5 Demonstration of cytoplasmic protein transfer by PTV particles. (A) Schematic depiction of the marker gene expression cassette present in indicator cell
lines. The ceruleanORF, encoding the blue-fluorescing cerulean protein, is flanked by two LoxP sites. Cre recombinase thus excises the ceruleanORF and induces
fading of blue fluorescence over time. WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Receptor-dependent Cre protein transfer
into indicator cell lines. MVwt receptor-negative CHO-K1-blue and MVwt receptor-positive CHO-hSLAM-blue and Raji-blue indicator cells were mock
transduced (mock) or transduced with HIVCre(VSV), transferring the cre gene (MOI of 10), or with the Cre protein transfer vector HIV-CreKatushka(VSV) or
HIV-CreKatushka(MVwt) (MOI of 15). At 14 days after transduction, fading of blue fluorescence was assessed by flow cytometry. Results of one representative
experiment are shown (n5 3). SSC, side scatter.
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OvaKatushka(bald), or HIV-OvaKatushka(MVwt), thus revealing the
absence of Ova-specific T cell induction under these conditions
(Fig. 7B). In contrast, splenocytes of IFNAR2/2 mice vaccinated
withHIV-OvaKatushka(VSV) showed a significant release of IFN-g,
i.e., 685.96 750.84 reactive T cells/106 splenocytes (restimulated
with Ova). Surprisingly, recall of IFN-g-producing T cells was
largely independent of the stimuli used. In linewith these findings,
no IFN-g-secreting Ova-specific T cells were observed among
splenocytes from mock-vaccinated IFNAR2/2-SLAMki mice and
animals vaccinated with HIV-GFPKatushka(MVwt) or recombinant
soluble Ova (Fig. 7C). In contrast, IFN-g-secreting T cells were
found in splenocytes from IFNAR2/2-SLAMki mice inoculated
with HIV-OvaKatushka(bald) (101.0 6 118.0 reactive T cells/10
6
splenocytes), HIV-OvaKatushka(MVwt) (212.8 6 288.2 reactive T
FIG 6 Immunostimulatory properties of ex vivo-transduced myeloid dendritic cells. (A) Schematic depiction of experimental procedures. (B) Analysis of
immune stimulation by Ova-PTVs. Prestimulated (1LPS) or unstimulated (2LPS) mDCs were mock transduced (gray area) or transduced with HIV-
OvaKatushka(bald) (green line),HIV-OvaKatushka(MVwt) (red line), orHIV-OvaKatushka(VSV) (blue line) vector preparations. Expression ofCD69 orCD86 among
the CD11c-positive DC population was analyzed by flow cytometry at 24 h posttransduction. (C and D) IL-2 or IFN-g secretion by Ova-specific OT-I (C) or
OT-II T cells (D) after incubation withmDCs transduced ex vivowith PTV particles transferring either GFP or Ova (MOI of 1 or 3) without envelope GPs (bald)
or MVwt-GFPs (MV) or VSV-G (VSV), as indicated, or untransduced mDCs in the presence of 10 mg or 50 mg of recombinant Ova, as indicated. Results of one
representative experiment are shown (n5 4 for panel C or 2 for panel D). Statistical significance was determined by a two-tailed unpaired Student’s t test. ns, not
significant; *, P, 0.05; **, P, 0.01; ***, P, 0.001; ****, P, 0.0001.
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cells/106 splenocytes), or HIV-OvaKatushka(VSV) (121.4 6 134.9
reactive T cells/106 splenocytes) but, again, largely independent of
the stimuli used for recall.
To identify the cause for the stimulus-independent recall,
pooled splenocytes were subsequently fractionated into un-
touched T cells and other cell types, the latter group containing
splenic APCs, bymagnetic cell sorting. After overnight incubation
in medium containing no IL-2, purified T cells were coincubated
with mDCs (generated from nonvaccinated syngeneic IFNAR2/2
or IFNAR2/2-SLAMki mice) pulsed with recombinant Ova or
Ova-derived immune-dominant peptides for CD81 or CD41 T
cell responses (Ova257–264 or Ova323–339, respectively). Alterna-
tively, purifiedT cells were coincubatedwith JAWSII and JAWSII-
Ova dendritic cells, the latter expressing ovalbumin. T cell reac-
tivity was then determined by IFN-g ELISpot analysis again. In
line with the results obtained for freshly isolated splenocytes,
no IFN-g secretion was observed for cocultures of pulsed
mDCs with T cells derived from IFNAR2/2 mice injected with
Opti-MEM (mock), recombinant Ova, HIV-OvaKatushka(bald),
HIV-GFPKatushka(MVwt), or HIV-OvaKatushka(MVwt) (Fig. 8A).
As expected, T cells from HIV-OvaKatushka(VSV)-injected mice
in coculture with pulsed syngeneic mDCs secreted IFN-g.
However, IFN-g secretion was observed only upon addition of
recombinant Ova or Ova257–264 peptide, characterizing Ova-
specific T cell responses (Fig. 8A). In addition, JAWSII-Ova
dendritic cells stimulated cytokine secretion by T cells obtained
from HIV-OvaKatushka(VSV)-vaccinated IFNAR
2/2mice while
causing no IFN-g release by T cells from other experimental
cohorts (Fig. 8A). T cells derived from IFNAR2/2-SLAMki
mice immunized with Opti-MEM (mock), recombinant solu-
ble Ova, HIV-OvaKatushka(bald), and HIV-GFPKatushka(MVwt)
were not activated upon cocultivation with pulsed mDCs or
JAWSII-Ova cells (Fig. 8B). However, IFN-g was secreted by T
cells from HIV-OvaKatushka(MVwt)- or HIV-OvaKatushka(VSV)-
vaccinated animals (Fig. 8B). Thus, by comparing IFN-g secretion
by T cells from MV receptor-negative IFNAR2/2 (Fig. 8A) and
MVreceptor-positive IFNAR2/2-SLAMkimice (Fig. 8B), receptor
specificity of HIV-OvaKatushka(MVwt) could also be demonstrated
in vivo. T cells fromHIV-OvaKatushka(VSV)-injected animals were
exclusively stimulated by mDCs pulsed with Ova257–264. No pro-
tein stimulus-dependent recall was observed for T cells from
HIV-OvaKatushka(MVwt)-injected mice, but cocultivation of
JAWSII-Ova cells selectively induced IFN-g production by T cells de-
rived from both HIV-OvaKatushka(VSV)- and HIV-OvaKatushka(MVwt)-
vaccinated mice. No IFN-g secretion was detected by the same T
cells upon coculture with JAWSII cells (Fig. 8B), confirming anti-
gen specificity of the T cells.
The retentate fraction of the magnetic cell separation (which
contained APCs) was incubated with splenocytes isolated from
C57BL/6, OT-I, orOT-IImice that contained no, CD81, or CD41
Ova-specific T cells, respectively. These cocultures were subjected
to IFN-g ELISpot analysis to provide evidence for Ova-peptide
presentation by APCs from vaccinated animals even 4 days after
booster vaccination, cell isolation, storage, and reculture. Interest-
ingly, IFN-g secretionwas indeed observed for at leastOT-I T cells
in coculture with the retentate of HIV-OvaKatushka(VSV)-immu-
nized IFNAR2/2mice (Fig. 8C). These data provide evidence that
a singular PTV-mediated antigen transfer induces antigen presen-
tation over a couple of days by transduced APCs. Thereby, the
potency of these vectors for prolonged antigen presentation
FIG 7 Analysis of immune-stimulatory properties of Ova-PTVs in vivo. (A)
Schematic depiction of experimental procedures. d, day; Splen., splenocytes.
(B andC) IFNAR2/2 or IFNAR2/2-SLAMkimice were vaccinated, and freshly
isolated splenocytes were subjected to IFN-g ELISpot analysis. Ova,
Ova323–339, and Ova257–264 were added for antigen-specific recall, whereas
ConA-supplemented or pure medium served as a control. ., the number of
IFN-g secreting spots is .1,000. Values are means 6 standard errors of the
means per group (n 5 5 to 6). Statistical significance was determined by a
two-tailed Mann-Whitney test (unpaired values between different animal
groups) or two-tailed Wilcoxon test (paired values of one animal group). ns,
not significant; **, P, 0.01.
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and immune stimulation by transduced APCs in vivo is indi-
cated. Moreover, these data suggest that the T cell activation by
residual Ova-presenting APCs among splenocyte preparations
is the reason for the initially observed stimulation-independent
recall of T cell activity derived from animals vaccinated with
HIV-OvaKatushka(VSV), HIV-OvaKatushka(MVwt), or HIV-
OvaKatushka(bald).
DISCUSSION
This study demonstrates for the first time the potential of antigen
transfer by lentiviral PTVs for the induction of substantial cellular
immune responses and thereby the potential for their use as vac-
cines. Initial characterization of GFP- and Ova-PTVs for receptor
specificity on receptor-transgenic CHO cells and B cell lines re-
vealed that vectors pseudotypedwithMVwt-GPsmediated specific
delivery into SLAM-positive cells only, in contrast to broadly
transducing VSV-G pseudotyped vectors. Cytoplasmic protein
transfer and functionality of the cargo protein were demonstrated
by Cre recombinase transfer, which mediated excision of a LoxP-
flanked cerulean ORF in receptor-positive indicator cell lines.
Moreover, ex vivo treatment of primary APCs, i.e., myeloid den-
dritic cells (mDCs), with Ova-PTVs resulted in stimulation of
Ova-specific T lymphocytes upon cocultivation with transduced
FIG 8 Analysis of splenocytes from vaccinatedmice after magnetic bead cell sorting separation into T cells and APC-containing retentate. (A and B) T cells from
IFNAR2/2mice or IFNAR2/2-SLAMki mice were cocultivated with syngeneic mDCs pulsed with Ova or immunodominant Ova peptides for CD41 or CD81 T
cell responses (Ova323–339 or Ova257–264, respectively). ConA or medium served as a control. In parallel, separated T cells were cocultured with JAWSII or
JAWSII-Ova DCs. Stimulation of T cells derived from animals injected with Opti-MEM (mock), recombinant ovalbumin (rOva), HIV-OvaKatushka(bald),
HIV-GFPKatushka(MVwt), HIV-OvaKatushka(MVwt), andHIV-OvaKatushka(VSV)was assessed by IFN-gELISpot analysis. (C andD)TheAPC-containing retentate
fraction from immunized IFNAR2/2mice (C) or IFNAR2/2-SLAMki mice (D) was cocultured with splenocytes isolated from C57BL/6 (BL/6), OT-I, or OT-II
mice. Stimulation of T cells by retentate was analyzed by IFN-g ELISpot assay. Statistical significance was determined by a two-tailed unpaired Student’s t test.
ns, not significant; *, P, 0.05; **, P, 0.01; ***, P, 0.001; ****, P, 0.0001.
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mDCs. The immunogenicity of PTVs in mice correlated with the
capacity of PTV-inoculated myeloid DCs to stimulate antigen-
specific T cells in vitro.
Initially, the optimal ratio of Gag/Pol to Gag-cargo/Pol for
production of lentiviral PTVswas assessed in order to obtainmax-
imum protein and gene transfer in transduced cells. In principle,
PTVs can be used for transient cell modification (22). Neverthe-
less, it is feasible to generate PTVs which additionally transfer a
vector genome encoding, e.g., amarker gene to facilitate detection
of transduction and titration of vector stocks (22; this study). In
the present study, gene transfer was shown to be ablated when
solely Gag-cargo/Pol packaging constructs were used for particle
generation. This dysfunction correlated with morphological
changes, i.e., disrupted Gag core and the presence of fewer and
irregularly arranged envelope proteins. Such morphological
changes have been described before andwere attributed to discon-
tinuities in the Gag-GFP layer induced by the GFP polypeptide
(45). OnlyGFP-PTVparticles containing at least 50%unmodified
structural proteins were shown to be infective and indistinguish-
able by electron microscopy from LV particles transferring no
cargo protein. This composition of similar amounts of Gag-cargo/
Pol andwild-typeGag/Pol allowing successful particle production
has been described also for gammaretroviral particles (22). By
successfully generating PTVs transferring ovalbumin or Cre re-
combinase (in addition to GFP), the variety of proteins intro-
duced into Gag by retroviral particles was expanded. Before, only
GFP, cyan fluorescent protein (CFP), monomeric red fluorescent
protein (mRFP), yellow fluorescent protein (YFP), Flp recombi-
nase, and b-lactamase had been demonstrated to be amendable
for protein transfer by retroviral vectors (46). These cargo pro-
teins were transferred into cells in considerable amounts, as, e.g.,
demonstrated by Ova-specific immunoblot analysis of PTV-
transduced indicator cell lines in this study.
During budding of an HIV-1 particle, approximately 5,000
Gag and Gag/Pol polyproteins assemble (47). Thus, using a 1:1
ratio of untagged gag to cargo-tagged gag in packaging plasmids,
approximately 2,500 cargo protein molecules should be incorpo-
rated per vector particle. However, when SLAM-targeted PTV
particle preparations were analyzed, only approximately 100 ng of
Ova/mg p24 protein and approximately 720 fg ofOva/transducing
unit were measured. These data indicate that only about 5.3% of
Gag molecules in PTV particles are tagged with Ova, which might
reflect increased incorporation ofwild-typeGag/Pol in vector par-
ticles due to steric requirements. However, 723 fg of Ova corre-
sponds to 9.73 106 Ova molecules per transducing unit of HIV-
OvaKatushka(MVwt). A labeling efficiency of 5.3% indicates the
presence of 1.83 108 Gag molecules in such preparations, which
is sufficient to generate approximately 3.7 3 104 particles given
the incorporation of 5,000Gagmolecules per particle. Thus, just 1
in 3.73 104MVwt-GP pseudotyped particles would be infectious.
This infectivity is clearly lower than that usually observed for ret-
roviral particles, where 1 in 100 to 1,000 particles is infective (46).
Nevertheless, infectivity is clearly codetermined by the glycopro-
teins used for pseudotyping retroviral vector particles (48, 49) and
may vary by at least two logs (49). Accordingly, glycoprotein-
specific differences have been observed also in this study when
VSV-G or MV-H/F expression plasmids were titrated against the
other constituents of PTVs during establishment of PTV genera-
tion (Fig. 1F), further strengthening the impact of the comparably
low infectivity of MVwt pseudotyped PTV particles when this is
assessed by gene transfer. For VSV-G pseudotypes, much higher
infectivity can be expected. This, as well as the different entry
pathway used, potentially causes degradation of cargo proteins in
endocytotic vesicles after VSV-G-triggered endocytosis, thus ac-
counting for the relatively lower protein transfer efficiency medi-
ated by HIV-GFPKatushka(VSV) on different target cell lines.
Targeting of PTVs to APCswas accomplished by pseudotyping
withmodified wild-typeMV-GPs due to their natural tropism for
SLAM and nectin-4 (24, 50, 51). This tropism was found to be
conserved in pseudotyped PTVs, as expected in analogy to lenti-
viral gene transfer vectors (33–35). Indeed, the similar specificities
of protein and gene transfer were also confirmed using CHO cells
expressing theMV receptors and naturally receptor-positive cells,
with one exception. The marmoset cell line B95a was susceptible
for protein transfer but highly resistant to gene transfer at anMOI
of 1. This may be explained by expression of the antiviral restric-
tion factor Trim5a in cotton-top tamarin cells (52) such as B95a.
Trim5a is well known to cause species-specific premature uncoat-
ing of incoming retroviral capsids, thereby interrupting reverse
transcription (53), and indeed restricts foamy virus in B95-8 cells
(54), the parental cells of the B95a line. In contrast to gene trans-
fer, incoming structural viral proteins are not impeded by this
restriction factor.
Interestingly, MV-GPs provide the opportunity to retarget
PTV tropism to a plethora of other targets of choice by utilizing
engineered MV-GPs with mutations ablating the natural MV re-
ceptor tropism but fused with binding domains like single-chain
antibodies (scFv) (55) or designed ankyrin repeat proteins
(DARPins) (56). With respect to APCs, successful targeting of
lentiviral gene transfer vectors to MHC-II molecules has been
demonstrated (19) and may be employed for retargeting of PTVs
also. On the other hand, inherently stable VSV-G confers very
high titers to pseudotyped lentiviral particles (57). This stability
may be utilized to achieve protein transfer with overall higher
transduction efficacy in vivo, as already demonstrated for gene
transfer vectors (19). Indeed, when the vectors for vaccination are
normalized to protein amounts only, VSV-G pseudotyped Ova-
PTVs were shown to be most efficient in inducing Ova-specific
immune responses, supporting this hypothesis. MVwt-GP pseu-
dotyped PTVs lagged behind in this setting since infectivity is up
to 200-fold lower when vector titers are compared to particle
numbers based on p24 ELISA or NanoSight analysis (data not
shown). Nevertheless, this method of normalization was used to
allow fair comparison of vector particle preparations not only
with each other but also with recombinant proteins. Here, PTVs
turned out to bemuchmore immunogenic, especiallywith respect
to induction of CD81 T cells. This phenomenon has already been
described for other antigens, e.g., HIV-1 Env presented by virus-
like particles (VLPs) eliciting a higher cellular response than sol-
uble forms of Env (58). This could be due to the stimulatory con-
text of the presented antigens in the VLP structure (albeit we did
not find evidence of a stimulatory nature of PTV preparations per
se in our experiments) or due to better uptake of particulate anti-
gen into the APCs (59). Which pseudotype particle will be supe-
rior in vivowhen applied at similar numbers of infectious particles
remains to be elucidated in future analyses.
For lentiviral gene transfer vectors transferring antigen-encod-
ing sequences, transduction of APCs in vivo has been shown to
trigger predominantly CD81 T cells, irrespective of entry target-
ing (16, 19) or no entry targeting (60, 61). Predominant induction
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of CD81T cell responses indicates cytoplasmic antigen transfer by
PTVs. This is in line with our strategy to release the cargo protein
into the target cell’s cytosol by insertion of the additional HIV-1
protease cleavage motif, as described before (22) and as demon-
strated in our study by cytosolic transfer and subsequent function
of Cre recombinase in the respective indicator cell lines. More-
over, Ova protein transfer also occurred exclusively in receptor-
positive cells, as assessed by immunoblot analysis after removal of
surface-bound virions by citric acid buffer treatment (32). Both
experiments indicate cytoplasmic protein transfer and exclude
passive surface adhesion of PTVparticles. This receptor specificity
determined in vitro was reflected by receptor-dependent induc-
tion of CD81 T cell responses in ex vivo cocultures of PTV-trans-
ducedmDCswithOva-specificT cells and in vivo after vaccination
of mice with PTVs. In the presence of the cognate cellular recep-
tor, PTVs thus demonstrated the capacity for cytoplasmic antigen
transfer and the subsequent stimulation of cellular immune re-
sponses by antigen presentation via MHC-I molecules (Fig. 9,
left). However, the observed induction of CD41 T cell responses
in the absence of receptor expression indicates receptor-inde-
pendent, nonspecific uptake of the particulate antigen via the
endosomal route, followed by lysosomal antigen processing and
presentation by MHC-II (Fig. 9, right). Such pseudotype-inde-
pendent nonspecific uptake of gammaretroviral and lentiviral
particles into human cells has been reported before also for parti-
cles pseudotyped with the MV vaccine strain GPs (32). Taken
together, these data can be used for proposing a model of PTV
interaction with APCs after inoculation and subsequent presenta-
tion of peptides via MHC-I or MHC-II (Fig. 9).
Surprisingly, T cell reactivity among splenocytes of vaccinated
animals was initially found to be independent of stimuli used for
recall 4 days after booster immunization. When isolated T cells
tranquilized by overnight cultivation in medium without IL-2
were used, this reactivity vanished but was recalled by antigen-
specific stimuli. Interestingly, persisting activation of T cells for a
few days after boost vaccination has already been demonstrated,
e.g., when activatedCD81T cells directed againstHIV-1 Envwere
detected 5 days after boosting (62). On the other hand, APCs of
PTV-vaccinated mice proved capable of stimulating Ova-specific
T cells of nonvaccinated, TCR-transgenic mice. This may be ex-
plained by intracellular storage of particle-associated Ova, fol-
lowed by rather constant processing and antigen presentation,
thus resulting in long-lasting T cell activation. Lysosome-like an-
tigen storage organelles, distinct fromMHCclass I andMHC class
II compartments, have been described inmature DCs, which pro-
vide an internal antigen source for several days, thereby facilitat-
ing a prolonged cytotoxic T cell cross-priming capacity of DCs
(63). It will be interesting to elucidate how and why PTV-associ-
ated antigens may be processed differently than proteinaceous
antigens after uptake by APCs.
In conclusion, we have demonstrated the capacity of PTVs to
efficientlymediate (targeted) transfer antigens into APCs, thereby
effectively triggering antigen-specific T cell responses in vitro and
in vivo. Thus, PTVs are an effective vaccine, the protective capacity
of which will be demonstrated in future studies. Furthermore, the
exact mode of action will be a matter of interest, giving room for
future enhancement of these vectors.
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ABSTRACT
In 2012, the first cases of infection with theMiddle East respiratory syndrome coronavirus (MERS-CoV) were identified. Since
then, more than 1,000 cases of MERS-CoV infection have been confirmed; infection is typically associated with considerable
morbidity and, in approximately 30% of cases, mortality. Currently, there is no protective vaccine available. Replication-compe-
tent recombinant measles virus (MV) expressing foreign antigens constitutes a promising tool to induce protective immunity
against corresponding pathogens. Therefore, we generatedMVs expressing the spike glycoprotein of MERS-CoV in its full-
length (MERS-S) or a truncated, soluble variant of MERS-S (MERS-solS). The genes encodingMERS-S andMERS-solS were
cloned into the vaccine strainMVvac2 genome, and the respective viruses were rescued (MVvac2-CoV-S andMVvac2-CoV-solS).
These recombinant MVs were amplified and characterized at passages 3 and 10. The replication of MVvac2-CoV-S in Vero cells
turned out to be comparable to that of the control virus MVvac2-GFP (encoding green fluorescent protein), while titers of MVvac2-
CoV-solS were impaired approximately 3-fold. The genomic stability and expression of the inserted antigens were confirmed via
sequencing of viral cDNA and immunoblot analysis. In vivo, immunization of type I interferon receptor-deficient (IFNAR2/2)-
CD46Gemice with 23 105 50% tissue culture infective doses of MVvac2-CoV-S(H) or MVvac2-CoV-solS(H) in a prime-boost regi-
men induced robust levels of bothMV- andMERS-CoV-neutralizing antibodies. Additionally, induction of specific T cells was
demonstrated by T cell proliferation, antigen-specific T cell cytotoxicity, and gamma interferon secretion after stimulation of
splenocytes withMERS-CoV-S presented by murine dendritic cells. MERS-CoV challenge experiments indicated the protective
capacity of these immune responses in vaccinated mice.
IMPORTANCE
AlthoughMERS-CoV has not yet acquired extensive distribution, being mainly confined to the Arabic and Korean peninsulas, it
could adapt to spreadmore readily among humans and thereby become pandemic. Therefore, the development of a vaccine is
mandatory. The integration of antigen-coding genes into recombinant MV resulting in coexpression of MV and foreign antigens
can efficiently be achieved. Thus, in combination with the excellent safety profile of the MV vaccine, recombinant MV seems to
constitute an ideal vaccine platform. The present study shows that a recombinant MV expressingMERS-S is genetically stable
and induces strong humoral and cellular immunity against MERS-CoV in vaccinated mice. Subsequent challenge experiments
indicated protection of vaccinated animals, illustrating the potential of MV as a vaccine platform with the potential to target
emerging infections, such as MERS-CoV.
In November 2012, a novel coronavirus was identified for thefirst time in a patient from Saudi Arabia who presented with
severe respiratory disease. Later, this viruswas termedMiddle East
respiratory syndrome coronavirus (MERS-CoV) (1). By 26 De-
cember 2014, 938 laboratory-confirmed cases of MERS-CoV,
mostly from Saudi Arabia and neighboring countries, had been
diagnosed and had resulted in 343 casualties (2). A few cases of
MERS-CoV were also detected in the United States, the United
Kingdom, Netherlands, Austria, France, Greece, Italy, and Ger-
many, indicating the virus’s principal potential for spread (2).
Fortunately, direct transmission upon contact with human pa-
tients seems to be limited, yet is still possible, as determined by
analysis of household contact infections among MERS patients’
families (3) and as evidenced by a recent cluster of MERS infec-
tions in South Korea, with 166 cases between 20 May and 19 June
2015, including 106 third-generation and 11 fourth-generation
cases (4, 5). As a natural reservoir, dromedary camels have been
identified as the most likely source, based on partially identical
genomes detected in viruses isolated from humans or camels (6,
7). Additionally, antibodies against the spike glycoprotein of
MERS-CoV with virus-neutralizing capacity were detected in
camels (8–10), and infection of humans with MERS-CoV have
been reported after contact with infected camels (11, 12). Inter-
estingly, while all other members of the C lineage of the Betacoro-
navirus genus have been found in different bat species (13, 14),
only closely related, most likely precursor viruses of MERS-CoV
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have been identified in Neoromicia capensis bats (15). Thus,
MERS-CoV has a zoonotic origin, but sustained infections, the
severity of the disease, and the risk of virus adaption to gain
efficient human-to-human transmission mandates the devel-
opment of effective vaccines to combat local infections and to
be prepared for the eventual occurrence of a global pandemic,
as previously observed with severe acute respiratory syndrome
coronavirus (SARS-CoV) in 2003 (16).
Occurring 10 years before the current MERS-CoV epidemic,
SARS-CoV was the first Betacoronavirus of zoonotic origin with
potentially fatal outcomes in human patients (1). Experimental
vaccines protecting animal models against SARS have been devel-
oped (17–19), and the properties of such SARS vaccines may be
applicable to vaccines that should protect against MERS-CoV in-
fections. Both neutralizing antibodies and T cell responses are
essential for prevention of SARS-CoV infection (17, 18). The spike
protein (S), a coronavirus class I fusion protein (20, 21), has been
identified as the most immunogenic antigen of SARS-CoV, as it
induces a strong humoral as well as cellular immune response (17,
19). Similarly, MERS-S constructs expressed by recombinant
modified vaccinia virus Ankara or recombinant adenoviral vec-
tors have already been demonstrated to induce neutralizing anti-
bodies (22, 23). The detected neutralizing capacity of induced
antibodies is expected, since the receptor-binding domain (RBD)
in the S1 domain of both SARS-CoV and MERS-CoV S proteins
mediate host-cell receptor binding as a prerequisite for cell entry
(24, 25). Thus, S1 is the main target of neutralizing antibodies
(26). Also the RBD ofMERS-CoV-S alone has been demonstrated
to induce strong neutralizing antibody titers (23, 27–31). In com-
bination with different adjuvants, even induction of T cell re-
sponses by the recombinant RBD has been described (31). Thus, a
prototypicMERS vaccine should be based onMERS-S expression,
since the induction of neutralizing antibodies has been shown to
be a direct correlate of protection in cases of SARS-CoV (32).
The measles vaccine is an efficient, live attenuated, replicating
virus that induces both humoral and cellular immune responses,
has an excellent safety record, and probably provides lifelong pro-
tection (33, 34). The vaccine’smanufacturing process is extremely
well established (35), andmillions of doses can be generated quite
easily and quickly. Generation of recombinant measles virus
(MV) fromDNAvia reverse genetics is feasible (35) and allows the
insertion of additional transcription units (ATU) by duplication
of sequences terminated by start and stop sequences (36). Hence,
genes expressing foreign antigens up to 6 kb can be cloned into the
MV backbone (36) and elicit coexpression of MV proteins and
inserted genes. Besides marker genes (37) or immunemodulators
(38), expression of antigens from foreign pathogens like hepatitis
B or C virus (39, 40), HIV (41), West Nile virus (WNV) (42, 43),
dengue virus (44), Chikungunya virus (CHIKV) (45), or SARS-
CoV (19) by recombinant MVs has already been demonstrated.
Thereby, robust immune responses against vector and foreign an-
tigens are induced after vaccination of transgenic,MV-susceptible
type I interferon receptor-deficient (IFNAR2/2)-CD46Ge mice
(46) or nonhumanprimateswith recombinantMVs, in general. In
particular, protection of vaccinated animals from lethal challenge
with WNV (42) or CHIKV (45) was demonstrated and indicated
the high efficacy of the system. Interestingly, prevaccinated ani-
mals with protective immunity against measles were still amend-
able to vaccination with the recombinant MV, since significant
immune responses against the foreign antigen(s) are consistently
induced (41, 45), and the MV-based CHIKV vaccine demon-
strated efficacy in phase I trials irrespective of measles virus im-
munity (47).
Here, we aimed to utilize the efficacy of the MV vaccine plat-
form to generate a live attenuated vaccine against MERS-CoV
based on recombinantMVvac2. This recombinant virus reflects the
MV vaccine strain Moraten (48), which has been authorized for
vaccination against measles. As the antigen, we choose theMERS-
CoV S glycoprotein to induce neutralizing antibodies and robust
cellular immunity. Two variants of the glycoproteinwere analyzed
as antigen: the full-length, membrane-anchored MERS-S, and a
truncated, soluble form lacking the transmembrane domain
(MERS-solS). Both variants include the S1 domain as a target
structure. The soluble protein variant should be taken up better by
B cells (49–51) and thus should induce humoral immune re-
sponses more efficiently (52), potentially boosting virus-neutral-
izing antibody titers (VNTs). The respective genes were inserted
into two different positions of the MV genome to modulate ex-
pression of the antigens, and all recombinant MVs were success-
fully rescued. Cells infected with such viruses expressed the de-
sired antigens. Indeed, immunization of IFNAR2/2-CD46Ge
mice induced strong humoral and cellular immune responses di-
rected against MV and MERS-CoV S which were sufficient to
protect vaccinated animals fromMERS-CoV infection. Thus,MV
platform-based vaccines are a powerful option to develop a
prepandemic vaccine against MERS-CoV.
MATERIALS AND METHODS
Cells.Vero cell (African greenmonkey kidney cells; ATCCCCL-81), 293T
cell (ATCC CRL-3216), and EL4 mouse T cell (ATCC TIB-39) lines were
purchased from ATCC (Manassas, VA, USA) and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS; Biochrom, Berlin, Germany) and 2 mM L-glutamine (L-Gln;
Biochrom). JAWSII dendritic cells (ATCC CRL-11904) were purchased
from ATCC and cultured in minimal essential medium alpha (MEM-a)
with ribonucleosides and deoxyribonucleosides (Gibco BRL, Eggenstein,
Germany) supplemented with 20% FBS, 2 mM L-Gln, 1 mM sodium
pyruvate (Biochrom), and 5 ng/ml murine granulocyte-macrophage col-
ony-stimulating factor (GM-CSF; Peprotech, Hamburg, Germany).
DC2.4 and DC3.2 murine dendritic cell lines (53) were cultured in RPMI
containing 10% FBS, 2 mM L-Gln, 1% nonessential amino acids (Bio-
chrom), 10mMHEPES (pH 7,4), and 50mM2-mercaptoethanol (Sigma-
Aldrich, Steinheim, Germany). All cells were cultured at 37°C in a humid-
ified atmosphere containing 6% CO2 for a maximum of 6 months of
culture after thawing of the original stock.
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Plasmids. The codon-optimized gene encoding MERS-CoV-S
(GenBank accession number JX869059) flanked with AatII/MluI bind-
ing sites in plasmid pMA-RQ-MERS-S was obtained by gene synthesis
(Invitrogen Life Technologies, Regensburg, Germany). A truncated
form of MERS-S lacking the transmembrane domain was amplified by
PCR, flanked with AatII/MluI binding sites, and fully sequenced. Both
antigens, as well as the immediate early cytomegalovirus (CMV) pro-
moter (54), were inserted into p(1)BR-MVvac2-GFP(H) or p(1)
MVvac2-ATU(P) (48) via AatII/MluI or SfiI/SacII, respectively, to gene-
rate p(1)PolII-MVvac2-MERS-S(H), p(1)PolII-MVvac2-MERS-S(P),
p(1)PolII-MVvac2-MERS-solS(H), and p(1)PolII-MVvac2-MERS-
solS(P), respectively. For construction of lentiviral transfer vectors encod-
ing the MERS-CoV antigens, the open reading frame (ORF) of MERS-S
was amplified by PCR with primers encompassing flanking NheI/XhoI
restriction sites and template pMA-RQ-MERS-S. Details on primers and
PCR procedures are available upon request. PCR products were cloned
into pCR2.1-TOPO (Invitrogen Life Technologies) and fully sequenced.
Intact antigen ORF was cloned into pCSCW2gluc-IRES-GFP (55) by us-
ing NheI/XhoI restriction sites to yield pCSCW2-MERS-S-IRES-GFP.
Production of lentiviral vectors. Viral vectors were produced using
293T cells and polyethylenimine (PEI; Sigma-Aldrich) transfection (56).
A total of 13 107 293T cells were seeded per 175-cm2 cell culture flask and
cultured overnight. To produce lentivirus vectors pseudotypedwith theG
protein of vesicular stomatitis virus (VSV-G), these cells were transfected
using a standard three-plasmid lentivirus vector system. Cells were trans-
fectedwith 17.5mg pCSCW2-MERS-S-IRES-GFP transfer vector, 6.23mg
pMD2.G, and 11.27 mg pCMVDR8.9 (57), as described previously (58).
Themediumwas exchanged 1 day posttransfection, andHIVMERS-S-IRES-GFP
(VSV-G) vector particles were harvested 2 and 3 days after transfection. For
harvest of vector particles, the supernatants of three culture flasks were fil-
tered (0.45-mm pore size), pooled, and concentrated by centrifugation
(100,000 3 g, 3 h, 4°C). Pellets were resuspended in DMEM and stored at
280°C.
Generation of antigen-expressing cell lines. Syngeneic target cells
based on the C57BL/6-derived DC lines JAWSII, DC2.4, and DC3.2, as
well as T cell line EL-4 were transduced with HIVMERS-S-IRES-GFP(VSV-G)
vector-containing supernatant to express MERS-S and the green marker
protein GFP (JAWSIIgreen-MERS-S, EL-4green-MERS-S, DC2.4green-
MERS-S, and DC3.2green-MERS-S), thereby presenting respective pep-
tides via major histocompatibility complex class I (MHC-I). EL-4 cells
were alternatively transduced with HIVTurboFP635(VSV-G) vectors (59) to
express red fluorescent Katushka protein as a negative control (EL-4red).
For this purpose, 1 3 105 target cells were seeded in 24-well plates and
transduced with 0.1, 1, or 10 ml of concentrated vector suspension. For
analysis of transduction efficiencies, cells were fixed in 1% paraformalde-
hyde (Merck Millipore, Darmstadt, Germany), and the percentages of
GFP-positive or Katushka-positive cells were quantified by flow cytom-
etry using an LSRII flow cytometer (BD,Heidelberg, Germany). Cell pop-
ulations revealing a 1 to 10% fraction of GFP-positive cells were used for
single-cell cloning by limiting dilution. For that purpose, cell dilutions
with 50 ml conditioned medium statistically containing 0.3 cells were
seeded per well in 96-well plates. Single-cell clones were cultured and
analyzed by flow cytometry. GFP-positive clones were selected for further
analysis.
Viruses. The viruses were rescued as described previously (54). In
brief, 5 mg of MV genome plasmids with MERS-CoV antigen ORFs were
cotransfected with plasmids pCA-MV-N (0.4 mg), pCA-MV-P (0.1 mg),
and pCA-MV-L (0.4 mg) encoding MV proteins necessary for genome
replication and expression. These plasmids were cotransfected into 293T
cells cultured in 6-well plates by using Lipofectamine 2000 (Invitrogen
Life Technologies). The transfected 293T cells were overlaid 2 days after
transfection onto 50% confluent Vero cells seeded in 10 cm-dishes. Over-
lay cultures were closely monitored for isolated syncytia, which indicated
monoclonal replicative centers. Single syncytia were picked and overlaid
onto 50% confluent Vero cells cultured in 6-well plates and harvested as
passage 0 (P0) by scraping and a freeze-thaw cycle of cells at the time of
maximal infection. Subsequent passages were generated after titration to
determine the 50% tissue culture infective dose (TCID50) of infectious
virus according to the method of Kaerber and Spaerman (60) and infec-
tion of Vero cells at a multiplicity of infeciton (MOI) of 0.03. The viruses
were passaged up to P10. MERS vaccine viruses and control viruses MV-
vac2-GFP(H) and MVvac2-GFP(P) in P3 were used for characterization,
and viruses in P4 were used for vaccination. MERS-CoV (isolate EMC/
2012) (1)was used for neutralization assays, and challenge viruswas prop-
agated in Vero cells and titrated as described above for recombinant MV.
All virus stocks were stored in aliquots at280°C.
Measles virus genome sequence analysis. The RNA genomes of re-
combinant MV in P3 or P10 were isolated using the QIAamp RNeasy kit
(QIAgen,Hilden, Germany) according to themanufacturer’s instructions
and resuspended in 50ml RNase-free water. Viral cDNAwas reverse tran-
scribed using the SuperScript II reverse transcription (RT) kit (Invitro-
gen) with 2 ml viral RNA (vRNA) as the template and random hexamer
primers, according tomanufacturer’s instructions. For specific amplifica-
tion of antigenORFs, the respective genomic regions of recombinantMVs
were amplified by PCR with primers binding to sequences flanking the
regions of interest and cDNA as the template. Detailed descriptions of
primers and procedures are available upon request. The PCR products
were directly sequenced (Eurofins Genomics, Ebersberg, Germany).
Western blot analysis. ForWestern blot analysis, cells were lysed and
immunoblotted as previously described (61). A rabbit anti-MERS-CoV
serum (1:1,000) was used as the primary antibody for MERS-CoV-S, and
a rabbit anti-MV-N polyclonal antibody (1:25,000; Abcam, Cambridge,
United Kingdom) was used for MV-N detection. A donkey horseradish
peroxidase (HRP)-coupled anti-rabbit IgG (H&L) polyclonal antibody
(1:10,000; Rockland, Gilbertsville, PA) served as the secondary antibody
for both. Peroxidase activity was visualized with an enhanced chemilumi-
nescence (ECL) detection kit (Thermo Scientific, Bremen, Germany) on
Amersham ECL hyperfilm (GE Healthcare, Freiburg, Germany).
Production of recombinant solubleMERS-CoV spike protein.The S
protein lacking the transmembrane domain was genetically tagged with
six His residues at its carboxy terminus. The resulting construct was in-
serted into a Semliki forest virus-derived self-replicatingRNAvector (SFV
replicon) downstream of the subgenomic promoter. These replicons were
transcribed in vitro and purified as previously described (62, 63). The
integrity of purified replicon was assessed by on-chip electrophoresis
(2100 BioAnalyzer; Agilent, Santa Clara, CA). To produce SFV vector
particles, replicon RNA and helper RNA were coelectroporated into
BHK21 cells by using a square-wave electroporator (one pulse, 750 V/cm
for 16 ms; BTX ECM 830; Harvard Apparatus, Holliston, MA). Particles
were harvested after 24 h, frozen in N2 (liquid), and stored at280°C. For
protein production, 23 107 BHK21 cells were transduced with SFV par-
ticles (MOI, 40) and harvested after 24 h. Cell pellets were lysed (phos-
phate-buffered saline [PBS], 0.2% Triton X-100, protease inhibitor cock-
tail [Roche]) for 30 min at 4°C. Afterwards, cells were sonicated, and
lysates were cleared by centrifugation (30 min, 21,000 3 g, 4°C). The
supernatantwas filtered (0.2mm), loaded on aHisTrap high-performance
(HP) column (17-5247-01; GE Healthcare), and washed with 10 volumes
of binding buffer (20 mM Na2HPO4, 0.5 M NaCl, 10 mM imidazole). S
protein was eluted with a gradient of binding buffer containing 0.5 M
imidazole followed by buffer exchange to PBS. Protein integrity was
checked byWestern blotting with amouse anti-His monoclonal antibody
(MAb; 1:50; Dianova, Germany).
Animal experiments. All animal experiments were carried out in com-
pliancewith the regulations of German animal protection laws and as autho-
rized by the RP Darmstadt. Six- to 12-week-old IFNAR2/2-CD46Ge mice
expressing humanCD46 were inoculated intraperitoneally (i.p.) with 13
105 TCID50 of recombinant MV or 200 ml Opti-MEM on days 0 and 28
and bled via the retrobulbar route on days 7, 28, 32, and 49 postinfection
(p.i.) under anesthesia. Serum samples were stored at220°C. Mice were
euthanized on day 32 or 49 p.i., and spleens were isolated. For challenge
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experiments, immunized mice were transduced intranasally (i.n.) on day
63 with 20 ml of an adenovirus vector encoding human DPP4 and
mCherry with a final titer of 2.53 108 PFU per inoculum (AdV-hDPP4;
ViraQuest Inc.) and challenged i.n. with 20ml ofMERS-CoVat a final titer
of 7 3 104 TCID50 on day 68. The mice were euthanized 4 days after
challenge, and representative left lobe lung samples were prepared for
RNA isolation.
Antibody ELISA.MV bulk antigens (10 mg/ml; Virion Serion, Würz-
burg, Germany) or recombinant MERS-S protein (20 mg/ml) in 50 ml
carbonate buffer (Na2CO3 at 30 mM, NaHCO3 at 70 mM; pH 9.6) was
used to coat wells of NuncMaxisorp 96-well enzyme-linked immunosor-
bent assay (ELISA) plates (eBioscience) and incubated overnight at 4°C.
The plates were washed three times with 150 ml ELISA washing buffer
(PBS, 0.1% [wt/vol]Tween 20) and blocked with 50 ml blocking buffer
(PBS, 5% bovine serum albumin [BSA], 0.1% Tween 20) for 2 h at room
temperature. Mice sera sampled on days27 or 49 were serially diluted in
ELISA dilution buffer (PBS, 1%BSA, 0.1%Tween 20), and 50ml/well was
used for the assay. The plates were incubated at 37°C for 2 h and washed
again with ELISAwashing buffer. Plates were incubated with 50ml/well of
HRP-conjugated rabbit anti-mouse IgG (Dako; 1:1,000 in ELISA dilution
buffer) at room temperature for 1 h. Subsequently, the plates were washed
and 100 ml tetramethylbenzidine substrate (eBioscience) was added per
well. The reactionwas stopped by addition of 50ml/well H2SO4 (1N), and
the absorbance at 405 nm was measured.
Neutralization assays. For quantification of VNTs, mouse sera were
serially diluted in 2-fold dilutions inDMEM.A total of 50 PFUofMVvac2-
GFP(P) or 200 TCID50 of MERS-CoV was mixed with serum dilutions
and incubated at 37°C for 1 h. Virus suspensions were added to 1 3 104
Vero cells seeded 4 h prior to assay in 96-well plates and incubated for 4
days at 37°C. VNTs were calculated as the reciprocal of the highest dilu-
tion that abolished infection.
ELISpot assays. Murine gamma interferon (IFN-g) enzyme-linked
immunosorbent spot (ELISpot) assays (eBioscience, Frankfurt, Ger-
many) were performed according to the manufacturer’s instructions us-
ing multiscreen immunoprecipitation (IP) ELISpot polyvinylidene diflu-
oride 96-well plates (Millipore, Darmstadt, Germany). A total of 53 105
splenocytes isolated 4 days after boost immunization were cocultured
with 5 3 104 JAWSIIgreen-MERS-S, DC2.4green-MERS-S, or DC3.2green-
MERS-S, or untransducedDCcell lines for 36 h in 200ml RPMI (10% fetal
bovine serum [FBS], 2 nM L-Gln, 1% penicillin-streptomycin). Medium
alone served as the negative control. Concanavalin A (ConA; Sigma-Al-
drich) at 10 mg/ml was used for demonstration of splenocyte reactivity.
RecombinantMV bulk antigens (Virion Serion) at 10mg/ml were used to
analyze MV-specific immune responses in vaccinated animals. Cells were
removed from the plates, and the plates were incubated with biotin-con-
jugated anti-IFN-g antibodies and avidin-HRP according to the manu-
facturer’s instructions. 3-Amino-9-ethyl-carbazole (AEC; Sigma-Al-
drich) substrate solution for development of spots was prepared
according to themanufacturer’s instructions usingAECdissolved inN,N-
dimethylformamide (Merck Millipore). Spots were counted using an
Eli.Scan ELISpot scanner (AE.L.VIS, Hamburg, Germany) and ELISpot
analysis software (AE.L.VIS).
T cell proliferation assay. Splenocytes isolated 3 weeks after booster
immunization were labeled with 0.5mMcarboxyfluorescein succinimidyl
ester (CFSE; eBioscience) as previously described (64). In brief, 5 3 105
labeled cells were seeded in RPMI 1640 supplemented with 10% mouse
serum, 2 nML-glutamine, 1mMHEPES, 1%penicillin-streptomycin, and
100 mM 2-mercaptoethanol in 96-well plates. Aliquots of 200 ml of me-
dium containing ConA (10mg/ml), MV bulk antigens (10mg/ml), or 53
103 JAWSIIgreen-MERS-S cells were added to each well, and cells were
cultured for 6 days. Medium and untransduced JAWSII cells served as
controls. Stimulated cells were subsequently stained with CD3-PacBlue
(1:50; clone 500A2; Invitrogen Life Technologies) and CD8-allophyco-
cyanin (1:100; clone 53-6.7; eBioscience) antibodies and fixed with 1%
paraformaldehyde (PFA) in PBS. Stained cells were analyzed by flow cy-
tometry using an LSR II flow cytometer (BD) and FACSDiva software
(BD).
Cytotoxic T lymphocyte (CTL) killing assay. For restimulation of T
cells isolated 4 days after booster immunization, 53 106 splenocytes were
cocultured with 5 3 104 JAWSIIgreen-MERS-S cells for 6 days in 12-well
plates in RPMI 1640 supplemented with 10% FBS, 2 nM L-glutamine, 1
mM HEPES, 1% penicillin-streptomycin, 2-mercaptoethanol (100 mM),
and 100 U/ml recombinant interleukin-2 (rIL-2; murine, Peprotech). A
total of 2 3 103 EL-4red cells were labeled with 0.5 mM CFSE and mixed
with 83 103 EL-4green-MERS-S cells per well. Splenocytes were counted
and cocultured with EL-4 target cells at the indicated ratios for 4 h. After-
wards, EL-4 cells were labeled with the fixable viability dye eFluor 780
(eBioscience), fixed with 1% PFA, and analyzed by flow cytometry using
an LSR II flow cytometer (BD) and FACSDiva software (BD). For deter-
mination of the antigen:NC EL-4 ratio, cell counts of living MERS-S-
expressing cells were divided by the counts for living negative controls.
Determination of viral RNA copy numbers and infectious virus in
mouse tissue. Samples of immunized and challenged mice (6- by 6-mm
tissue slices of approximately 0.035 6 0.011 g [mean 6 standard devia-
tion]) excised from the centers of left lung lobes were homogenized in 1
ml DMEM with ceramic beads (diameter, 1.4 mm) in a FastPrep SP120
instrument three times for 40 s at 6.5 m/s. The homogenate was centri-
fuged for 3 min at 2,400 rpm in a Mikro 200R centrifuge (Hettich Lab
Technology) to remove tissue debris. Live virus titers in supernatant (in
TCID50 per milliliter) were determined on Vero cells as described above.
Aliquots of 100 ml of the supernatants were used for RNA isolation with
the RNeasy minikit (Qiagen) according to the manufacturer’s instruc-
tions. The RNA amount wasmeasured with the NanoDropND-100 spec-
trophotometer. Total RNAwas reverse transcribed and quantified by real-
time PCR using the SuperScript III OneStep RT-PCR System (Invitrogen
Life Technologies) as described previously (65) with the primer pair upE-
Fwd and upE-Rev and the probe upE-Prb on an ABI7900 high-through-
put fast real-time PCR system (Life Technologies Instruments).
Additionally, for every sample of the transduced and infected mice,
evidence for successful hDPP4 transduction was determined by real-time
RT-PCR for mCherry with the OneStep RT-PCR kit on a Rotor Gene Q
apparatus (both from Qiagen). Primers and probe (Tib-Molbiol, Berlin,
Germany) were as follows: mCherry forward, CATGGTAACGATGAGT
TAG; mCherry reverse, GTTGCCTTCCTAATAAGG; mCherry probe,
6-carboxyfluorescein (FAM)–TACCACCTTACTTCCACCAATCGG–BBQ
(BlackBerry quencher). Primers and probe were used at final concentra-
tions of 0.4 mM and 0.2 mM, respectively. The quantitative reverse tran-
scription-PCR (qRT-PCR) programwas as follows: 50°C for 30min; 95°C
for 15 min; 40 cycles of 95°C for 15 s, 48°C for 30 s, and 72°C for 20 s. All
samples for mCherry were evaluated in one run to exclude an impact of
different conditions on the results in different runs. Quantification was
carried out using a standard curve based on 10-fold serial dilutions of
appropriate cloned RNA ranging from 102 to 105 copies. Briefly, PCR
fragments were generated using the primers described above. For cloning,
the TOPO TA cloning kit with pCR2.1-TOPO plasmid (Invitrogen) and
Escherichia coli were used. Inserts were examined for correct orientation
and length, amplified with plasmid-specific primers, purified, and tran-
scribed into RNA by using the SP6/T7 transcription kit (Roche).
Histopathological and immunohistochemical examination of lung
tissue. Lungs of vaccinated and mock-vaccinated mice transduced with
AdV-hDPP4 were collected on day 4 postchallenge withMERS-CoV. Tis-
sue was fixed in 4%PFA and embedded in paraffin. Sections were cut with
a Leica RM2255 microtome (Leica Biosystems) and stained with hema-
toxylin and eosin (H&E). For detection ofMERS-CoV, a rabbit polyclonal
antibody against MERS-CoV spike protein S1 (100208-RP; Sino Biologi-
cal Inc., Beijing, China) diluted 1:50 was used. To monitor adenovirus
transduction, amousemonoclonal antibody againstmCherry (ab125096;
Abcam) diluted 1:250 was used after antigen retrieval with target retrieval
solution (Dako) for 23 min at 97°C. To block unspecific binding, slides
were incubated for 10 min with 20% nonimmune pig serum (MERS-
MV as Vaccination Platform against MERS-CoV
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CoV) or for 30 min with 20% nonimmune horse serum (mCherry). Pri-
mary antibodies were incubated overnight at 4°C. A pig anti-rabbit IgG
and a biotinylated horse anti-mouse IgG served as secondary antibodies
for MERS-CoV and mCherry, respectively. For detection of antigen-an-
tibody complexes, the ABC method for mCherry and the rabbit PAP
method for MERS-CoV were used in combination with diaminobenzi-
dine for staining. Papanicolaou stain was used for counterstaining.
Statistical analysis. To compare the means of different groups from
growth curves, neutralization assays, andELISpot assays, a nonparametric
one-way analysis of variance (one-way ANOVA) was performed. For the
proliferation assay, the mean differences between control and vaccinated
groups were calculated and analyzed by using an unpaired t test. To all
three groups in the CTL killing assays, a linear curve was fitted for antigen
versus the log-transformed effector-target ratio (E:T). The P values for
differences in slopes were calculated, andMVvac2-MERS-S(H) orMVvac2-
MERS-solS(H) was compared with the control, MVvac2-ATU(P). For
analysis of challenge data, mean ratios and 95% confidence intervals were
calculated based on log-transformed and back-transformed data. The ra-
tio, instead of the difference, was chosen due to the rather log-normal
distribution of the data. The widths of the confidence intervals caused
high variability of the data, and limited sample sizes were used (n 5 10
observations each). For comparisons between groups, theWilcoxon two-
sample test was used. P values were not adjusted formultiple comparisons
due to the explorative character of the study.
RESULTS
Generation and expression of MERS-CoV-S by recombinant
MVvac2. Since the spike protein (S) of SARS-CoV has been shown
to potently induce humoral and cellular immune responses,
MERS-S was chosen as the appropriate antigen to be expressed by
the recombinant MV vaccine platform. In addition to full-length
MERS-S, a truncated form lacking the transmembrane and cyto-
plasmic domains (MERS-solS), was cloned into two different
ATUs either behind P (post-P) or H (post-H) cassettes of the
vaccine strainMVvac2 genome (Fig. 1A). Virus clones of all recom-
binant genomeswere successfully rescued and amplified up to P10
in Vero cells, with titers of up to 63 107 TCID50/ml. The stability
of the viral genomes was demonstrated via sequencing of viral
genomes after RT-PCR (data not shown). Besides the exclusion of
mutations or deletions of the antigen-encoding genes, the verifi-
cation of antigen expression is essential for vaccine function and,
thus, virus characterization. Western blot analysis of Vero cells
infected with the different MVvac2-MERS vaccines revealed ex-
pression of the antigen (Fig. 1B). Interestingly, the expression of
both S and solS was higher when cells were infected with viruses
encoding antigens in post-H ATU compared to the post-P con-
structs. Therefore, growth kinetics were analyzed to check if the
insertion or expression of the S antigen variants into or by recom-
binant MV, respectively, impaired the vaccines’ replication (Fig.
1C and D). For that purpose, the vaccine viruses containing the
MERS-S or MERS-solS gene in post-H (Fig. 1C) or post-P (Fig.
1D) positions were analyzed in parallel to the correspondingMV-
vac2-GFP control viruses. MVvac2 encoding full-length, mem-
brane-bound MERS-S grew comparably to the control viruses;
onlyMVvac2-MERS-solS(P) (Fig. 1D) andMVvac2-MERS-solS(H)
(Fig. 1C) revealed an approximately 3-fold-reduced maximal vi-
rus titer, albeit no statistical significance was observed [1.53 105
TCID50/ml for MVvac2-MERS-solS(P) and 4.7 3 10
5 TCID50/ml
for MVvac2-MERS-solS(H) versus 4.7 3 10
5 for MVvac2-GFP(P)
FIG 1 Generation and characterization of MVvac2-MERS-S and MVvac2-MERS-solS. (A) Schematic depiction of full-length MERS-S and a soluble variant
lacking the transmembrane and cytoplasmatic region (MERS-solS) (upper schemes) and recombinant MVvac2 genomes used for their expression (lower
schemes). Antigen or antigen-encoding genes are depicted in dark gray; MV viral gene cassettes (light gray) are annotated. MluI and AatII restriction sites used
for cloning of antigen-encoding genes into post-P or post-H ATU are highlighted (B) Immunoblot analysis of Vero cells infected at an MOI of 0.03 with
MVvac2-MERS-S, MVvac2-MERS-solS, or MVvac2-GFP(H) (MVvac2), as depicted above the lanes. Uninfected cells served as mock controls. Blots were probed
using rabbit serum reactive against MERS-CoV (upper blot) or mAb reactive against MV-N (lower blot). Arrows indicate specific bands. (C and D) Growth
kinetics of recombinant MV on Vero cells infected at an MOI of 0.02 with MVvac2-MERS-S (MERS-S), MVvac2-MERS-solS (MERS-solS), or MVvac2-GFP
encoding extra genes in post-H (C) or post-P (D) ATU. Titers of samples prepared at the indicated time points postinfection were determined on Vero cells.
Means and standard deviations of three independent experiments are presented. ns, not significant.
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and 1.2 3 106 TCID50/ml for MVvac2-GFP(H)] (Fig. 1C). Thus,
cloning and rescue of MVs expressing MERS-CoV antigens, even
at the cost of an 4,049 bp additional genome length, were achieved
easily and relative quickly. All constructs expressed the inserted
antigens without significant impact on viral replication.
Antibodies with neutralizing capacity directed against MV
or MERS-CoV are induced by MVvac2-MERS-S and MVvac2-
MERS-solS. To test the efficacy of the MVvac2-MERS vaccines in
vivo, genetically modified IFNAR2/2-CD46Ge mice were chosen,
since they are the prime small animal model for analysis of MV-
derived vaccines (46). Based on the higher antigen expression of
MERS-S and MERS-solS if cloned into the post-H position of the
MV genome, the respective viruses were used for vaccination.
Thus, 6 mice per group were inoculated via the i.p. route on days
0 and 28, each time with 13 105 TCID50 of MVvac2-MERS-S(H),
MVvac2-MERS-solS(H), or MVvac2-ATU(P), the latter a recombi-
nant control virus without an insertion of a foreign antigen-en-
coding gene cassette into an otherwise-empty additional tran-
scription unit. Medium-inoculated mice served as negative
controls. At 21 days after boost immunization, sera of immunized
mice were compared to prebleed sera by ELISA on antigen-coated
plates for antibodies binding to MV bulk antigens or MERS-S
(Fig. 2A and B). Indeed, sera of mice vaccinated with MVvac2-
MERS-S(H) or MVvac2-MERS-solS(H) clearly encompassed IgG
binding to MERS-S (Fig. 2B), whereas no antibodies were found
inmice before vaccination (Fig. 2A) or in controlmice.Moreover,
sera of mice vaccinated with any recombinant MV had IgG in the
serum that bound to MV bulk antigens, as expected, indicating
successful vaccination withMVs and general mouse reactivity. To
determine the neutralizing capacity of the induced antibodies, the
potential of serum dilutions to neutralize 200 TCID50 of MERS-
CoV or 50 PFU of MVvac2-GFP(H) (Fig. 3A to C) was assayed. All
mice immunized with recombinant MV (including the control
virus) indeed developed MV VNTs already after the first immu-
nization (Fig. 3B). These titers were boosted approximately 6-fold
upon the second immunization (512 to 3,072 VNT) (Fig. 3C).
Evidence for induction of neutralizing antibodies against MERS-
CoVwas only found inmice vaccinated withMVvac2-MERS-S(H)
or MVvac2-MERS-solS(H), as expected. The VNT against MERS-
CoV reached a titer of 96 to 167 after the first immunization (Fig.
3B) and was boosted about 5- to 7-fold by the second immuni-
zation (Fig. 3C). Mice immunized with MVvac2-MERS-S(H) in-
duced slightly higher MERS-CoV VNTs than didMVvac2 express-
ing the truncated form of the spike protein (167 versus 96 after the
first and 874 versus 640 after the second immunization) (Fig. 3B
and C). However, this difference was not statistically significant.
No VNTs against MV or MERS-CoV were detected in control
mice inoculated with medium alone. In summary, both recombi-
nant MVs expressing MERS-S or MERS-solS specifically induced
significant amounts of antibodies in immunized mice capable of
neutralizing MV as well as MERS-CoV.
Splenocytes of animals vaccinated with MVvac2-MERS-S or
MVvac2-MERS-solS secrete IFN-g uponMERS-S-specific stimu-
lation. To analyze the ability of MV-based vaccine viruses to in-
FIG 2 Induction of antibodies that specifically bind MERS-S (a-MERS-S) or
MV (a-MV) antigens. Sera of mice vaccinated on days 0 and 28 with indicated
viruses were sampled on days 27 (prebleed, A) and 49 (B) and analyzed for
antibodies that bound MERS-S or MV bulk antigens by ELISA. Medium-
inoculated mice served as mock controls. Antibodies binding to recombinant
MERS-S or MV bulk antigens were detected at an optical density of 405 nm in
the ELISA.Means and standard deviations of each group are depicted (n5 6).
Filled triangles, MVvac2-MERS-S(H); filled circles, MVvac2-MERS-solS(H);
open circles, mock controls; open squares, MVvac2-ATU(P).
FIG 3 Analysis of neutralizing antibodies. VNTs for animals vaccinated on
days 0 and 28 with the indicated viruses and sampled on day27 (A and D), 28
(B and E), or 49 (C and F) for complete neutralization of 200 TCID50 of
MERS-CoV or 50 PFU of MV. Medium-inoculated mice served as mock con-
trols. VNTs were calculated as reciprocals of the highest dilution abolishing
infectivity. Dots represent single animals (n5 10); horizontal lines represents
mean per group. The y axis starts at the detection limit; all mice with VNTs at
the detection limit had no detectable VNT. ns, not significant; *, P, 0.05; ***,
P, 0.0001.
MV as Vaccination Platform against MERS-CoV
November 2015 Volume 89 Number 22 jvi.asm.org 11659Journal of Virology
 
113
duceMERS-CoV-specific cellular immune responses, splenocytes
of animals vaccinated with MVvac2-MERS-S(H) or MVvac2-
MERS-solS(H), or control animals inoculated with medium or
MVvac2-ATU(P), were analyzed for antigen-specific IFN-g secre-
tion by ELISpot assay. For this purpose, mice were immunized
following the described prime-boost scheme, and splenocytes
were isolated 4 days after the second immunization. To restimu-
late the antigen-specific T cells in vitro, syngeneic murine DC cell
lines (JAWSII, DC2.4, and DC3.2) had been genetically modified
by lentiviral vector transduction to stably expressMERS-S protein
and thereby presented the respective T cell MHC epitopes. Single-
cell clones were derived by flow cytometric sorting of single GFP-
positive cells. Antigen expression by transduced DCs was verified
by Western blot analysis (data not shown).
ELISpot assays using splenocytes of vaccinated animals in co-
culture with JAWSII-MERS-S revealed about 2,400 IFN-g-secret-
ing cells per 13 106 splenocytes after immunization withMVvac2-
MERS-S or MVvac2-MERS-solS (Fig. 4A). In contrast, control
mice revealed a background response of about 200 IFN-g-pro-
ducing cells per 13 106 splenocytes. As expected, restimulation of
T cells by JAWSII presenting no exogenous antigen revealed only
reactivity in the background range (Fig. 4A). To rule out clonal or
cell line-associated artifacts, antigen-specific IFN-g secretion by
splenocytes of MVvac2-MERS-S- or MVvac2-MERS-solS-vacci-
nated mice was confirmed by stimulation with transgenic DC2.4
(Fig. 4B) or DC3.2 (Fig. 4C) cell clones expressingMERS-S. These
cell lines stimulated 1,200 to 2,300 IFN-g-secreting cells per 1 3
106 splenocytes in animals receiving the recombinant MERS vac-
cines, whereas no background stimulation of respective controls
was observed. The differences between MV control and MVvac2-
MERS-S- orMVvac2-MERS-solS-vaccinatedmice were significant
for all cell lines. Additionally, cellular immune responses targeting
MV antigens were detected upon stimulation with MV bulk anti-
gens in vaccinated mice that had received any recombinant virus,
as expected. However, MV bulk antigens stimulated only about
930 to 1,500 IFN-g-secreting cells per 13 106 splenocytes of MV-
vaccinated animals. Finally, splenocytes of all mice revealed a sim-
ilar basic reactivity to unspecific T cell stimulation, as confirmed
by similar numbers of IFN-g-secreting cells uponConA treatment
(Fig. 4D). Remarkably, both stimulation by ConA or MV bulk
antigens resulted in lower numbers of IFN-g1 cells than stimula-
tion by DCs expressing MERS-S, indicating an extremely robust
induction of cellular immunity against this antigen. Thus, the gen-
eratedMV-based vaccine platform expressingMERS-S or MERS-
solS not only induces humoral but also strong MERS S-specific
cellular immune responses.
MVvac2-MERS-S(H) or MVvac2-MERS-solS(H) induce anti-
gen-specific CD81 CTLs. While ELISpot analyses revealed anti-
gen-specific IFN-g secretion by vaccinated mice’s T cells, we next
aimed at detecting antigen-specific CD81 CTLs, which would be
important for clearance of virus-infected cells. For that purpose,
proliferation of CD81 T cells upon stimulation with MERS-S was
analyzed 3 weeks after the boost via a flow cytometric assay. Mice
were immunized as described above, and splenocytes were iso-
lated 21 days after the boost. JAWSII cells expressing MERS-S
were used for restimulation of MERS-S-specific T cells. The
splenocytes were labeled with CFSE and subsequently cocultured
with JAWSII-MERS-S cells or, as a control, with parental JAWSII
cells for 6 days and finally stained for CD3 and CD8 before being
analyzed by fluorescence-activated cell sampling for proliferation,
detectable by the dilution of the CFSE stain due to cell division.
T cells of mice vaccinated with MVvac2-MERS-S or MVvac2-
MERS-solS revealed an increase in the population of CD31CD81
CFSElow cells after restimulation with JAWSII-MERS-S cells com-
pared to restimulation with parental JAWSII without MERS anti-
gens (Fig. 5A). In contrast, T cells of control mice did not reveal
this pattern, but the CFSElow population remained rather con-
stant, as expected. This specific increase in CD31 CD81 CFSElow
cells, which was significant for MVvac2-MERS-S-vaccinated and
nearly significant (P5 0.0505) forMVvac2-MERS-solS-vaccinated
mice, indicated that CD31 CD81 CTLs specific for MERS-S pro-
liferated upon respective stimulation. Thus, MERS-specific cyto-
toxic memory T cells are induced in mice after vaccination with
MVvac2-MERS-S(H) or MVvac2-MERS-solS(H).
Induced T cells revealed antigen-specific cytotoxicity. To
demonstrate the effector ability of induced CTLs, a killing assay
was performed to directly analyze antigen-specific cytotoxicity
(Fig. 5B). Splenocytes of immunized mice isolated 4 days post-
booster vaccination were cocultured with JAWSII-MERS-S or the
nontransduced control JAWSII cells for 6 days to restimulate an-
tigen-specific T cells. When these restimulated T cells were coin-
cubated with a defined mixture of EL-4green-MERS-S target and
EL-4red control cells (ratio, 4:1), only T cells fromMVvac2-MERS-
S(H)-vaccinated or MVvac2-MERS-solS(H)-vaccinated mice sig-
nificantly shifted the ratio of live MERS-S-expressing target cells
to control cells in a dose-dependent manner (Fig. 5B). This anti-
gen-dependent killing was also dependent on restimulation with
JAWSII-CoV-S cells, since naive T cells did not shift significantly
the ratios of target to nontarget cells.
These results indicated that CTLs isolated from MVvac2-
MERS-S(H)- or MVvac2-MERS-solS(H)-vaccinated mice are ca-
pable of lysing cells expressing MERS-S. Neither splenocytes of
FIG 4 Secretion of IFN-g after antigen-specific restimulation of splenocytes.
(A to C) IFN-g ELISpot analysis results with splenocytes ofmice vaccinated on
days 0 and 28 with indicated viruses, isolated 4 days after boost immunization
and after coculture with JAWSII (A), DC2.4 (B), or DC3.2 (C) dendritic cell
lines transgenic for MERS-S or untransduced controls (NC). (D) To analyze
cellular responses directed against MV, splenocytes were stimulated with 10
mg/ml MV bulk antigens (MV-N) or left unstimulated (unst.). The reactivity
of splenocytes was confirmed by ConA treatment (10 mg/ml). Presented are
means and standard deviation per group (n 5 6). ns, not significant; *, P ,
0.05; **, P, 0.01.
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control mice restimulated with JAWSII-MERS-S nor splenocytes
of MERS-S-vaccinated mice restimulated with control JAWSII
cells showed such an antigen-specific killing activity. These results
demonstrated that the MV-based vaccine platform induces fully
functional antigen-specific CD81 CTLs in vaccinated mice when
applied as a MERS-CoV vaccine.
Vaccination of mice with MVvac2-MERS-S(H) or MVvac2-
MERS-solS(H) rescues animals from challenge with MERS-
CoV. The induction of strong humoral and cellular immune re-
sponses directed against MERS-CoV in mice vaccinated with
MVvac2-MERS-S(H) or MVvac2-MERS-solS(H) indicated that
those animals are possibly protected against a challenge with
MERS-CoV. To investigate the efficacy of the candidate vaccines,
two independent experiments were performed in which groups of
five mice were either vaccinated with MVvac2-MERS-S(H),
MVvac2-MERS-solS(H), or control MV [MVvac2-ATU(P)] or left
untreated. All mice immunized withMVvac2-MERS-S(H) orMV-
vac2-MERS-solS(H) showed VNTs directed against MERS-CoV,
with titers up to 1,280 for MERS-S and up to 960 for MERS-solS.
No MERS-CoV-neutralizing antibodies were detected in control
mice (data not shown). Since themurine DPP4 does not serve as a
functional MERS-CoV entry receptor (66) andmice are therefore
not susceptible toMERS-CoV infection, the vaccinatedmice were
i.n. transduced with a recombinant adenoviral vector to express
human DPP4 (AdV-hDPP4) in murine airways. At 5 days after
airway transduction with AdV-hDPP4, mice were infected i.n.
with 7 3 104 TCID50 MERS-CoV. Four days later, animals were
euthanized, lungs were isolated, the tissue was homogenized, and
homogenates were used for purification of total RNA and virus
titration. In the lungs of mock-infected control mice, MERS-CoV
RNA was detected by qRT-PCR (9,649 6 3,045 MERS-CoV ge-
nome copies/ng RNA) (Fig. 6A). Mice vaccinated with control
MVvac2-ATU(P) showed slightly lower copy numbers of viral
RNA (5,923 6 3,045 MERS-CoV genome copies/ng RNA) (Fig.
6A). Vaccination with MVvac2-MERS-S(H) or MVvac2-MERS-
solS(H) resulted in near-complete reduction of viral loads to 746
60 genome copies/ng RNA or 51 6 32 genome copies/ng RNA,
respectively (Fig. 6A). Next, titers of infectious virus were deter-
mined in the lung tissue. While the titers were generally low, they
corresponded to the qRT-PCR data. In mock-treated control mice,
titers of up to 5,000 TCID50/ml were determined (mean, 8686 692
TCID50/ml) and in lungs of mice vaccinated with the vaccine back-
bone without MERS antigen [MVvac2-ATU(P)], 1,673 6 866
TCID50/ml were detected. A considerable albeit statistically not sig-
nificant reduction of infectious virus titers was found in mice vacci-
nated with MVvac2-MERS-S(H) or MVvac2-MERS-solS(H) com-
pared to mock control mice (Fig. 6B). These results revealed that,
indeed, vaccinationwith the recombinantmeasles viruseswas able to
protect mice against a challenge withMERS-CoV.
MERS-CoV infection of transduced mice was not always suc-
cessful, which was indicated by a completely negative PCR result
for viral genomes in about 40% of all animals. In approximately
30% of MERS-CoV-negative animals, PCR for the mCherry gene
was negative, indicating that transduction was not successful and
explaining why these mice were not susceptible. Why the remain-
ing transduced mice were not infected is currently unclear. How-
ever, even when the dropout animals were included in statistical
analysis, the difference between mean viral loads of the medium
control group and MVvac2-MERS-solS(H)-treated mice (ratio,
278.2; 95% confidence interval, 1.52 to 50,904) stayed significant
(P 5 0.0329). Protection of the MVvac2-MERS-S(H)-vaccinated
group was close to significance (P 5 0.057) compared to mock-
treated animals (ratio, 149.2; 95% CI, 0.82 to 27,301).
Histological analyses were performed to analyze if the reduced
viral load in mice vaccinated with MVvac2-MERS-solS(H) or
MVvac2-MERS-S(H) was matched by decreased pathological
changes in mouse lungs (Fig. 7). For this purpose, lungs were
examined with H&E staining to visualize inflammation. Addi-
tionally,MERS-S andmCherry expressionwas determined by im-
munohistochemistry using antigen-specific antibodies. Consis-
tent with the qRT-PCR results, all mice that were positive in the
FIG 5 Induction of MERS-S-specific CTLs. (A) Proliferation assay using
splenocytes of mice vaccinated on days 0 and 28 with MVvac2-MERS-S(H) or
MVvac2-MERS-solS(H) and isolated 21 days after boost immunization, after
coculture with JAWSII dendritic cell lines transgenic for MERS-S (right, filled
triangles), or untransduced controls (left, filled circles). Depicted are the per-
centages of CD81 T cells with low CFSE staiing, indicating proliferation in the
samples. Results for splenocytes of vaccinated mice are displayed individually
and the trend between paired unstimulated and restimulated samples is out-
lined. Splenocytes of control vaccinated mice [open circles, mock; open
squares, MVvac2-ATU(P)] were pooled. (B and C) Killing assay using spleno-
cytes of mice vaccinated on days 0 and 28 and isolated 4 days after boost
immunization. Splenocytes were coculturedwith untransduced JAWSII (B) or
with antigen-presenting JAWSII-MERS-S (C) or for 6 days. Activated CTLs
were then cocultured with EL-4-MERS-S target cells (antigen) and EL-4red
control cells (NC) at the indicated effector:target (E:T) ratios for 4 h. Ratios of
living target versus nontarget cells (antigen:NC) were determined by flow cy-
tometry. Filled triangles, MVvac2-MERS-S(H); filled circles, MVvac2-MERS-
solS(H); open circles,mock; open squares,MVvac2-ATU(P). Results shown are
means and standard deviation of each group (n5 6). ns, not significant; *, P,
0.05; ***, P, 0.0001.
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qRT-PCR for themCherry gene expressedmCherry in epithelia of
the lungs, demonstrating successful transduction (Fig. 7, right col-
umn). The histopathological examination of H&E-stained lung
tissues clearly showed differences between the vaccinated mice
and controls (Fig. 7, left column). In the mock (Opti-MEM) as
well as vector control [MVvac2-ATU(P)] groups, large areas of
inflamed tissue were observed to be densely packed with lympho-
cytes, macrophages and, to a lesser extent, neutrophils and eosin-
ophils. Moreover, hyperplasia of the bronchus-associated lym-
phoid tissue was present to various degrees. These inflamed areas
colocalized with expression of MERS-CoV spike protein (Fig. 7,
middle column). Mice that were vaccinated with recombinant
MV expressing MERS-S showed fewer signs of inflammation and
consistently lowerMERS-S expression after challengewithMERS.
These differences were most obvious in lungs of MVvac2-MERS-
solS(H)-vaccinated animals, where only small foci of inflamma-
tion could be observed. These results revealed that vaccination
with recombinant MV expressing MERS S reduced pathological
changes in the lungs of MERS-CoV-infected mice.
DISCUSSION
In this study, we have demonstrated the capacity of recombinant
MV encoding different forms of theMERS-CoV S glycoprotein to
induce both strong humoral and cellular immune responses that
revealed a protective capacity in a challenge model of mice vacci-
nated with these stable live-attenuated vaccines. So far, different
strategies to develop vaccines against MERS-CoV have been pro-
posed, including recombinant full-length S protein (67) or the
receptor-binding domain (RBD) ofMERS-S (27, 28, 30, 31, 68), as
well as platform-based approaches using modified vaccinia virus
Ankara (MVA) (22) or adenoviral vectors (AdV) (23) encoding
MERS-S. Similar to our MV-based vaccine, these experimental
vaccines induced humoral immune responses with virus-neutral-
izing capacities. Among vectored vaccines, immunization with
MVA- or AdV-expressing MERS-S resulted in VNTs of approxi-
mately 1,800 or 1,024, respectively, when used to immunize
BALB/c mice. Vaccination with MVvac2-MERS-S or MVvac2-
MERS-solS induced somewhat lower VNTs of about 840, which is
an extremely robust titer if it is taken into account that mice were
immunizedwith 103-fold fewer virus particles thanwithMVAand
106-fold lower particles than with replication-deficient AdV.
Moreover, transgenic IFNAR2/2-CD46Gemice have been used in
our study with defects in type I IFN receptor signaling. Knockout
of the type I IFN receptor results in reduced adaptive immune
responses (68–70), since type I IFNs are an important link be-
tween the innate and adaptive immunity via, among others fac-
tors, activation of DCs (71), leading to a disadvantage for the
mouse adaptive immune system. Nevertheless, these mice have to
be used routinely to analyze efficacy of MV-based vaccines in a
small animal model (46), since wild-type mice are not susceptible
to MV infection for mainly two reasons. First, murine homo-
logues ofMV receptors cannot be used for cell entry (69), with the
exception of nectin-4 (70). Second, MV replication is strongly
impaired by type I IFN responses (71, 72), andmice with an intact
IFNAR feedback loop failed to be susceptible to MV infection
(46). Therefore, the IFNAR2/2-CD46Ge mouse strain transgenic
for humanMV vaccine receptor CD46 and with a knockout of the
IFNAR is used to analyze MV-based vaccines. Additionally, the
mouse strain backgrounds (BALB/c versus C57BL/6) differ in T
helper cell responses (BALB/c, predominantly Th2; C57BL/6, pre-
dominantly Th1 responses [73]), which reflects the different bal-
ance of cellular versus humoral immunity (74, 75). Thus, the
mouse model which had to be used in this study certainly is dis-
advantageous with respect to VNTs. To directly compare efficacy
of the different vector systems, all vectors should ideally be used
side by side in the same animal model. This may be a focus of
future studies. The VNTs of about 1,000 induced by three immu-
nizations with recombinant RBD are hardly comparable to our
results, since other protocols for determination of VNTs were
used in the other studies (27, 31). Interestingly, the expression of
the soluble version of S by MV did not enhance VNTs. This is
consistent with humoral immunity induced by DNA vaccines tar-
geting SARS-CoV. Plasmids encoding soluble SARS-S lacking the
transmembrane domain provoked lower VNTs than membrane-
bound variants (32). An altered, less physiological conformation
of the S protein has been proposed to result from deletion of the
transmembrane domain, which should be responsible for worse
immune recognition and lower antibody titers binding to the na-
tive, correctly folded S proteins in virus particles. In contrast, the
soluble S1 domain of MERS-S expressed by AdV actually induced
FIG 6 Viral loads afterMERS-CoV challenge in vivo. (A and B) Viral loads, determined as genome copies per nanogram of RNA (A) or infectious virus titers (B)
in the lungs of prevaccinated mice after transduction with DPP4-encoding AdV 21 days after boost and challenge with MERS-CoV 25 days after boost. Two
independent experiments (n5 4 to 5 per group). Error bars, standard errors of the means (SEM). Dotted line, limit of detection (LOD of qPCR,,1.7 copies/ng
RNA). ns, not significant; *, P, 0.05. (C) AdV transduction control mCherry mRNA results (in copies per nanogram of RNA). Error bars, SEM.
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slightly higher VNTs than did full-length S (23). However, soluble
constructs consisting of the MERS S1 and S2 domains have not
been compared to the soluble S1 domain yet. Interestingly, re-
combinant MV expressing soluble MERS-S revealed slightly im-
paired replication in comparison to control MV, in contrast to
MV expressing full-length MERS-S. This impaired viral replica-
tion might be based on cytotoxicity of MERS-solS, probably as a
result of an altered folding or the solubility of the S protein. Cyto-
toxic effects of the S protein have already been observed for the S2
domain of SARS-S (76–80), but not for other coronaviruses, like
mouse hepatitis coronavirus (81). However, both MV-based vac-
cines encoding either the soluble or the full-length variant of
MERS-S did induce strong VNTs and cellular immune responses.
The protective capacity of humoral immune responses against
CoV infection is controversial. Neutralizing antibodies have been
identified as correlates of protection against SARS-CoV challenge,
since passive serum transfer was sufficient to rescue animals from
challenge (32, 82) and T cell depletion did not impair protection
(32). In contrast, immunization with the nucleocapsid protein
resulted in protection against the coronavirus infectious bronchi-
tis virus (IBV) without induction of neutralizing antibodies (83,
84), indicating the capacity of cellular immune responses for IBV
protection. Anyway, the antigenic potential of S for induction of
CD41 or CD81 T cell immunity has already been demonstrated
for SARS-CoV (32, 85) by using recombinant protein or DNA
vaccines. Also for MERS-CoV, application of RBD protein to-
getherwith adjuvants has been shown to induce cellular immunity
(27, 31). We demonstrated in this study that induction of cellular
immunity by a vectored vaccine works independently from adju-
vants or the application strategy. The MV-based vaccine induced
very strong MERS-S-specific CD81 T cell responses, revealed by
ELISpot, killing, and proliferation assays. The broad repertoire of
FIG 7 Histopathological changes and immunohistochemical analysis of lungs after challenge. Analysis of lung tissue of representative prevaccinated mice (as
indicated) after transduction with hDPP4-encoding AdV and challenge with MERS-CoV. Pictures arranged in a row were from samples of the same individual
mouse. Paraffin-fixed tissue was stained withH&E (first column; scale bar, 200mm), with Ab againstMERS-CoV-S antigen (middle column; scale bar, 100mm),
and as a control of AdV transduction against mCherry (right column; scale bar, 50 mm).
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reactivity, in the case of antigen-specific proliferation also 21 days
after the booster immunization, indicated induction of both a
functional effector and memory T cell repertoire by MVvac2-
MERS-S andMVvac2-MERS-solS. Thereby, the extraordinary high
number of IFN-g-secreting T cells in vaccinated mice both
stresses the potential of the vaccine platform and underlines the
immunogenicity of MERS-S.
On top, the present study tested whether the induced immune
responses protected mice against a challenge infection with
MERS-CoV. Indeed, vaccination with MVvac2-MERS-S or
MVvac2-MERS-solS significantly reduced viral loads in the lungs
of vaccinated mice after challenge with MERS-CoV. As expected,
this reduction of viral load correlated with reduced pathological
alterations in the lung, indicating that MV-derived MERS vac-
cines were able to confer protection againstMERS-CoV infection.
At least 4 mice out of each group did not reveal any MERS-CoV
infection nor any pathological lung alterations indicating failure
of infection in these individuals. In 30% of those mice, transduc-
tion with the recombinant adenovirus expressing human DPP4
did not appear to be successful. However, the majority of mice
with no signs of MERS-CoV infection at all showed expression of
mCherry, indicating that transduction was successful. Currently,
the reason for the failure to infect these animals is unclear.
The direct correlates of protection in the vaccinated mice re-
main to be determined in future studies. Most recently, mice
transgenic for human DPP4 have been developed that allow anal-
ysis of MERS-CoV infection on a more robust and physiologic
basis (86). These could only be used for analysis of MV-based
vaccines after intercrossing them with IFNAR2/2-CD46Ge or
similarmouse strains to obtainmice simultaneously susceptible to
MV and MERS-CoV, which may also be a focus of future work.
Efficacy of MVvac2-based MERS vaccines has been demon-
strated in MV-naive mice. Theoretically, preexisting antivector
immunity against theMVbackbonemay be considered a potential
limitation both for the specific MERS vaccines tested in this study
and for use of recombinant MV as a vaccine platform, in general,
for MV-immunized patients (87). However, it has been clearly
demonstrated both inmice (41, 45) and nonhuman primates (41)
with humoral immune responses regarded to be protective against
measles that vaccination with recombinant MVs encoding anti-
gens of HIV-1 (41) or Chikungunya virus (45) still induced sur-
prisingly robust antigen-specific immune responses. Most inter-
estingly, when the efficacy of recombinantMV-CHIKV vaccine in
a phase I trial in human volunteers was analyzed, the vaccine was
recently shown to be effective in inducing anti-CHIKV immune
responses irrespective of preexisting antimeasles immunity (47).
These data question the “sterilizing” character of measles immu-
nity and clearly indicate the potential of recombinant MV as a
promising vaccine platform for vaccination against MERS-CoV
or other infectious agents, in general. Indeed, the efficacy of MV-
based recombinant vaccines has been demonstrated preclinically
with quite a range of different pathogen antigens, e.g., HBV (39),
dengue virus (44), WNV (42), and CHIKV (45). Additionally, the
efficacy ofMV to induce immune responses against coronaviruses
has been shown for the S protein and nucleocapsid protein of
SARS-CoV (19). All these recombinant vaccines have in common
that they are based on a very-well-known platform: MV vaccines
have been shown to exhibit an extremely beneficial safety profile
in light of themillions of applied doses over the last 40 years. Only
heavily immune-suppressed patients are excluded from measles
vaccination campaigns, but the protection holds over decades and
is thought to be most likely for life (33, 34).
Most interestingly, a quite similar recombinant vaccine based
on a rhabdovirus, a member of another family within theMonon-
egavirales order, is currently being tested in the clinic as an exper-
imental vaccine against Ebola virus (EBOV) infection. Recombi-
nant VSV encoding the Ebola Zaire strain glycoprotein. replacing
VSV-G (VSV-ZEBOV) was shown to be effective in animal mod-
els (88, 89) and is now being tested in phase I trials for safety in
human patients (90), in preparation to beingmoved to the field to
combat current EBOV epidemics. Thereby, the potential interest
in such platform-based vaccines to combat emerging or reemerg-
ing infections is impressively highlighted.
Taken together, MV vaccine strain Moraten-derived recombi-
nant MVvac2 vaccines are effective vaccines against MERS-CoV,
inducing both humoral and cellular immune responses protective
for vaccinated animals. Thereby, the capacity of the recombinant
MV-based vaccine platform for fast generation of effective vac-
cines has been demonstrated also with a more general view to
future emerging or reemerging infections, but also with a view on
MERS-CoV. MV-MERS-S provides an opportunity for further
development of this experimental vaccine to be prepared espe-
cially to reduce the risk of pandemic spread of this disease.
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7. APPENDIX – UNPUBLISHED METHODS 
Cells 
MDCK (Canis familiaris kidney) (ATCC® CCL-34™), cell lines were purchased from ATCC 
(Manassas, VA, USA) and cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS; Biochrom, Berlin, Germany) and 2 mM L-Gln (Biochrom). Cells were cultured at 37°C 
in a humidified atmosphere containing 6% CO2 for a maximum of 6 months of culture after 
thawing of the original stock. 
Plasmids 
The codon-optimized gene encoding MERS-N (Genebank accession no. JX869059) flanked 
with AatII/MluI (for exchange of GFP in p(+)PolII-MVvac2-GFP(H) or (+)PolII-MVvac2-GFP(P)) 
or NheI/XhoI (for exchange of gluc in pCSCW2-gluc-IRES-GFP) binding sites in plasmid pMA-
RQ-MERS-N was obtained by gene synthesis (Invitrogen Life Technology, Regensburg, 
Germany). The genes encoding the hemagglutinin H7 or neuraminidase N9 of the virus 
isolate A/Shanghai/2/2013 (H7N9) were amplified by PCR flanked with AatII/MluI or 
NheI/XhoI binding sites using pCAGGS-HA and pCAGGS-NA as templates, The genes 
encoding CCHFV-G-FL, CCHFV-preGc-FL, CCHFV-preGc, CCHFV-Gc-FL, CCHFV-Gc, CCHFV-
preGn, CCHFV-Gn, CCHFV-solGn, or CCHFV-N were amplified by PCR flanked with 
AatII/MluI binding sites using reverse transcribed CCHFV cRNA as template. All constructs 
were fully sequenced. Respective plasmids p(+)PolII-MVvac2-Antigen and pCSCW2-Antigen-
IRES-GFP were generated as described (172). 
Viruses 
Recombinant MV viruses were rescued and passaged as described (172). Reassortant 
influenza virus A/Puerto Rico/8/34 (PR8) expressing the hemagglutinin and 
neuraminidase of H7N9 (H7N9 A/Shanghai/2/2013-A/PR/8/34) were kindly provided by 
Prof. Matrosovich from the University of Marburg. The reassortant virus was used for IPMA, 
neutralisation and hemagglutinin inhibition assay (HAI). All virus stocks were stored in 
aliquots at -80°C. 
Western blot Analysis 
For western blot analysis, infected cells were lysed and immunoblotted as previously 
described (172) with the following modifications: A rabbit anti-MERS-CoV serum (1:1,000) 
was used as primary antibody for detection of MERS-CoV-S, a rabbit anti- α-H7N1 serum 
(1:5,000) for detection of H7, a rabbit anti-MV-N polyclonal antibody (1:25,000) (Abcam, 
Cambridge, UK) for detection of MV-N, mouse monoclonal antibodies CCHFV-preGc#11E5, 
CCHFV-preGn#5A4 or #7F5 and CCHFV-N#9D5 (1:1,000 beiressources, Manassas, US) for 
AP P E N DI X  –  UN PU B LI S HE D  ME T H OD S  
 
 123 
detection of CCHFV-preGc, CCHFV-preGn and CCHFV-N, respectively. Donkey HRP-coupled 
anti-rabbit IgG (H&L) serum (1:10,000) (Rockland, Gilbertsville, PA) or rabbit anti- mouse 
IgG (H&L) (1:1,000; Dako, Waldbronn, Germany) were used as secondary antobodies. 
Neuraminidase activity assay 
1104/well Vero cells cultured in 96 well- black polystyrene plates with clear bottom 
(Corning, Wiesbaden, Germany) were infected at an MOI of 0.05 to 5 with MVvac2-N9(H) or 
MVvac2-N9(P) for 48 hours at 37°C. Supernatants were removed and 50 µL of 0,2 mM 2′-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminate (MUNANA) (Sigma, stock solved in DMF 
(N,N-dimethylformamide)) diluted in NA-Assay buffer (pH 7.0; 4 mM CaCl2; in TBS) was 
added. Plates were incubated for 30 min at 37°C. 100 µL NA-assay stopp buffer (pH 10.7; 
25% Ethanol; 0,1 M Glycin; 0,3% Tween 20; in H2O) was added and plates were incubated 
for 30 min at 37°C. Free 4-methylumbelliferone was determined using a spectrofluorometer 
(excitation light of 365 nm; fluorescence emission at 450 nm). Concentration of -
methylumbelliferone was calculated according to a 4-methylumbelliferone salt (Sigma) 
standard curve.  
Treatment of mouse sera 
For H7N9 neutralisation and HAI assay sera were heat-inactivated for 30 minutes at 56 °C 
and afterwards treated 1:5 with receptor destroying enzyme (RDE, Sigma, solved in calcium 
saline solution pH 7.2) at 37°C over night. Sera were 1:2 diluted with 1.5% sodium citrate 
solution and incubated at 56°C for 30 minutes. Treated sera were stored at -20°C. 
Immunoperoxidase Monolayer Assay (IPMA) 
1104/well MDCK cells cultured in 96 well-plates were infected at an MOI of 0.2 with H7N9-
reassorted influenza virus strain A/Shanghai/2/2013-A/PR/8/34. Two dpi, supernatants 
were discarded and infected plates were heat-dried at 65°C for 8 h. 50 µl of 2-fold serially 
diluted mice sera were incubated with the dried cells for 2 h at room temperature. After 
one-time washing with PBS for 20 min, the plates were incubated with peroxidase-
conjungated rabbit anti- mouse IgG (H&L) (1:750 in PBS; Dako) for 1 h at room temperature. 
3-amino-9-ethylcarbazole (AEC) substrate solution substrate solution for visualization of 
infected cells was prepared as described (172) using 3-amino-9-ethyl-carbazole (Sigma-
Aldrich) dissolved in N,N-dimethylformamide (Merck Millipore). After one-time washing 
with PBS for 20 min 50 µl/well of AEC solution were added. The reaction was stopped by 
addition 50 µl/well of H2O. Antibody titers were calculated as the reverse of the highest sera 
dilution allowing staining of infected cells.  
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Neutralisation Assays 
For quantification of virus neutralising titers (VNT), mouse sera were two-fold serially 
diluted in DMEM. MV neutralisation assay was performed as described (172). For testing 
neutralisation of H7N9 influenza virus, 100 TCID50 of H7N9 A/Shanghai/2/2013-
A/PR/8/34 virus were incubated with two-fold serial sera dilutions for 20 min at room 
temperature. 2104 MDCK cells were added to the virus suspension in 96-wells and 
incubated at 37°C for 2 d. IPMA staining using a polyclonal ferret anti-PR/8 serum to 
visualize influenza infection was performed as described above. Virus neutralising titers 
(VNT) were calculated as the reciprocal of the highest dilution abolishing infection. 
Hemagglutinination Inhibition Assay (HAI-Assay) 
HAI assays were performed according to standard protocols (126). Four hemagglutination 
units (HAU) of H7N9 A/Shanghai/2/2013-A/PR/8/34 in 25 µl PBS were added to 25 µl of 
2-fold serially diluted sera in 96-U-well plates (Nunc) starting with a dilution of 1:10. 
Following incubation for 30-45 min at room temperature, 50 µl of 0.75% chicken red blood 
cells (RBCs) in Alsever’s solution (Sigma) were added. The plates were incubated at room 
temperature until hemagglutination was observed. The HAI titer was calculated as the 
reciprocal of the highest serum dilution preventing hemagglutination of RBCs by influenza 
virions. 
Enzyme-linked lectin assay (ELLA) 
Polystyrene 96-well plates (Nunc MaxSorp) were coated overnight with 100 µl fetuin (25 
µg/ml, Sigma) in 0.1 M PBS.  To determine an appropriate antigen, i.e. virion concentration 
to be used for ELLA, H7N9 A/Shanghai/2/2013-A/PR/8/34 suspension was serially diluted 
in Dulbecco’s PBS (pH 7.4; 0.9 mM CaCl2; 0.5 mM MgCl2; 1 % BSA; 0.5 % Tween). Virus 
dilutions were afterwards dispensed into Fetuin-coated plates. ELLA was conducted as 
described previously (57) and plates afterwards read at 490 nm. The virus dilution resulting 
in 90-95 % of maximum signal was chosen as the appropriate concentration for testing the 
anti-neuraminidase activity of the respective mouse sera. Sera of mice were heat-
inactivated at 56°C for 30 min and 2-fold serially diluted in PBS. 50 µl of sera dilutions in 
duplicates were dispensed into Fetuin-coated plates, and 50 µl of the previously determined 
virion dilution added. ELLA was performed as described before (57). The percentage of NA 
activity was calculated as the quotient of the mean serum absorbance divided by the mean 
absorbance of the virus only.  The 50% end-point NAI titer was defined as the reciprocal of 
the highest dilution resulting in at least 50% inhibition of maximum signal in the assay. 
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°C Degree celsius 
α anti 
aa Amino acid 
Ab Antibody 
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ATF-2/c-Jun Activating transcription factor-2/c-Jun 
APC Antigen presenting cell 
ATU Additional transcription unit 
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BL/6 C57BL/6 
bp Base pare 
BSL Biosafety level  
cDC Conventional dendritic cell 
cDNA Complementary DNA 
CDC Complement dependent cytotoxicity (CDC)  
CFSE Carboxyfluorescein succinimidyl ester 
CCHFV Crimean–Congo haemorrhagic fever virus 
CD Cluster of differentiation  
CHIKV Chikungunya virus 
CPE Cytopathic effect 
CoV Corona virus 
CCR7 C-C chemokine receptor type 7 
ConA Concanavalin A  
CpG Cytosin-phosphatidyl-Guanin 
CTL Cytotoxic T cells 
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DC Dendritic cell  
DNA Deoxyribonucleic acid 
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ELISA Enzyme linked immunosorbent assay 
ELISpot Enzyme linked immuno spot assay 
ELLA Enzyme-linked lectin assay 
env Envelope glycoprotein 
ER Endosplasmatic reticulum 
et al. Et alii (and others) 
F Fusion protein 
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FACS Fluorescence activated cell sorting 
Fc Fragment crystallizable 
Fig. Figure 
Gag Group-specific antigen 
GFP Green fluorescent protein 
GM-CSF Granulocyte macrophage colony-stimulating factor 
Gp Glycoprotein 
h Hours 
H/HA Hemagglutinin 
HAI Hemagglutinin inhibition assay 
HAV Hepatitis A virus 
HBV Hepatitis B virus 
HIV Human immunodeficiency virus 
hpi Hours post infection 
HSV Herpex simplex virus 
IC50 50% inhibitory concentration  
IFN Interferon 
IFNAR Interferon-α/β receptor 
Ig Immunoglobulin  
i.n. Intranasal 
i.p. Intraperitoneal 
IPA Immune peroxidase assay 
IPC Interferon producing cell 
IPMA Immune peroxidase monolayer assay 
IL Interleukin 
IRES Internal ribosomal entry site 
IRF Interferon regulatory factors 
ISG Interferon stimulated genes 
kDa Kilodalton 
kbp Kilo base pare 
LPD2 laboratory of genetics and physiology 2 
LV Lentivirus 
LV-PTVs Lentiviral protein transfer vectors  
MDA-5 Melanoma differentiation antigen 5 
mDC Myeloid Dendritic cells 
MERS-CoV Middle East respiratory syndrome coronavirus 
MERS-N MERS-Nucleocapsidprotein 
MERS-S MERS-Spike protein 
mg Milligram  
MHC Major histocompatibility complex 
min Minute  
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ml Mililiter 
µm Micro meter 
MMDC Monocyte-derived DCs  
MOI Multiplicity of infection 
mRNA Messenger RNA 
MV Measles virus 
MVA Modified vaccinia virus ankara 
MyD88 Myeloid differentiation primary response gene 88 
N Nucleoprotein 
NA Neuraminidase 
nAb Neutralising antibodiy 
NAI Neuraminidase inhibition assay 
NC Negative control 
NF-κB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NK cells Natural killer cells 
nm Nano meter 
ns Not significant 
OD Optical density 
o/n Over night 
ORF Open reading frame 
OT Ovalbumin-specific TCR transgenic 
Ova Ovalbumin 
P Passage 
PAMP Pathogen associated molecular patterns  
PC Positive control 
PCR Polymerase chain reaction 
pDC Plasmacytoid dendritic cells 
PEC Peritoneal exudate cells 
PFU Plague forming unit 
p.i. Post infection 
Pol Polymerase 
qRT-PCR Quantitative reverse transcription 
RBD Receptor binding domain 
RIG-1 Retinoic Acid Inducible Gene I 
RLR Retinoic acid inducible gene (RIG-I)-like receptors (RLRs) 
rMV Recombinant Measles virus 
PRR Pattern recognition receptors 
RNA Ribonucleic acid 
RNP Ribonucleoprotein 
RSV Respiratory syncytial virus 
SARS-CoV Severe acute respiratory syndrome coronavirus 
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sec Seconds 
SIV Simian immunodeficiency viruses 
SLAM Signaling lymphocytic activation molecule 
ss Single-strand 
STAT Signal transducers and activators of transcription 
Tab. Table 
TCID50 Tissue culture infective dose 50 % 
TCT T cell receptor 
TH cell T helper cell 
TLR Toll-like receptor 
TM Transmembrane  
TNF- α Tumor necrosis factor-α  
TRIF TIR-domain-containing adapter-inducing interferon-β 
UV Ultraviolett 
VLP Virus like particle 
VNT Virus neutralising titer 
VSV Vesicular stomatitis virus 
VSV-G Glycoprotein of vesicular stomatitis virus 
WHO World health organization 
WNV West nile virus 
wt Wild type 
w/o Without  
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